Rollen von Atemwegsepithel und Alveolarmakrophagen zur Aufrechterhaltung von Homöostase während chronischer Atemwegserkrankung by Boehme, Julia
  
 
 
 
 
Multifaceted contributions of airway epithelial cells 
and alveolar macrophages to homeostasis 
surveillance in chronic respiratory disease 
 
 
 
Von der Fakultät für Lebenswissenschaften 
 
der Technischen Universität Carolo-Wilhelmina zu Braunschweig 
 
zur Erlangung des Grades einer 
 
Doktorin der Naturwissenschaften 
 
(Dr. rer. nat.) 
 
genehmigte 
 
D i s s e r t a t i o n 
 
 
 
 
 
 
 
von Julia Désirée Boehme 
aus Peine  
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1. Referent:  Professor Dr. Michael Steinert 
2. Referentin:  
3. Referent:  
Professorin Dr. Dunja Bruder 
Professor Dr. Mathias Hornef 
eingereicht am: 19.10.2015 
mündliche Prüfung (Disputation) am: 
 
Druckjahr 2016 
26.02.2016 
 
 
 Vorveröffentlichungen der Dissertation 
Teilergebnisse aus dieser Arbeit wurden mit Genehmigung der Fakultät für 
Lebenswissenschaften, vertreten durch den Mentor der Arbeit,  
in folgenden Beiträgen vorab veröffentlicht: 
Publikationen  
Boehme, J.D., Pietkiewicz, S., Lavrik, I.N., Jeron, A. & Bruder, D. Morphological and 
functional alterations of alveolar macrophages in a murine model of chronic inflammatory 
lung disease. Lung (2015). DOI: 10.1007/s00408-015-9797-4 
Boehme, J.D., Stegemann-Koniszewski, S., Autengruber, A., Peters, N., Wissing, J., 
Jänsch, L., Jeron, A. & Bruder, D. Chronic lung inflammation primes pIgR/SIg mechanisms 
and augments humoral immunity to Streptococcus pneumoniae. Mucosal Immunology (In 
Revision). 
Tagungsbeiträge  
Vorträge 
Jeron, A., Boehme, J., Stegemann-Koniszewski, S., Wissing, J., Jänsch, L., Bruder, D. 
Chronic lung inflammation enhances humoral immunity to Streptococcus pneumoniae via the 
pIgR/sIg axis. (Talk held by Andreas Jeron) 4th European Congress of Immunology (ECI) 
Vienna (September 2015). 
Boehme, J., Stegemann-Koniszewski, S., Autengruber, A., Peters, N., Wissing, J., 
Jänsch, L., Jeron, A. & Bruder, D. Alveolar Overexpression of the Polymeric 
Immunoglobulin Receptor in the Inflamed Lung as a Novel Mechanism for Antibody-mediated 
Immune Exclusion of Bacterial Pathogens. (Talk held by Dunja Bruder) 17th International 
Congress of Mucosal Immunology (ICMI 2015), Berlin (July 2015). 
Boehme, J., Weller, M., Kasnitz, N. & Parzmair, G. Innate immune regulation and infection. 
HZI Graduate School Annual Retreat, Hahnenklee (2014). 
Boehme, J., Rogge, K. Mucosal inflammation: impact on secondary immune responses. HZI 
Graduate School Annual Retreat, Hahnenklee (2013). 
Boehme, J. Impact of chronic autoimmune-mediated pulmonary inflammation on 
pneumococcal pneumonia. 36th Symposium of the North-German Immunologists, Borstel 
(2013).
 Posterbeiträge  
Boehme, J., Jeron, A., Stegemann-Koniszewski, S., Bruder, D.: Alveolar epithelial 
regulation of pIgR-expression in chronic lung disease: A compensatory mechanism to 
prevent fatal pneumococcal invasion? 44. Jahrestagung der Deutschen Gesellschaft für 
Immunologie, Bonn (2014). 
Boehme, J., Jeron, A., Stegemann-Koniszewski, S., Gereke, M. & Bruder, D.: Impact of 
chronic autoimmune-mediated lung inflammation on Streptococcus pneumoniae infection. 
43. Jahrestagung der Deutschen Gesellschaft für Immunologie, Mainz (2013). 
   
 
 
 
 
 
 
Für Daniel, Mama und Papa 
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1  Abstract  
Experimental and epidemiologic evidence points to substantially altered immunity towards 
airborne pathogens in individuals with chronic respiratory disease (CRD). The identification 
of immunologic factors underlying this phenomenon would help to better understand 
infectious disease pathogenesis and to improve anti-infectious therapies for this cohort. 
Thus, the first part of this thesis aimed to elucidate the impact of chronic pulmonary 
inflammation on infection with the common respiratory pathogen Streptococcus pneumoniae. 
To this end, the SPC-HAxTCR-HA transgenic mouse model which is based on the 
recognition of a pulmonary self-antigen by self-antigen specific T cells, finally leading to 
chronic pulmonary inflammation associated with several pathologic features of human CRD, 
was utilized. Unexpectedly, in vivo infection experiments revealed increased 
antipneumococcal resistance of pre-diseased SPC-HAxTCR-HA mice, indicative of 
inflammation-induced protective mechanisms. As the alveolar macrophage (AM) phagocytic 
capacity was similar between healthy and pre-diseased mice, two different strategies for 
unbiased analyses were pursued to examine the protective microenvironment in SPC-
HAxTCR-HA lungs: gene expression as well as the bronchoalveolar lavage fluid (BALF) 
proteome was compared between healthy and pre-diseased mice by using whole-genome 
microarray and LC-MS/MS technology. Both analyses pointed to an induction of the 
polymeric immunoglobulin receptor (pIgR)/secretory immunoglobulin (SIg) axis in SPC-
HAxTCR-HA lungs, which was in high accordance with elevated airway SIg levels and airway 
epithelial pIgR-expression in this group. Finally, by using in vitro pneumococcal binding 
assays an increased opsonizing activity of SPC-HAxTCR-HA BALF - and thus a protective 
contribution of the inflammation-primed airway epithelium to SIg-mediated reinforcement of 
the lung mucosa against bacterial adhesion and tissue penetration – could be confirmed. 
In the SPC-HAxTCR-HA model chronic inflammation has previously been shown to 
encompass profound molecular as well as phenotypic changes of alveolar type II (ATII) cells 
and the self-antigen specific T cell compartment. Though AMs are known to be able to 
communicate with both cell types, a comprehensive investigation of these cells has so far not 
been addressed. The second part of this thesis therefore aimed to examine the phenotype of 
AMs as well as their immunoregulatory potential in hosts with CRD. Cytometric, 
transcriptional and functional evaluation of these cells uncovered a markedly altered, 
activated phenotype and a blunted pro-inflammatory immune response to pneumococcal 
ligands, suggesting a partial impairment of these cells during respiratory infection. 
Furthermore, extensive in vivo clodronate liposome-depletion studies revealed that this cell 
type is essential for preventing the development of bronchopneumonia in SPC-HAxTCR-HA 
lungs. Here, no or only minor roles of AMs as pulmonary scavengers and controllers of self-
antigen specific T cells could be found in SPC-HAxTCR-HA lungs. Interestingly and in high 
accordance with the neutrophil-dominated disease phenotype in AM-depleted SPC-HAxTCR-
HA lungs, ATII-specific gene expression of IL-8 analogues was highly up-regulated in this 
group, revealing so far unrecognized immunoregulatory cooperativity between AMs and ATII 
in CRD. 
Taken together, the present work identified inflammation-primed pulmonary epithelial cells as 
effective mucosal safeguards against respiratory infection with Streptococcus pneumoniae. 
Moreover, the AM/ATII axis was identified to be an element presumably involved in 
surveilling pulmonary homeostasis in CRD.  
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2  Introduction 
Respiration is a process crucial for survival but at the same time challenges the individual 
with a plethora of demanding immunological tasks. Owed to its primary function the lung is 
continuously exposed to the outside environment harboring a wide array of harmless 
substances but also toxic gases and particles as well as infectious threats. The accurate 
discrimination between self vs. non-self as well as innocuous vs. dangerous antigens is 
critical for preserving organ function. On the one hand, autoimmunity or allergy and the 
resulting pathology can lead to severe tissue damage, on the other hand improper 
recognition and elimination of pathogens leaves the host vulnerable to microbial spread. It is 
therefore of utmost interest how pulmonary immunity manages these balancing acts during 
homeostasis but particularly in individuals with pre-existing respiratory ailments.  
Regardless of our increasing knowledge about the underlying principles and the 
development of alleviating therapies during the past decades, non-communicable chronic 
respiratory diseases (CRDs) affect hundreds of millions of people worldwide with increasing 
prevalence. For instance, chronic obstructive pulmonary disease (COPD) is projected to be 
the fourth leading cause of death by 2030 (Mathers et al. 2006). Here the pathogenesis is 
generally considered to be a product of complex and continuous physiologic reactions in the 
lung that start long before the disease phenotype manifests and becomes clinically apparent. 
Despite different etiologies, chronic respiratory disorders typically involve inflammation-
induced macroscopic adaptations (i.e. airway remodeling, cellular infiltrations) and - more 
importantly - complex changes in the lung microenvironment including substantially altered 
immune cell function, regulatory networks and composition of soluble mediators. Details of 
the physiological implications of these alterations for immune regulation and host defense 
are still not fully understood. 
The following introductory chapters deal with principles of pulmonary immunity, with a focus 
on airway epithelial cells and alveolar macrophages, chronic respiratory disease, as well as 
the respiratory pathogen Streptococcus pneumoniae and pneumococcal pneumonia. 
 
2.1 Structure of the respiratory tract 
The human respiratory tract comprises a surface area of approximately 70m2 and utilizes a 
versatile set of physical (cough, cilial beating), chemical (mucus, antimicrobial molecules) 
and cellular (phagocytes) mechanisms to maintain homeostasis (Holt et al. 2008). Basically, 
the airway anatomic compartment can be subdivided into the upper respiratory tract 
(nasopharynx down to larynx) and the lower respiratory tract (from the portion of the larynx 
below the voice box down to the alveoli). The nasopharynx represents the first line of 
defense by working as a size-exclusion mechanism against penetration of airborne antigens 
bigger than 2-3µm into the lower respiratory tract. Moreover, mucus secretion as well cilial 
beating by distinct epithelial cell types that line the upper and lower (excluding alveoli) 
respiratory tract constantly mediates the transport of particles from the terminal bronchioles 
back to the trachea, this cooperative mechanism is known as ‘mucociliary clearance’. Yet, in 
some chronic respiratory diseases this instrument is defective due to structural modifications 
of epithelial cells (chronic bronchitis) or an altered composition of the mucus (cystic fibrosis; 
Nicod 1999). 
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In addition, airway mucosal DCs (AMDCs) that reside within and beneath the epithelial layer 
sample airborne antigen and can initiate the onset of an adaptive immune response in the 
local draining lymph nodes. Moreover, the submucosal space of the conducting airways 
harbors macrophages, T cells and plasma cells (mainly producing dimeric IgA; Holt, 
Strickland et al. 2008, Figure 1). 
 
Figure 1: Structure and cellular composition of the lower respiratory tract. 
Inhaled air passes through trachea, bronchi, alveolar ducts (bronchioles) into alveoli. Each compartment of the 
lower respiratory tract is lined with ciliated and/or secretory epithelial cell types. Local antigen is sampled by 
alveolar macrophages and/or dendritic cells (DCs, see a and b). Antigen-bearing respiratory DCs migrate via 
afferent lymphatics (c) into the local draining lymph nodes and activate antigen-specific naive T cells which 
proliferate upon priming. Proliferated effector T cells migrate into the lung parenchyma (d) and spread 
systemically via efferent lymphatics (e). Figure taken from Holt, Strickland et al. 2008.  
 
 Epithelial cell types in the lower respiratory tract  2.1.1
The mucosal surface of the lower respiratory tract (from trachea down to the bronchioles) 
contains a pseudostratified epithelium dominated by ciliated cells and interspersed with 
submucosal glands (Figure 2). Basal cells which are located underneath the epithelial 
surface set up the progenitor pool for both ciliated and secretory cells which need to be 
reconstituted e.g. following lung injury. Besides ciliated cells a number of secretory cells 
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(serous, Clara, neuroendocrine and goblet cells) are found in the respiratory epithelium. The 
conducting airways and submucosal glands synthesize and secrete a plethora of molecules 
that unspecifically mediate aggregation, entrapment and killing of microbes (Whitsett et al. 
2015). Gas exchange takes place in the alveoli, where epithelial cells are in close proximity 
to the pulmonary capillaries. Only two epithelial cell types are found in the alveolus: 
squamous alveolar type I epithelial cells (ATI cells) cover approximately 90% of the alveolar 
surface in the human lung and closely interact with the endothelial cells during respiration. 
Cuboidal alveolar type II epithelial cells (ATII cells) are critically involved in surfactant 
homeostasis by producing surfactant proteins (SP-A, SP-B, SP-C and SP-D; Whitsett et al. 
2010). These proteins – together with surfactant lipids – are crucial for preserving surface 
tension and proper ventilation of the alveoli. Moreover, surfactant proteins A and D 
(collectins) have antimicrobial activity (Wright 2005). Importantly, ATII cells are self-renewing 
cells and serve as ATI-precursors (Barkauskas et al. 2013).  
Airway epithelial cells (AECs) form a tight barrier against exogenous substances and 
microorganisms by expressing intercellular connective proteins (claudins, connexins, 
paranexins, adhesions and zonula occludins) that deliver structural integrity to the respiratory 
mucosal barrier (Whitsett and Alenghat 2015). Disruption of tight junction protein complexes 
was shown to increase epithelial permeability (LaFemina et al. 2014) and inflammation 
(Georas et al. 2014, Grainge et al. 2013) thereby contributing to lung injury.  
 
 
Figure 2: Epithelial and macrophage immunological mechanisms in the lower respiratory tract. 
Airway epithelial cells (AECs) and alveolar macrophages (AMs) are exposed to allergens, pathogen-derived 
molecular patterns (PAMPs) and molecules derived from cell stress and/or death (danger-associated molecular 
patterns, DAMPs). These are continuously removed by mucociliary clearance and alveolar macrophage-
associated mechanisms, but are also recognized by pattern-recognition receptors (PRRs) expressed by AECs & 
AMs. Adapted from Whitsett and Alenghat 2015. 
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Their multifaceted roles as pulmonary gatekeepers make AECs critical elements of the 
respiratory innate immune system. Importantly, they also have been shown to participate in 
the initiation and regulation of adaptive immune responses. For instance, by nitric oxide (NO) 
production AECs can interfere with functional activation of Th1 and Th2 cells (Eriksson et al. 
2005) and by release of B-cell activating factor, they modulate airway B cell accumulation 
and/or activation (Kato et al. 2006). 
 
2.2 Mechanisms of respiratory humoral immunity  
 AEC-derived mediators 2.2.1
AECs secrete a plethora of soluble factors with broad direct and indirect antimicrobial 
functions and thereby actively reinforce the mucosal surface against bacterial, viral and 
fungal invaders. For example, by producing small cationic antimicrobial peptides of the β-
Defensin family AECs are believed to be involved in the clearance of pathogens (e.g. 
Haemophilus influenzae) from the lung (Moser et al. 2002) but also orchestrate 
chemoattraction of T cells, dendritic cells and macrophages (Beisswenger et al. 2005). 
Moreover, lysozyme, one of the most abundant antimicrobial proteins in the lung which is 
also secreted by AECs, was shown to critically enhance bacterial clearance in vivo after 
infection with Pseudomonas and Streptococcus species (Akinbi et al. 2000). Other AEC-
secreted substances directly or indirectly implicated in immunity towards infectious agents 
are mucins, surfactant proteins A and D (collectins), serum amyloid A, complement 
components and other antimicrobial peptides (e.g. cathelicidins, histatins, lactoferrin; Bals 
2000, Cleaver et al. 2014, Holt, Strickland et al. 2008, Strunk et al. 1988). Interestingly, 
epithelial antimicrobial production is regulated by exposure to inflammatory stimuli (e.g. 
pathogens, cytokines; Harder et al. 2000, O'Neil et al. 1999, Singh et al. 1998). 
 
 Secretory antibodies and AECs: cooperativity mediates protection 2.2.2
Similar to what has been reported for the gastro-intestinal and the genitourinary tract innate 
mucosal immunity in the respiratory tract critically depends on secretory immunoglobulins 
(SIgs). While submucosal plasma cells locally produce natural, mostly dimeric, IgA (Strugnell 
et al. 2010) it is still a matter of debate which B cell subsets contribute to local and systemic 
natural IgM levels (Ehrenstein et al. 2010). Both immunoglobulin subtypes are characterized 
by a common structure: the joining chain (J chain), which has an important role in the 
process of antibody transport onto the mucosal surface. 
By directed cooperation with the humoral immune system AECs provide broad, unspecific 
protection of the pulmonary mucosa against a multitude of respiratory pathogens. Upon 
binding of the J chain by the polymeric immunoglobulin receptor (pIgR), which is expressed 
by AECs, active endosome-mediated transcytosis of the pIgR-antibody complex through the 
epithelium is initiated. After proteolytic cleavage IgA and IgM are released into the pulmonary 
lumen, bound to a small pIgR-subunit, the secretory component (SC). 
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A considerable portion of SIgA is polyreactive, i.e. it binds a plethora of antigens such as 
commensal bacteria and autoantigens and is thus also known as ‘natural IgA’ (Shroff, Meslin 
et al. 1995, Bos, Jiang et al. 2001, Notkins 2004). By binding to microbial surfaces natural 
IgA, which is the predominant immunoglobulin found in mucosal secretions, sterically inhibits 
pathogen adhesion and invasion of epithelial cells – this mechanism is known as ‘immune 
exclusion’ (Strugnell and Wijburg 2010, Figure 3). Moreover, SIgA/pIgR complexes have 
functions in intracellular virus neutralization as well as antigen excretion from subepithelial 
compartments back to the mucosal lumen (Strugnell and Wijburg 2010).  
Furthermore, early control of infection is mediated by concerted actions of IgM and 
complement component C1q (Brown et al. 2002). These are constituents of the classical 
complement pathway which has previously been shown to be the dominant complement 
activation pathway required for antipneumococcal defense. Several in vivo studies evidence 
crucial roles for pIgR and SIgs in host immunity towards pathogenic bacteria and viruses 
(Blutt et al. 2012, Brown, Hussell et al. 2002, Sun et al. 2004, Tjarnlund et al. 2006). 
 
Figure 3: Principle of SIg transport in the lung. 
(1) Stimulation with endogenous or exogenous ligands activates pathways that trigger PIGR gene expression. (2) 
Newly synthesized pIgR molecules are transported to the basolateral site of airway epithelial cells. (3) Dimeric IgA 
(dIgA), locally produced by plasma cells, binds to pIgR and initiates transepithelial transport cascades. (4) dIgA-
coupled and unoccupied pIgR are transcytosed through epithelial cells. (5) Proteolytic cleavage of pIgR at the 
apical surface releases secretory IgA (SIgA) and secretory component (SC). (6) Binding of SIgA (and SC) to 
bacteria prevents their adhesion and invasion. The illustrated mechanism also applies to transepithelial transport 
of IgM onto the mucosal surface. Adapted from Johansen et al. 2011. 
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Identification of the factors that regulate pIgR-expression – and consequently the rate of 
mucosal SIg transcytosis - revealed a multitude of endogenous as well as exogenous 
modulators involved in this transport mechanism. These are summarized in Table 1.  
Table 1: Regulators of pIgR-expression. 
Adapted from Kaetzel 2005. 
Stimuli  Nature of regulation (↑up, ↓down), tissue 
Cytokines   
IFN-γ ↑ human intestinal epithelial cell line (Sollid et al. 1987) 
TNF-α ↑ mouse intestinal epithelium (Moon et al. 2014) 
IL-1β ↑ mouse intestinal epithelium (Moon, VanDussen et al. 
2014) 
IL-4 ↑ human intestinal epithelial line (Schjerven et al. 2000) 
IL-17 ↑ mouse intestinal & pulmonary epithelium (Jaffar et al. 
2009, Moon, VanDussen et al. 2014) 
TGFβ ↓ human lung epithelial cells (Gohy et al. 2014) 
Hormones   
Estradiol ↑ rat endometrium (Kaushic et al. 1995) 
Progesterone ↓ rat endometrium (Kaushic, Richardson et al. 1995) 
Glucocorticoids ↑ 
↓ 
rat intestinal epithelial cell line, rat intestine (Li et al. 1999) 
rabbit mammary gland (Rosato et al. 1995) 
Prolactin ↑ rabbit mammary gland (Rosato, Jammes et al. 1995) 
Dietary factors   
Retinoic acid  ↑ human intestinal epithelial cell line, in concert with IL-4, 
IFN-γ, TNF-α (Sarkar et al. 1998) 
Microbial factors   
Butyrate ↑ human intestinal epithelial cell line (Kvale et al. 1995) 
LPS ↑ mouse intestinal epithelium (Moon, VanDussen et al. 
2014) 
B. thetaiotaomicron ↑ intestinal epithelium (during colonization of germ-free 
mice) (Hooper et al. 2001) 
dsRNA ↑ human intestinal epithelial cell line (Schneeman et al. 
2005) 
Reovirus ↑ human intestinal epithelial cell line (Pal et al. 2005) 
S. boulardii ↑ rat intestinal epithelium (Buts et al. 1990) 
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2.3 Chronic respiratory disease (CRD) 
The term chronic respiratory diseases (CRDs) comprises a series of non-communicable lung 
disorders with different etiopathologies and clinical pictures. Being the most prevalent CRDs 
with globally increasing incidence (Mannino et al. 2007, Pearce et al. 2007), asthma and 
COPD are addressed in this paragraph.  
Both diseases generally manifest in airway obstruction, yet this process is reversible in 
asthma while found to be progressive and mostly irreversible in COPD (Barnes 2008). 
The majority of asthmatic patients are diagnosed with atopy, i.e. the presence of 
immunological hypersensitivity towards environmental antigens such as pollen or animal 
danders (Barnes 2008). In contrast, the predominant cause for COPD pathogenesis is 
exposure to noxious substances such as tobacco smoke and the associated direct as well as 
indirect inflammatory cascades triggered by these particles (Brusselle et al. 2011). 
Interestingly, COPD is also discussed to involve an autoimmune etiology (Agusti et al. 2003). 
Both diseases are characterized by lung inflammation, which can massively increase during 
phases of acute exacerbation. While inflammatory processes in asthma mostly occur in the 
large conducting airways (bronchi), COPD manifests in small airway and parenchymal 
inflammation (Barnes 2000, Jeffery 2000). The immunological mechanisms orchestrating 
both diseases are partly mirrored in their histopathologic appearances. Bronchial biopsies 
taken from asthmatic individuals show eosinophilic infiltration, activated mucosal mast cells 
and T cells. Moreover, basement-membrane thickening (subepithelial collagen deposition) is 
a characteristic hallmark of this disease (Benayoun et al. 2003). In COPD lungs increased 
infiltrations of T cells and neutrophils are observed (Hogg 2004). In large contrast to 
asthmatic lungs emphysema (a major cause for airflow limitation) - as a result of enhanced 
proteolytic degradation of alveolar wall components - is a salient feature of COPD pathology 
(Ohnishi et al. 1998). 
The clinical symptoms associated with asthma as well as COPD significantly deteriorate 
during acute exacerbations; the latter are a major cause for severe disease complications 
and hospitalization (Celli et al. 2007, Wark et al. 2006). Infections with airborne pathogens 
pose a huge risk for acute asthma and COPD disease exacerbations. While viral pathogens 
(e.g. rhinoviruses) usually trigger asthma deterioration, viruses as well as bacteria (e.g. 
Haemophilus species, Streptococcus pneumoniae) are found in exacerbating COPD patients 
(Barnes 2008. Sethi et al. 2008). In both CRDs exacerbations are intimately linked to 
increased lung inflammation, increased leukocyte infiltration and higher amounts of pro-
inflammatory molecules compared to those conditions found in the steady state (Barnes 
2008).  
 
2.4 Streptococcus pneumoniae and pneumococcal pneumonia 
The Gram-positive, lancet-shaped bacterium Streptococcus pneumoniae (also referred to as 
‘the pneumococcus’) belongs to the group of α-streptococci. It is an encapsulated 
diplococcus which grows in pairs or chains and is a facultative anaerobic microorganism. 
Pneumococci are the most prevalent bacterial respiratory pathogens worldwide and etiologic 
agents of sepsis, bacterial meningitis, otitis media and pneumonia (van der Poll et al. 2009). 
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They frequently colonize the upper respiratory tract where they reside asymptomatically on 
the nasopharyngeal epithelium, however – depending on predisposing factors on the host 
site and bacterial virulence factors – bacterial microaspiration into the lower airways can 
proceed into pneumonia and eventually into invasive pneumococcal disease (IPD). 
Pneumococcal disease incidence is particularly high in infants, the elderly and patients who 
have immunodeficiencies or undergo immunosuppressive therapies, respectively. In this 
regard, complications of respiratory pneumococcal infections are frequently found in 
individuals with pre-existing impaired pulmonary conditions, such as antecedent influenza 
virus infection or chronic lung disease (van der Poll and Opal 2009).  
 Pneumococcal virulence factors 2.4.1
Pneumococcal virulence greatly varies among the 93 known serotypes (Calix et al. 2010). 
Here the composition and thickness of the polysaccharide capsule is a major determinant 
(Figure 4), as this constituent prevents entrapment in the mucus layer and neutrophil 
extracellular traps (NETs) and counteracts opsonophagocytosis (Hyams et al. 2010, Nelson 
et al. 2007, Wartha et al. 2007). Moreover, most pneumococcal strains display a remarkable 
plasticity: via phase variation they are able to modify their capsular composition (opaque vs. 
transparent colony morphology) which allows for the rapid adaptation in response to 
environmental cues present in the particular host tissue (van der Poll and Opal 2009).  
The pneumococcal exotoxin pneumolysin (Figure 4), a cholesterol-dependent cytolysin that 
effects pore formation in cholesterol-containing membranes and thus host cell lysis, is found 
in almost all invasive pneumococcal isolates (van der Poll and Opal 2009). Reported 
activities of this constituent include inhibition of cilial beating on respiratory epithelial cells 
(Feldman et al. 1990), disruption of tight junctions of the epithelial layer (Rayner et al. 1995), 
inhibition of phagocyte respiratory burst (Paton et al. 1983) as well as induction of cytokine 
synthesis (Cockeran et al. 2002). Accumulating evidence suggests a pivotal role for 
pneumolysin in the development of pneumonia as well as IPD (Kadioglu et al. 2008). 
Interestingly, a recent in vivo study identified pneumolysin to induce AEC apoptosis and to 
block release of antifibrogenic prostaglandin E2 thereby causing disease progression in a 
model of lung fibrosis exacerbation. With fibrosis being a chronic respiratory disease, this 
mechanism highlights the importance of pneumococcal infection as comorbidity of individuals 
with underlying chronic pulmonary conditions (Knippenberg et al. 2015). 
In addition, a number of pathogenicity factors, that mediate bacterial adhesion to epithelial or 
extracellular matrix components, have been identified, such as ChoP, CbpA or PavA 
(Kadioglu, Weiser et al. 2008, Figure 4). Effective evasion of host humoral immunity is also 
mediated by PspA, which prevents binding of complement component C3 onto the bacterial 
surface but also protects pneumococci from the antimicrobial activities of lactoferrin (Shaper 
et al. 2004, Tu et al. 1999). In addition to these factors, secretion of a zinc metalloproteinase 
cleaving human IgA1 (which accounts for 90% of the IgA in the human airways) is 
considered to be a factor counteracting humoral immunity (Kadioglu, Weiser et al. 2008, 
Figure 4). However, given the predominant function of IgA as mediator of immune exclusion 
it remains a matter of debate whether the residual cleaved Fab fragments on the bacterial 
surface might be similarly potent in preventing attachment of pneumococci to the mucosal 
surface.  
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Pneumococcal virulence and survival critically depends of nutrient availability. Consequently 
several bacterial virulence factors associated with microelement supply have evolved. For 
example, pneumococcal iron acquisition and uptake are mediated by PiaA and PiuA systems 
(Kadioglu, Weiser et al. 2008). Moreover, structural analyses of the lipoprotein PsaA 
revealed a divalent metal-ion-binding site that can bind zinc or manganese ions, and PsaA 
mutants were shown to require manganese supplementation (Dintilhac et al. 1997, Lawrence 
et al. 1998, Figure 4). 
 
Figure 4: Virulence factors of Streptococcus pneumoniae.  
PsaA=pneumocoocal surface antigenA. PiaA/PiuA=pneumocoocal iron acquisition and uptake. PsrP= 
pneumocoocal serine-rich repeat protein. NanA=neuraminidase. Eno=enolase. PavA=pneumocoocal adhesion 
and virulence. LytA=autolysin. StrA=sortase A. Hyl=hyluronate lyase. LTA=lipoteichoic acid. PspC= 
pneumococcal surface protein C. PspA=pneumocoocal surface protein A. Cps=polysaccharide capsule. 
Figure taken from van der Poll and Opal 2009. 
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 Role of pattern recognition for host defense against Streptococcus 2.4.2
pneumoniae 
The presence of receptors recognizing conserved pathogen-associated molecular patterns 
(PAMPs) is a central element in rapid host immunity towards S. pneumoniae and other 
pathogens. Pattern recognition receptors on alveolar macrophages (AMs) and AECs which 
are important for antibacterial defense include Toll-like receptors (TLRs) and NOD-like 
receptors (NODs). In addition to lipopolysaccharide (LPS) TLR4 recognizes pneumolysin 
(Malley et al. 2003). Moreover, heterodimerization of TLR2 with either TLR1 or TLR6 enables 
recognition of a broad range of bacterial lipopeptides and lipoteichoic acid. The intracellular 
receptor TLR9 recognizes unmethylated CpG dinucleotides, mainly present in prokaryotic 
DNA. While the loss of TLR1, TLR2, TLR4 and TLR6 has been shown to only marginally 
affect susceptibility during infection with Streptococcus pneumoniae, TLR9 was reported to 
have a crucial role in antipneumococcal host defense in the lower respiratory tract; mainly by 
governing MyD88-dependent phagocytosis and intracellular killing by AMs (Albiger et al. 
2007). In this regard the adaptor molecule MyD88 (myeloid differentiation factor 88), which 
signals downstream of all TLR pathways (except TLR3), was previously shown to be crucial 
for antipneumococcal host defense (Albiger et al. 2005). In addition to TLR-dependent 
mechanisms intracellular sensing of S. pneumoniae is achieved by NOD-like receptors. Here 
NOD2, recognizing a conserved bacterial muramyldipeptide, was shown to be activated 
during pneumococcal infection and identified to be critical for NF-ĸB activation by S. 
pneumoniae (Opitz et al. 2004). 
In addition to a versatile TLR repertoire AMs possess scavenger receptors, such as MARCO 
and CD36, which initiate phagocytic uptake of unopsonized particles. Both of these 
molecules were shown to be critical for innate host defense during pneumococcal pneumonia 
(Arredouani et al. 2004, Sharif et al. 2013, Figure 5).  
Upon PRR-mediated sensing of bacterial, viral or fungal pathogens AMs as well as AECs 
secrete a wide range of pro-inflammatory cytokines and chemokines in an IRF- or NF-ĸB-
dependent manner (Figure 5). By cell-specific interruption of NF-ĸB signaling it was 
demonstrated that AECs are predominant producers of CXCL5, GM-CSF and CCL20 
whereas the lung net TNF-α, IL-1α, IL1-β, CXCL1 and CXCL2 response during early 
pneumococcal pneumonia is shaped by AMs (Pittet et al. 2011, Yamamoto et al. 2014). Here 
TNF-α is of particular interest as absence of this cytokine is linked to increased susceptibility 
to bacterial infection (Laichalk et al. 1996, van der Poll, Keogh, Buurman, et al. 1997). 
Actions of TNF-α include regulation of neutrophil-attracting chemokines, expression of 
neutrophil-endothelial cell-adhesion molecules but also directly increase of activity of 
phagocytic cells (Fan et al. 1991, Mukhopadhyay et al. 2006, Tessier et al. 1997). Moreover, 
AECs as well as AMs can produce IL-6 in response to microbial ligands and this cytokine is 
suspected to orchestrate activation of vital agonist as well antagonist mediators during 
bacterial pneumonia (van der Poll, Keogh, Guirao, et al. 1997). 
An important hallmark of pulmonary bacterial infection is neutrophil extravasation into the 
lung (Figure 5). This is generally a result of a lung-blood chemokine gradient and several 
ligand-receptor interactions between activated neutrophils, endothelial and epithelial cells. 
CXCL1, CXCL2 and CXCL5, belonging to the ELR+ CXC-chemokine family and ligands of 
CXCR2 on the neutrophil surface, have been described to substantially contribute to 
neutrophil mobilization into the airways during early pneumonia (Gibbs et al. 2014, Mehrad et 
al. 1999, Strieter et al. 2002). 
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Figure 5: Host defense during pneumococcal pneumonia.  
Pneumococci that enter the lower airways are recognized by pattern recognition receptors: TLRs on AECs and 
alveolar macrophages (AM) and AM-receptors, such as macrophage receptor with collagenous structure 
(MARCO). At low infectious doses AECs and AM clear infection without help from recruited neutrophils (PMNs), 
by release of pro-inflammatory cytokines, complement products (C’), tissue factor (TF), antimicrobial peptides 
(AMPs) and surfactant protein-D (SP-D). At high infectious doses PMN recruitment through endothelial layers is 
mediated by C’5a, neutrophil-attracting chemokines, galectin-3, pneumolysin (Ply) and pneumococcal-derived N-
formyl-methionyl-leucyl-phenylalanine (fMLP). PAFR=platelet-activating factor receptor. Adapted from van der 
Poll and Opal 2009. 
 
2.5 Macrophage phenotypes and functions 
Besides their pivotal roles in mediating antimicrobial innate host defense, macrophages 
orchestrate pleiotropic physiological reactions involved in homeostasis, inflammation, 
metabolism and tissue remodeling. Consequently, a salient hallmark of the macrophage 
lineage is their great diversity and plasticity, enabling these cells to rapidly and dynamically 
adapt in response to a plethora of environmental signals in the respective tissue (Figure 6).  
In analogy to the Th1/Th2 dichotomy, which is applied for T lymphocytes, rough classification 
into M1/M2 phenotypes is also common for the macrophage lineage. However, Mosser and 
Edwards proposed a nomenclature, in which macrophages are classified by their pre-
dominant functions in the maintenance of homeostasis: host defense, wound healing and 
immune regulation (Mosser et al. 2008).  
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Figure 6: Macrophage polarization in pathology.  
Dynamic changes of macrophage polarization patterns may occur during evolution of pathology, e.g. during 
transition from acute to chronic infection. Mixed phenotypes can however coexist. Figure taken from Sica et al. 
2012. 
 
Classically activated (M1) macrophages are characterized by high expression of pro-
inflammatory cytokines (e.g. IL-12, IL-23 IL-1β and TNF-α), high production of reactive 
nitrogen and oxygen species, promotion of Th1/Th17 responses and powerful antimicrobial 
and anti-tumorigenic activities. M1 polarization occurs in response to LPS, TNF-α or IFN-γ, 
and results in enhanced antigen-presenting and phagocytic capacity, enhanced production of 
matrix metalloproteinases (MMPs) 7 and 9 and up-regulation of the transcription factor IRF5 
(Boorsma et al. 2013, Mosser and Edwards 2008).  
Alternatively activated (M2) macrophages are induced by IL-4 and IL-13, under the influence 
of the transcription factor IRF4, and produce the anti-inflammatory cytokine IL-10. Moreover, 
typical genes associated with M2-polarization are resistin-like alpha (Retlna, Fizz1) and 
chitinase-like 3 protein (Chi3l3, Ym1). M2 macrophages participate in anti-helminth immunity, 
wound healing and tumor progression. They are characterized by efficient phagocytic 
activity, high expression of scavenger, mannose and galactose receptors and the production 
of ornithine and polyamine through the arginase pathway (Boorsma, Draijer et al. 2013, 
Mosser and Edwards 2008, Sica and Mantovani 2012). Of note, macrophage polarization 
was shown to be associated with different iron recycling capabilities of M1 vs. M2 cells. In 
this regard, M2 cells were demonstrated to have an iron-deficient phenotype, including a 
Introduction 
23 
 
large, yet labile, intracellular iron pool, spontaneous iron release and limited storage capacity 
(Corna et al. 2010).  
A third macrophage subgroup is termed M2-like or also ‘regulatory’ macrophages. This group 
shares some features with M2 macrophages (e.g. high expression of mannose and 
scavenger receptors) but has a distinct chemokine profile. Activating stimuli include IL-10, 
TGFβ, antibody immune complexes, apoptotic cells glucocorticoids and PGE2. Yet, these 
stimuli have to be associated with a second (stronger) stimulus, such as TLR ligation, to 
induce IL-10 production. Transcriptional regulation of this subset is believed to involve the 
nuclear receptor PPARγ (Lawrence et al. 2011). Unlike M2 macrophages, regulatory 
macrophages are not involved in extracellular matrix repair, and can express high levels of 
the co-stimulatory molecules CD80 and CD86 (Boorsma, Draijer et al. 2013, Mosser and 
Edwards 2008, Figure 7).  
 
Figure 7: Macrophage subsets and their characteristics.  
TGM2=transglutaminase 2; YM1=chitinase-like protein-3; FIZZ1/Retlna=resistin-like alpha; Arg-1=arginase-1; 
PGE2=prostaglandin E2; PPRγ=peroxisome proliferator-activated receptor gamma (also: PPARγ). Adapted from 
Boorsma, Draijer et al. 2013. 
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2.6 Pleiotropic roles of alveolar macrophages in homeostasis and 
disease 
Alveolar macrophages (AMs) are the most abundant cells in the airways; they constitute up 
to 95% of the leukocyte populations recovered by bronchoalveolar lavage (Holt 1986). 
Alveolar macrophages are derived from a fetal monocyte population that colonizes the 
airways during the first days after birth (Guilliams et al. 2013). Interestingly, it was previously 
shown that alveolar macrophages have a remarkable capacity for self-renewal and that this 
is the predominant mechanism by which replenishment of this population is achieved during 
homeostasis and following influenza-induced depletion (Hashimoto et al. 2013). Moreover, 
alveolar macrophages are long-lived cells, with a turnover rate of only 40% in 1 year (Maus 
et al. 2006). 
Most studies do not distinguish between airway macrophages that reside in the mucus layer 
of the bronchus and the bronchioles and those located in the alveoli (Figure 8). Due to the 
experimental procedure (bronchoalveolar lavage) required for isolation of airway 
macrophages, a mixture of these cells is obtained and unique markers classifying either one 
or the other cell type are not known thus querying the existence of distinct populations 
(Hussell et al. 2014). In accordance with other in vivo studies the airway macrophages 
analyzed in this study are also referred to as ‘alveolar macrophages (AMs)’. 
 
 Role of the AM/T cell axis in pulmonary immunity 2.6.1
T cell-mediated pulmonary immunity is a double-edged sword as it is known to be vital for the 
clearance of inhaled pathogen. At the same time, excessive, uncontrolled T cell responses 
are implicated in various disease settings, such as asthma and autoimmune disorders 
(Ohashi 2002, Robinson 2010). The suppression of T cell responses is therefore a key 
element of pulmonary immune regulation.  
Human and rodent alveolar macrophages were shown to actively suppress T cell 
proliferation. One molecule likely to be involved in this process is nitric oxide (NO). This 
molecule was demonstrated to be constitutively expressed in rat AMs and it regulates T cell 
activation by interfering with the Jak3/STAT5 signaling pathway (Bingisser et al. 1998). 
Moreover, AMs can secrete PGE2 (Roth et al. 1993). PGE2 induces among others 
differentiation of Foxp3+ T cells, inhibits T cell proliferation and induces T cell anergy.  
In addition, AM-derived retinoic acid and TGFβ1 were shown to play a role in the conversion 
of naive CD4+ T cells into IL-10 secreting Foxp3+ T cells (Coleman et al. 2013), although 
lung-resident tissue macrophages can secrete these molecules, too (Soroosh et al. 2013). 
Similar to PGE2 TGFβ1 is known to suppress T lymphocyte activation (Roth and Golub 1993, 
Figure 9). 
Murine AMs are poor antigen-presenting cells (Lipscomb et al. 1986, Lyons et al. 1986, 
Toews et al. 1984), yet they are capable of transporting antigen to the lung–draining lymph 
nodes (Kirby et al. 2009). AMs from humans are believed to promote T cell anergy as a 
consequence of reduced antigen-presenting capacity and a lack of expression of the co-
stimulatory molecule CD86 (Blumenthal et al. 2001). 
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Figure 8: Cellular interactions in the lung.  
Alveolar macrophages reside in the alveoli, next to alveolar type I and II epithelial cells. Macrophages in the large 
and small airways are in contact with the mucus layer (produced by goblet cells in the bronchi & bronchioles) and 
secretory Clara cells (mostly in bronchioles, nowadays referred to as ‘club cells’). Commensal (and pathogenic) 
bacteria can be found in all compartments. Alveolar macrophages can induce forkhead box P3 (FOXP3) 
expression in naive and activated CD4
+
 T cells via secretion of TGFβ and retinoic acid. Moreover, TGFβ and 
prostaglandins suppress T cell activation. Adapted from Hussell and Bell 2014. 
 
 Role of the AM/AEC axis in pulmonary immunity 2.6.2
Considering the fact that AECs and AMs are directly juxtaposed, it is not surprising that a 
number of AM/AEC communication strategies have so far been discovered. Nevertheless, 
while the role of the AECs as regulators of AM activation (e.g. via SP-A, TGFβ, CD200, IL-
10) is widely appreciated (Hussell and Bell 2014), little knowledge exists about the reverse 
communication.  
It was previously demonstrated that AM-derived pro-inflammatory cytokines (e.g. TNF-α) can 
activate alveolar epithelial and endothelial signaling cascades, which consequently facilitates 
neutrophil extravasation into the airspaces (Kuebler et al. 2000). Moreover, AM-released 
mediators (HB-EGF and PDGF-, IGF-1 and FGF-1-like molecules) were shown to exert 
stimulatory effects on AEC proliferation (Leslie et al. 1997, Melloni et al. 1996). To date, only 
a few studies however have addressed the immunosuppressive potential of AMs on AECs. 
Being dedicated pulmonary scavengers, AMs indirectly exhibit immunosuppressive functions 
by the overall reduction of microbial factors, allergens, cellular debris and apoptotic cells, 
thus antagonizing the initiation of a pro-inflammatory immune response by AECs (Figure 2). 
In this regard, AMs were shown to have an essential anti-inflammatory role during murine 
pneumococcal pneumonia, possibly by engulfment of apoptotic neutrophils (Knapp et al. 
2003).  
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A recent report identified connexin43 (a protein involved in gap junction channel formation) 
on ATII cells and AMs to be a critical element responsible for down-regulating LPS–induced 
secretion of epithelial-specific (CXCL5) as well as AM-specific (MIP1-α) pro-inflammatory 
mediators. This study suggested alveolus-attached AMs to intercommunicate 
immunosuppressive signals to the epithelium, thereby reducing PAMP–induced pulmonary 
inflammation orchestrated by both cellular players (Westphalen et al. 2014). 
Moreover, Bourdonnay and colleagues demonstrated that AM-derived suppressor of cytokine 
signaling (SOCS) proteins 1 and 3, which are transcellularly delivered to AECs via exosomes 
and microparticles, inhibit STAT1 and STAT3 activation and thus interfere with pro-
inflammatory signaling pathways in these cells (Bourdonnay et al. 2015). 
 
 Role of AMs in termination and resolution of inflammation  2.6.3
Manifold physiological processes are involved in the termination of inflammation and re-
establishment of tissue homeostasis in the lung. These include among others inhibition of 
intra-alveolar leukocyte influx, phagocytosis of apoptotic PMNs and initiation of alveolar 
repair mechanisms (Figure 9). Accumulating evidence suggests crucial roles for AMs in 
these mechanisms. 
 
Figure 9: Alveolar macrophage-orchestrated processes for termination and resolution of alveolar 
inflammation.  
Figure taken from Herold, Mayer, et al. 2011. 
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AMs produce e.g. a series of lipid-related mediators (Balter et al. 1988, Beck-Speier et al. 
2005), which participate in the resolution of inflammation in the lungs by directly interfering 
with neutrophil functions. For example, the prostaglandins PGE2 and PGD2, which are 
synthesized in a cyclooxygenase-dependent manner, promote in an auto- and paracrine 
fashion the synthesis of lipoxins by AMs but also other leukocytes. Lipoxins are 
lipoxygenase-derived double oxygenated eicosanoids, ultimately inhibiting recruitment of 
neutrophils as well as their pro-inflammatory functions at sites of inflammation (Chiang et al. 
2006). Interestingly, cyclooxygenases and lipoxygenases are prominent pharmaceutical 
targets enabling to interfere with inflammatory immune responses. Other examples of pro-
resolving lipid mediators are resolvins, protectins and maresin1, derived from omega-3 
polyunsaturated fatty acid, eicosapentaenoic acid and docosahexaenoic acid, respectively. 
Resolvin E1 attenuates NF-ĸB activation (Arita et al. 2005) and antagonizes the pro-
inflammatory leukotriene B4 receptor BLT1 on leukocytes, thereby exerting anti-inflammatory 
functions, e.g. by dampening neutrophil migratory capacities (Arita et al. 2007). Moreover, 
the molecule macrophage mediator in resolving inflammation 1 (maresin1) was also found to 
antagonize pathologic neutrophil functions by promoting their apoptosis in a caspase-
dependent fashion (Gong et al. 2015).  
Another strategy by which macrophages can antagonize immunopathology is the 
interference with key elements of epithelial and endothelial leukocyte recruitment cascades. 
For instance, via the blockade of the IL-1β signaling pathway on alveolar epithelial cells, 
downregulation of CXCL2 secretion and ICAM-1 expression pathologic intra-alveolar 
neutrophil influx and subsequent lung pathology was shown to be down-regulated during 
acute lung inflammation (Herold, Tabar, et al. 2011). In this regard, by using a model of LPS-
induced lung injury Dean and colleagues demonstrated that MMP-12, a known product of 
macrophages, is able to cleave CXC-chemokines at the ELR motif, thus inhibiting binding of 
these mediators to their respective receptors and interfering with e.g. neutrophil chemotaxis 
(Dean et al. 2008).  
A number of molecules, produced by wound-healing macrophage subsets, are implicated in 
the reestablishment of the epithelial and endothelial barrier function. Tissue repair and 
proliferation mechanisms are promoted by macrophage-derived fibronectin 1, TGFβ-induced 
matrix associated protein and insulin-like growth factor 1 (Herold, Mayer et al. 2011). In 
addition, it was demonstrated that AMs release the epithelial growth factors platelet-derived 
growth factor, fibroblast growth factors, heparin-binding EGF-like growth factor, TGFβ and 
vascular endothelial growth factor (Granata et al. 2010, Leslie, McCormick-Shannon et al. 
1997, Medeiros et al. 2009, Melloni, Lesur et al. 1996). Moreover, ATII express CD74, which 
upon interaction with macrophage migration inhibitory factor (MIF) is involved in MIF-induced 
ATII–proliferation (Marsh et al. 2009). Besides, macrophage-derived growth factors might be 
involved in the reinforcing tight junctions in airway epithelial monolayers (Terakado et al. 
2011). Lastly, uptake of apoptotic cells by macrophages effects secretion of vascular 
endothelial growth factor (VEGF) and macrophage-derived VEGF is believed to be involved 
in regulation of the endothelial barrier after lung injury (Golpon et al. 2004, Granata, Frattini 
et al. 2010).  
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2.7 Macrophage phenotypes in COPD 
Exposure to smoke or other noxious particles and the resulting pulmonary inflammation are 
the main risk factors in people susceptible for the development of COPD. Alveolar wall 
destruction (emphysema), which is one hallmark of this disease, is thought to be a product of 
inflammatory macrophage and neutrophil recruitment, which ends up in the release of 
elastolytic enzymes (e.g. MMPs or neutrophil elastase; Brusselle, Joos et al. 2011). 
Concordantly, increased numbers of inflammatory macrophages and neutrophils are found in 
airways and/or lung parenchyma of COPD patients (Finkelstein et al. 1995, Lacoste et al. 
1993). The role of AMs in this context becomes evident by AM-depletion e.g. in rodent 
models of cigarette-smoke or elastase-induced emphysema. Here, a superior role of AMs in 
perpetuating lung pathology was demonstrated (Ofulue et al. 1999, Ueno et al. 2015).  
There are several lines of evidence describing the involvement of both M1 and M2 alveolar 
macrophages in COPD pathogenesis. 
Increased iNOS (an inducible isoform of nitric oxide synthase; associated with M1 
macrophages) expression in AMs was found in COPD patients (Ichinose et al. 2000). 
Expression of these molecules generates reactive oxygen species (ROS) and nitric oxide 
(NO); both being effectors of oxidative stress, which participates in COPD pathogenesis (Ito 
et al. 2009). Moreover, cytotoxic CD8+ T cells (Tc1 cells) that infiltrate the lungs in COPD are 
important producers of IFN-γ, an M1-polarizing cytokine (O'Shaughnessy et al. 1997, Saetta 
et al. 1999). Accordingly, constitutive pulmonary IFN-γ expression in mice is associated with 
emphysema (Wang et al. 2000). Breakdown of extracellular matrix in COPD is thought to 
involve MMPs and pulmonary macrophages from COPD patients produce higher amounts of 
the M1-marker MMP-9 (Russell et al. 2002). 
In contrast, the matrix metalloprotease MMP-12 which also induces emphysema in mice 
(Hautamaki et al. 1997) is a hallmark of M2-polarized macrophages (Kahnert et al. 2006). 
MMP-12 is used as a marker for alternative activation of alveolar macrophages in smokers 
(Woodruff et al. 2005). However, given the anti-inflammatory role of MMP-12 (i.e. 
antagonizing neutrophil chemoattraction, see section 2.6.3) its general role in COPD 
pathogenesis is so far not fully understood. M2 macrophages in mice were also found to 
secrete chitinase and chitinase-like proteins such as Ym1 (also known as chitinase-like 3 or 
CHI3L3) and Ym2 (chitinase-like 4), which can bind to extracellular matrix structures and are 
associated with matrix reorganization and wound healing (Lee et al. 2011, Mosser and 
Edwards 2008). Expression of Ym1 and Ym2 in M2 alveolar macrophages is interesting in 
view of the fact that elevated chitinase levels and chitinase-positive macrophages are also 
found in BAL from smokers with COPD (Letuve et al. 2008) thereby linking the M2 
macrophage subset to COPD. 
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2.8 The SPC-HAxTCR-HA mouse model for CRD 
In order to dissect the impact of chronic respiratory disease and the associated 
microenvironmental and cellular adaptations on different aspects of pulmonary immunity the 
SPC-HAxTCR-HA mouse model was previously established in our lab (Bruder et al. 2004). 
SPC-HA mice express a model antigen (the influenza/A/PR8/34 hemagglutinin; HA) under 
the control of the surfactant protein C (SP-C) promotor, which is exclusively active in alveolar 
type II epithelial cells (ATII). Breeding of SPC-HA mice with T cell receptor (TCR) transgenic 
(6.5) mice expressing a major histocompatibility complex (MHC) class II-restricted HA-
specific TCR (Kirberg et al. 1994) generates double transgenic SPC-HAxTCR-HA mice. In 
newborn SPC-HAxTCR-HA mice recognition of alveolar self-antigen by self-antigen specific 
T cells effects the development of severe CD4+ T cell-mediated lung inflammation (Bruder, 
Westendorf et al. 2004). In histopathologic analyses these lungs display massive multifocal 
interstitial, perivascular and peribronchial lymphocytic and plasmacytic infiltrations. Moreover, 
the destruction of alveolar architecture (emphysema) as well as hemosiderosis are two 
hallmarks found to be associated with lung disease in the SPC-HAxTCR-HA model. Despite 
the rapid and massive onset of CD4+ mediated immunepathology in neonates, lung disease 
does not proceed into fatal tissue destruction or death in older mice. In this regard several 
immunologic mechanisms leading to self-tolerance and thus the establishment chronic, yet 
controlled, lung disease in adult SPC-HAxTCR-HA mice have previously been identified. 
These include T cell anergy, associated with decreased pro-inflammatory cytokine response 
of self-specific CD4+ T cells and reduced proliferative capacity (Bruder, Westendorf et al. 
2004). Moreover, the conversion of naive CD4+ T cells into Foxp3+ regulatory T cells (Tregs) 
by means of ATII-derived TGFβ was demonstrated to be another immunoregulatory element 
in lungs of adult SPC-HAxTCR-HA mice (Gereke et al. 2009). 
 
 
Figure 10: Scheme of the double transgenic SPC-HAxTCR-HA mouse model. 
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3  Aim of the study 
In the context of this work two aspects were addressed.  
In the first part mechanisms underlying altered pulmonary immunity against respiratory tract 
infections in hosts with chronic respiratory disease (CRD) were to be elucidated. To this end 
SPC-HAxTCR-HA mice, intrinsically developing autoimmune-mediated lung inflammation, 
were utilized in a bacterial infection model using the common respiratory pathogen 
Streptococcus pneumoniae. In order to identify possible cellular pathways and molecules 
involved in altered antipneumococcal defense, comparative transcriptomic, proteomic and 
histological analyses of healthy SPC-HA and pre-diseased SPC-HAxTCR-HA lungs were to 
be performed. The protective capacities of lung-resident cells (alveolar macrophages, airway 
epithelial cells) as well as humoral mediators in SPC-HA and SPC-HAxTCR-HA mice were to 
be compared between both mouse groups.  
The second part of this work focused on the immunoregulatory roles of alveolar 
macrophages (AMs) in CRD. The latter has previously been described to involve complex 
immune responses of alveolar epithelial as well as T effector cells. Yet knowledge on the role 
of AMs, which are in intimate contact with both cell types, is so far incomplete. Therefore, the 
phenotype and function of AMs in CRD was to be elucidated using the SPC-HAxTCR-HA 
mouse model. In order to determine the impact of chronic inflammatory priming on the AM 
phenotype, comparative morphologic, transcriptional and functional analyses were to be 
performed. Moreover, the in vivo role of AMs in healthy SPC-HA and pre-diseased SPC-
HAxTCR-HA mice was to be assessed using depletion experiments. In order to estimate the 
immunologic function of AMs in chronic respiratory disease, the autoreactive T cell 
phenotype as well as alveolar epithelial phenotype was to be compared in AM-depleted and 
AM-sufficient SPC-HA and SPC-HAxTCR-HA mice.  
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4  Materials and Methods 
4.1 Materials 
 Buffers, solutions and media 4.1.1
ACK buffer 
0.15mM NH4Cl, 1mM KHCO3, 0.1mM EDTA pH8.0, pH 7.2 - 7.4 
 
Blocking buffer 
5% nonfat dry milk in Blotting buffer, pH 7.4 
 
Blotting buffer 
25mM Tris pH 7.4, 150 mM NaCl, 0.1% (v/v) Tween-20 
 
ELISA (SIgA) assay diluent 
PBS, 1% (w/v) BSA, 1% (v/v) Tween-20 
  
ELISA (SIgA) coating buffer 
100mM NaHCO3, 33mM Na2CO3, pH 9.5 
 
ELISA (SIgA) wash buffer 
PBS, 0.05% (v/v) Tween-20 
 
ELISA (SIgA) stop solution 
2N H2SO4 
 
Lung digestion medium 
IMDM GlutaMAX (Gibco), 5% (v/v) FBS, Collagenase D (c: 0.2mg/mL, Roche), DNase (c: 
10µg/mL, Sigma) 
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PBS 
PBS tablets (without Ca/Mg) were purchased (Life technologies) and PBS solution was made 
according to manufacturer’s instructions.  
RIPA buffer 
25mM TrisHCl pH 7.6, 150mM NaCl, 1% (v/v) IGEPAL CA-630, 1% (w/v) sodium 
deoxycholate, 0.1% (w/v) SDS  
 
FACS buffer 
PBS, 2mM EDTA pH 8.0, 2% FBS (v/v) 
 
Columbia Agar 
Columbia Agar supplemented with 5% sheep blood was purchased from BD (Heidelberg, 
Germany).  
 
Todd Hewitt – yeast (THY) medium 
3.7g Todd Hewitt broth (Sigma-Aldrich), 1g Bacto-Yeast extract (BD) ad 100 mL MilliQ water 
  
SDS running buffer (10x) 
25mM Tris, 192mM Glycine, 0.1% (w/v) SDS, pH 8.3  
 
SDS transfer buffer 
25mM Tris, 192mM Glycine, 20% Methanol (v/v), 0.1% SDS, pH 8.4  
 
TBS (10x) 
1.4M NaCl, 200mM Tris, pH 7.4 
 
TBS-T 
TBS (1x), 0.1% (v/v) Tween-20  
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 Bacteria 4.1.2
Streptococcus pneumoniae TIGR4 is an encapsulated serotype 4 strain isolated from the 
blood of a 30-year-old male patient in Kongsvinger, Norway (Tettelin et al. 2001). TIGR4 has 
been previously shown to cause invasive pneumococcal disease in mice (Sandgren et al. 
2005). This strain is available at the American Type Culture Collection (ATCC® BAA-334TM). 
 Mice 4.1.3
SPC-HA mice expressing the influenza A/PR8/34 hemagglutinin (HA) under the 
transcriptional control of the human surfactant protein C (SP-C) promoter exclusively in ATII 
have been described elsewhere (Bruder, Westendorf et al. 2004). TCR-HA transgenic mice 
expressing a TCR αβ specific for the I-Ed-restricted HA-peptide 110–120 from A/PR8/34 HA 
have been described previously (Kirberg, Baron et al. 1994). In SPC-HAxTCR-HA mice the 
concomitant expression of HA as neo self-antigen and generation of HA-specific CD4+ T cells 
establishes an autoimmune milieu (Bruder, Westendorf et al. 2004). Mice were bred in the 
animal facility at the Helmholtz Centre for Infection Research and were kept under specific-
pathogen-free (SPF) conditions. All animal experiments were performed according to 
national guidelines and were approved by local government institutions (Niedersächsisches 
Landesamt für Verbraucherschutz und Lebensmittelsicherheit, file no. 33.14-42505-04-
14/1715). In all experiments SPC-HA and SPC-HAxTCR-HA mice were used between 12 to 
24 weeks of age. Mice were euthanized by either CO2 inhalation or cervical dislocation. 
 Antibodies 4.1.4
Flow cytometric analyses, sorting of bacterial cells or lung single cell suspensions were 
performed using the following antibodies: 
Table 2: Utilized antibodies and conjugates for FACS.  
Specificity Clone Label/conjugate Manufacturer  
F4-80 BM8 biotinylated, 
APC 
BioLegend 
CD11b M1/70 PE, Pacific blue BioLegend 
Ly6G 1A8 PE-Cy7 BioLegend 
CD3ɛ 145-2C11 FITC BioLegend 
TCR-HA 6.5 Alexa647 own production 
CD43 1B11 PE BioLegend 
CD11c N418 APC, FITC BioLegend 
IgA C10-3 FITC BD Pharmingen  
IgM DS-1 PE BD Pharmingen 
CD16/32 (AT2 sorting) 2.4G2 none BD Pharmingen 
CD16/32 (blocking) 93 none BioLegend 
CD19 6D5 PE BioLegend 
CD45 30-F11 none BioLegend 
rat IgG polyclonal PE BD Pharmingen 
Streptavidin  PE-Cy7 BioLegend 
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For histological analyses of lung tissue, western blot analyses and secretory immunoglobulin 
ELISA following antibodies were used:  
Table 3: Utilized antibodies for immunoblot, immunohistochemistry and ELISA. 
Specificity Clone Label/conjugate Manufacturer  
pIgR polyclonal none R&D Systems 
IgA 11-44-2 biotinylated SouthernBiotech 
goat IgG (H+L) polyclonal HRPO Jackson ImmunoResearch 
GAPDH 14C10  Cell Signaling 
 
 Oligonucleotide sequences 4.1.5
Table 4: Primers used for quantitative real-time RT-PCR analyses. 
Gene Sequence forward primer (5’->3’) Sequence reverse primer (5’->3’) 
Actb CTTCTTTGCAGCTCCTTCGT TCCTTCTGACCCATTCCCAC 
Clca3 CAGGCACGGCTAAGGTTG GGAGGTGACAGTCAAGGTGAG 
Cxcl1 GCCACACTCAAGAATGGTCG TTACTTGGGGACACCTTTTAGC 
Cxcl2 AGATACTGAACAAAGGCAAGGCT CGAGGCACATCAGGTACGAT 
Cxcl5 CCTACGGTGGAAGTCATAGC AGCTTTCTTTTTGTCACTGCC 
Cxcl9 GAGTTCGAGGAACCCTAGTG GGGATTTGTAGTGGATCGTG 
Retlna ACGAGTAAGCACAGGCAGTT TGCCAATCCAGCTAACTATCCC 
Glycam1 AGCCCACAGATGCCATTC GAAGGCTCCTTGGAAAGGTC 
Igj GCATGTGTACCCGAGTTACC TTCAAAGGGACAACAATTCGG 
Msr1 GGAATAAGAGGTATTCCAGGTG TTTGTCCTTTAGGTCCAGGAG 
Pigr GTGCCCGAAACTGGATCACC TGGAGACCCCTGAAAAGACAGT 
Ptgs2 CATCCCCTTCCTGCGAAGTT CTCCTTATTTCCCTTCACACCCA 
Raldh2 TAAGAGGCCGAGGCTGAAGAGCAC TGGGGTTCATTGGAAGGCAGAAAG 
Rps9 CTGGACGAGGGCAAGATGAAGC TGACGTTGGCGGATGAGCACA 
Tgfb ACCGCAACAACGCCATCTAT GTAACGCCAGGAATTGTTGC 
 
4.2 Methods 
 Pneumococcal infections 4.2.1
Pneumococci were grown overnight on Columbia blood agar plates at 37°C and 5% CO2, 
single colonies were resuspended and cultured in THY medium to mid-logarithmic phase 
(OD600nm 0.3-0.5), washed, and diluted in PBS to the desired concentration. True CFU were 
determined by growing serial dilutions of the inoculums on blood agar plates. Bacterial 
suspensions were administered to mice via oropharyngeal aspiration. Mice were 
anesthetized by intraperitoneal injection of ketamine/xylazine and a total of 20-50µL of 
bacterial inoculum was continuously applied to the oropharynx and inhaled by the mouse. 
For preparation of ethanol-killed pneumococcal extracts S. pneumoniae TIGR4 was grown to 
mid-logarithmic phase as described above. Serial inoculums of the bacterial suspension 
were plated to determine CFU. 2mL of bacterial suspension was spun down (17900xg, 3min, 
RT), the supernatant was removed, and the bacterial pellet was resuspended in ice-cold 
ethanol (70% v/v) and incubated at 4°C for 1h. The bacterial suspension was again spun 
down and the pellet was resuspended in 1mL sterile PBS/Glycerol solution (25% v/v). Plating 
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after ethanol-treatment was carried out to verify effective bacterial killing. Ethanol-killed 
bacterial suspensions were stored at -70°C. In order to assess the in vivo inflammatory 
response to pneumococcal ligands, mice were oropharyngeally administered with 20µL 
ethanol-killed bacterial suspension (equivalent to 106 CFU).  
 Determination of bacterial load 4.2.2
During the first 3 days following pneumococcal infection mice were monitored every day for 
the development of invasive pneumococcal disease. To this end, 5µL of peripheral blood was 
recovered by puncturing the tail vein with a sterile cannula (0.45mm diameter). To determine 
bacterial burden in the airways, the trachea was cannulated and bronchoalveolar lavage 
(BAL) was performed by flushing the lungs with 1mL ice-cold PBS. Typically a volume 
between 0.7 - 0.9mL could be retrieved. Lungs and trachea were aseptically removed, 
placed in sterile tubes with 1mL ice-cold PBS and mechanically homogenized using a 
Polytron PT 1300 D homogenizer (KINEMATICA AG, Luzern, Switzerland). Serial dilutions of 
tissue homogenates, BAL fluid (BALF) and blood were plated onto Columbia blood agar 
plates and bacterial inoculums were counted after 16-24h incubation at 37°C at 5% CO2. 
 In vivo phagocytosis assay 4.2.3
S.pneumoniae TIGR4 was grown to mid-logarithmic phase as described before. 3mL of 
bacterial suspension was washed twice with PBS, again resuspended in PBS with 5µM Cell 
Proliferation Dye eFluor®670 (eBioscience) and incubated for 10min at 37°C in the dark. 
Staining reaction was stopped by adding PBS/1% BSA (w/v) and incubating another 5min on 
ice. Bacterial cells were washed three times with PBS/1% BSA (w/v) and resuspended in 
PBS. Serial dilutions of bacterial suspensions were performed to determine CFU. Mice were 
oropharyngeally administered with 0.5-1x107 CFU in 50µL, sacrificed 90min post 
administration and BAL was performed twice with a total volume of 1.5mL PBS. Obtained 
cells were erythrocyte-depleted by treatment with ACK buffer, Fcγ-receptors were blocked 
with anti-CD16/CD32, cells were stained with anti-F4-80 and phagocytosis was analyzed 
using FACS. Alveolar macrophages (AMs) were identified as F4-80+, autofluorescencehigh 
and side scatterhigh cells. Relative phagocytic capacity of each sample was determined by 
calculating: median fluorescence intensity (MFI) of e670-positive AMs over the mean of all 
MFIs of e670-positive AMs of the control group (SPC-HA mice). 
 
 Isolation of mouse leukocytes 4.2.4
Mice were sacrificed by CO2 inhalation or cervical dislocation. Bronchoalveolar lavage was 
performed by flushing the lungs with 1mL ice-cold PBS. Typically a volume between 0.7- 0.9 
mL could be retrieved. Bronchoalveolar lavage fluid (BALF) was spun down (420xg, 10min, 
4°C), BALF supernatants were removed and cell pellet was depleted of erythrocytes by 
treatment with hypotonic ACK buffer. Obtained cells were then further processed for e.g. 
RNA isolation or cytometric analyses. 
For isolation of lung tissue leukocytes the thorax was opened, the lung was removed and 
thoroughly minced with scissors. Lung tissue pieces were then transferred into a 15mL tube 
containing 3mL pre-warmed digestion media, followed by enzymatic digestion at 37°C for 
45min. To improve tissue disintegration, the lung digestion mix was sheared every 5min 
using a transfer pipette. After 30min of enzymatic digestion another 2mL digestion medium 
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were added to every tube. To stop enzymatic activity 5mM EDTA was added to the reaction 
mix, followed by incubation for another 5min. Lung cell suspension was passed through a 
100µM cell strainer and washed with IMDM. Cells were pelleted by centrifugation (420xg, 
15min, 4°C) and cells were erythrocyte-depleted by treatment with ACK buffer. Reaction was 
stopped by addition of FACS buffer, cells were again spun down and resuspended in 4mL 
IMDM. Lymphocytes were enriched by differential density-centrifugation, i.e. 4mL of lung cell 
suspension was carefully overlayed to 4mL Ficoll (Ficoll-PaqueTM Plus, GE Healthcare) and 
centrifuged (780xg, 20min, 20°C). Lymphocytes were harvested from the interphase, washed 
and FACS staining protocol was applied. 
 Flow cytometry 4.2.5
Antibody-stainings of murine single cell suspensions as well as pneumococcal cells were 
performed in 96-well microplates (U-shaped wells). Cell suspensions were prepared in FACS 
buffer (murine cells) and cells were pelleted by centrifugation (420xg, 10min, 4°C). For 
surface staining, cells were incubated with the indicated antibodies (diluted in FACS buffer, 
100µL/well) for 10min at 4°C in the dark. Cells were then washed with FACS buffer 
(100µL/well), resuspended in 150-250µL FACS buffer and subsequently analyzed using 
either a Fortessa or LSRII FACS instrument (BD, New Jersey, USA). 
 
 In vivo antibiotics (ABX) treatment  4.2.6
For antibiotic in vivo treatment sucrose (2% w/v), ampicillin sodium salt (1.33 g/L, equivalent 
of 1.25 g/L ampicillin) and chloramphenicol (0.29g/L) were dissolved in autoclaved tap water. 
Solutions were then sterilized by filtration (0.22µM) and mice were supplied with ABX-water 
ad libitum. Control groups received sucrose-water. Drinking water was changed biweekly. 
 
 Depletion of alveolar macrophages 4.2.7
In order to deplete alveolar macrophages, mice were oropharyngeally administered 50µL 
clodronate liposomes (=250µg encapsulated clodronate, purchased from ClodLip BV, 
Amsterdam, The Netherlands). Control mice received 50µL sterile PBS or –where indicated- 
50µL PBS Liposomes (ClodLip BV). 
 
 Isolation and purification of alveolar macrophages  4.2.8
BAL cells were erythrocyte-depleted and incubated in DMEM (Gibco, supplemented with 
10% fetal bovine serum and antibiotics) for 90min at 37°C, 5% CO2 in bacteriological plastic 
petri dishes. Non-adherent-cells were then removed by extensively rinsing the surface with 
PBS. To verify effective purification, adherent cells were detached by treatment with 0.05% 
Trypsin/EDTA (Gibco), stained with antibodies against F4-80 and CD11c and analyzed by 
flow cytometry. For RNA analysis, adherent cells were directly lysed on the plastic surface by 
treatment with RLT buffer (Qiagen, supplemented with 1% mercaptoethanol) and RNA 
extraction protocol was applied. RNA was extracted and purified using RNeasy Mini and 
RNase free DNase kit (both Qiagen) according to the manufacturer’s instructions. 
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 Pulse oximetry 4.2.9
Arterial blood oxygen saturation in untreated mice was monitored using the MouseOx system 
(Starr Life Sciences Corp., Oakmont, PA). Measurements were performed on non-
anesthetized mice. Data from constant measuring periods (>30sec) were analyzed. 
 
 Enzyme-linked immunosorbent assay (ELISA) 4.2.10
ELISA kits for mouse IgA and IgM (eBioscience, Frankfurt am Main, Germany), mouse IL-6 
and TNF-α (BioLegend, London, United Kingdom) and mouse Albumin (Bethyl 
Laboratories,Inc., Montgomery) were used according to the manufacturer’s instructions and 
using recommended buffer formulations. 
 
4.2.10.1 SIgA-ELISA 
For SIgA-detection Nunc MaxiSorp plates were coated overnight with 100µL monoclonal rat 
anti-mouse IgA (SouthernBiotech, Birmingham, 2µg/mL, diluted in ELISA coating buffer). 
Plates were washed and blocked with 200µL/well ELISA assay diluent (1h, RT, shaking). 
Plates were washed again and incubated with 100µL of serial dilutions of BALF samples (2h, 
RT, shaking). Plates were washed again and incubated for 1h with 100µL secondary 
antibody solution (polyclonal goat anti-mouse pIgR; R&D Systems, Minneapolis, MN, 
1µg/mL) followed by polyclonal donkey anti-goat-HRP for 30min (Jackson ImmunoResearch, 
West Grove, PA, 0.16µg/mL) and TMB substrate. Plates were read at 450 and 570nm. Due 
to the lack of a SIgA protein standard, relative quantification was performed. Results are 
expressed as the OD at 450nm (wavelength- and blank-corrected) at indicated dilutions. 
 
 Immunoblot 4.2.11
Lungs were mechanically homogenized in 5mL ice-cold RIPA lysis buffer. Cell debris was 
removed by centrifugation (15min, 5250xg, 4°C) and supernatants were stored at -70°C. 
Protein concentrations of the samples were measured using the BCA Protein Assay Kit (Life 
Technologies) according to the manufacturer’s protocol. Equal amounts of protein were 
separated by SDS-PAGE (8%) in an electrophoresis chamber with SDS running buffer and 
subsequently transferred to a PVDF membrane using an electroblot chamber. Membrane 
was blocked with 5% (w/v) nonfat dry milk in TBS-T buffer for 1h and subsequently washed 
in TBS-T buffer. Target was identified using anti-pIgR antibody (0.2µg/mL) in TBS-T buffer 
with, reference protein was identified using anti-GAPDH (Cell Signaling Technology, Inc., 
Beverly, MA). For detection standard horseradish peroxidase conjugated polyclonal 
secondary antibodies were used together with ECL western blotting substrate (Life 
Technologies, Darmstadt, Germany). 
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 Bacterial binding assay. 4.2.12
BAL was performed as described using 1mL PBS. Cells were separated by centrifugation 
(420xg, 10min, 4°C) and BALF supernatants were stored at -70°C. 96-well microplates were 
incubated with 1% (w/v) BSA/PBS. Freshly grown pneumococci were washed twice with 
blocking buffer, seeded into microwells (1-4x106 CFU) and incubated (45min, 4°C) with 
undiluted BAL supernatants. Bacteria were washed once with PBS and stained using anti-
mouse IgA or anti-mouse IgM. Immunoglobulin binding was quantified by flow cytometry. 
 
 Sample Preparation for LC-MS/MS analysis 4.2.13
Proteins were purified by chloroform/methanol precipitation. Protein pellets from each sample 
were reduced with 10mM DTT, alkylated with 20mM jodoacetamide and digested with 
sequencing grade modified trypsin (Promega) as recommended in a ratio of 1:50 at 37°C 
overnight. The peptide solutions were vacuum-dried, and peptides were resolved in 0.2% 
TFA in water; desalted on self-packed LiChroprep RP-18 (Merck) SPE columns; eluted with 
0.2% TFA, 60% ACN in water; and again vacuum-dried. 
 
 Mass spectrometry and data analysis 4.2.14
 LC-MS/MS analyses of desalted samples were performed on an Acquity ultraperformance 
LC system (Waters Corp., Milford, MA) connected to a LTQ Orbitrap XL mass spectrometer 
(Thermo Finnigan Corp., San Jose, CA). Peptides were flushed onto a C18 precolumn (5μm 
Symmetry C18, 180μm × 20mm, Waters Corp.) with a flow rate of 15μL/min and washed at 
constant flow for 3min. Peptides were separated on an analytical column (1.7μm BEH130, 
75μm × 150mm, Waters Corp.) with UPLC buffer A (0.1% formic acid in water) and UPLC 
buffer B (0.1% formic acid in acetonitrile) via linear 120min gradients at a flow rate of 300 
nL/min controlled with Acquity UPLC software V1.22. Eluting peptides were ionized using 
PicoTip emitter needles (New Objective Inc., Woburn, MA), voltages of 1.7kV and a capillary 
temperature of 200°C. Data-dependent acquisition of MS and MS/MS data was under control 
of XCalibur software V2.1 (Thermo Finnigan). Survey Scans were acquired in the Orbitrap 
mass analyzer with a resolution of 60.000 at m/z 400. For full scans 5x105 ions were 
accumulated within a maximum injection time of 500ms and detected in the Orbitrap 
analyzer. Sequential isolation of the five most intense ions with charge states ≥ 2 was set to 
a target value of 5x104 (signal threshold: 2x104, isolation width: 4.0Da) with a maximum 
injection time of 500ms. CID mode was used for detection of produced fragment ions. 
Database searches were performed using Proteome Discoverer (1.4; Thermofisher) 
connected to a Mascot Server (2.4.06) in the UniProtKB/Swiss-Prot database (2015_01 
taxonomy, Mus musculus with 16,702 sequences). Proteins were accepted as identified 
when at least one unique, search engine rank 1 and high confident peptide showed an 
individual score above 30, which indicates identity or extensive homology (p < 0.05) based 
on the search parameter settings used (enzyme, trypsin; maximum missed cleavages, 1; 
fixed modification: methylthio (Cys; variable modifications, phosphorylation (Ser, Thr, Tyr) 
and oxidation (Met); peptide tolerance, 10ppm; MS/MS tolerance, 0.4Da). Sample 
preparation and mass spectrometry acquisition was performed by Josef Wissing (HZI).  
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 Microarray 4.2.15
RNA from whole lung tissue was isolated and purified using RNeasy Midi and RNase free 
DNase kit (both Qiagen, Hilden, Germany). Samples were amplified, labeled, fragmented 
and hybridized to GeneChip® Mouse Gene 1.0 ST arrays (Affymetrix) and treated according 
to manufacturer’s instructions. Microarray scanning was performed using an Affymetrix GCS 
3000 scanner and GCOSv1.1 software. Data analyses were conducted using GeneSpring 
GX software (Agilent technologies). The data were summarized, log2 transformed and 
normalized with the Robust Multi-array Analysis (RMA) algorithm. Cluster analyses were 
performed with Genesis software 1.7.6, applying a z-score transformation. Gene-ontology 
analyses were performed using Cytoscape software 3.2.0 and ClueGo plugin. Microarray 
data are deposited at Gene Expression Omnibus (http://www.ncbi.nlm.nih.gov/geo/) under 
accession ID: GSE66531. 
 
 Quantitative real-time RT-PCR 4.2.16
RNA from whole lung homogenates was transcribed into cDNA using M-MLV RT polymerase 
(Invitrogen, Carlsbad, CA) according to the manufacturer’s instructions. Quantitative PCR 
(qPCR) was conducted using the LightCycler 480 SYBR Green I Mastermix and LightCycler 
480 instrument (both Roche, Mannheim, Germany). Transcript levels were normalized to the 
housekeeping gene Rps9. For gene expression analyses of alveolar macrophages and 
alveolar epithelial cells, RNA was isolated and purified using RNeasy Mini and RNase free 
DNase kit (both Qiagen). RNA was analyzed using the SensiFASTTM SYBR® No-ROX One-
Step Kit (Bioline, Luckenwalde, Germany) according to the manufacturer’s instructions. 
Transcript levels were normalized to the housekeeping gene Actb. 
 
 Histology 4.2.17
For histopathological evaluation lungs were perfused with 10mL PBS, fixed in 4% 
paraformaldehyde and embedded in paraffin. 4µM sections were stained with hematoxylin & 
eosin. Histology was performed by Prof. Achim D. Gruber and Dr. Olivia Kershaw 
(Department of Veterinary Pathology, Freie Universität Berlin). For pIgR-localization perfused 
lungs were frozen in Tissue-Tek O.C.T. (Sakura Finetek GmbH, Staufen, Germany). 6µm 
acetone-fixed cryosections were blocked with anti-CD16/CD32, incubated with goat anti-pIgR 
primary antibody, blocked with 5% (v/v) donkey serum and incubated with FITC-conjugated 
donkey anti-goat secondary antibody (Jackson ImmunoResearch). Alveoli were identified by 
DAPI nuclear counterstain. Fixed tissue sections were analyzed by fluorescence microscopy, 
using the inverted Eclipse Ti-U, NIS-Elements imaging software (Nikon, Tokyo, Japan) and 
ImageJ software. 
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 Imaging flow cytometry  4.2.18
Samples were analyzed with the imaging flow cytometer FlowSight® (Amnis®, part of EMD 
Millipore). The 405nm, 488nm, 642nm, 785nm lasers were used for excitation. Debris and 
doublets were gated out. Channel 1 (435 - 505nm), Channel 6 (SSC, 745 - 800nm) Channel 
3 (560 - 595nm), Channel 5 (642 - 745nm), Channel 7 (435 - 505nm), Channel 11 (642 - 
745nm) were measured and at least 10,000 events of single cells per sample were collected. 
Color compensation was necessary due to overlapping emission spectra. For analysis the 
IDEAS version 6.0 was used. Gating strategy was the following: First, focused single cells 
are identified (using ‘gradient root mean square’ of the bright field image then bright field 
area and aspect ratio, respectively). Alveolar macrophages were identified as F4-80+ and 
CD11c+. To exclude T cells from morphological analyses in imaging flow cytometry, cell 
suspensions were additionally stained with antibody against CD3. Alveolar macrophages 
were analyzed by applying the image-based features intensity, area, and bright detail 
intensity on the SSC-channel. 
 
 Panoptic staining: Pappenheim method 4.2.19
For analyses of alveolar macrophage phenotype, bronchoalveolar lavage cells from naive 
SPC-HA and SPC-HAxTCR-HA mice were isolated and erythrocyte-depleted by treatment 
with ACK buffer. Cells were spun (800rpm, 15min, RT) onto SuperFrost® glass slides 
(Thermo Scientific, Schwerte, Germany), air-dried and stained with May-Grünwald-reagent 
(Merck, Darmstadt, Germany). After 3min neutral water pH 7.2 was added and stained for 
1min. Staining solution was removed and cells were stained with Giemsa-reagent (Merck, 
1:10 diluted in ddH2O) for 15min. Slides were then washed, air-dried and samples were 
covered with Neo-Mount (Merck) reagent and sealed by glass cover slips. Images were 
captured at 63x oil immersion objective using an Axio Imager Z2 microscope equipped with 
AxioCam MRc5 and ZEN software (both Carl Zeiss Microscopy GmbH). 
 
 Fluorescence-activated cell sorting of ATII cells  4.2.20
Isolation and purification of murine ATII cells was performed using a previously described 
protocol which had been established in our lab. Mice were euthanized by CO2 inhalation and 
lungs were perfused as described above. 2mL dispase (37°C) followed by 0.5mL 1% low-
melt agarose (45° C) was intratracheally instilled into the lungs via an indwelling canula. In 
order to solidify the agarose, lungs were covered with a paper towel and ice for 2min. Whole 
lungs were then excised, heart and thymus were removed. Lungs were digested for 45min in 
2mL of pre-warmed (37°C) dispase, minced in 7mL DMEM (supplemented with 100µL 
DNase and anti-CD16/32 antibody) and incubated for 10min at RT. Lung cell suspensions 
were filtered through 100µm, 48µm and 30µm nylon gauze and spun down (15min, 900rpm, 
4°C). Following erythrocyte-depletion by ACK buffer, cells were stained with fluorescence-
labelled antibodies against F4-80, CD11c, CD45, CD11b and CD19, followed by a secondary 
staining step with PE-labelled goat anti-rat IgG. FACS was performed by Lothar Gröbe (HZI) 
using BD FACSAria and Beckman Coulter MoFlo cell sorters. ATII cells were sorted by 
negative selection as depicted in Figure 11. 
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Figure 11: Gating strategy for isolation of murine ATII cells from lung cell suspensions using FACS.  
Lineage-positive (PE, APC and FITC-positive) cells were excluded by negative selection (R1-R3). Granular 
(SSC
high
), single cells were selected and sorted (R4-R6). Adapted from Gereke et al. 2012.  
 
 Statistical analyses 4.2.21
Statistical evaluation was performed using Graph Pad Prism Software (Graph Pad Software, 
La Jolla). Unpaired, two-tailed Mann-Whitney-test was chosen to compare two groups, if not 
otherwise stated. For comparison of multiple groups one-way or two-way ANOVA followed by 
Bonferroni post-test was applied.
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5  Results 
5.1 Impact of chronic lung inflammation on pulmonary immunity 
to respiratory pneumococcal infection  
 Airway pathology and increased lung permeability in SPC-HAxTCR-5.1.1
HA mice 
It is well-known that chronic respiratory diseases (CRDs) alter host immunity towards 
airborne pathogens in humans and mice. However, the underlying immunological 
mechanisms are incompletely understood. The first part of this thesis aimed to elucidate 
factors of CRD involved in altered antimicrobial immunity towards respiratory infection. To 
this end SPC-HAxTCR-HA transgenic mice that intrinsically develop autoimmune-mediated 
inflammation were utilized in an infection model with the common respiratory pathogen 
Streptococcus pneumoniae. 
In order to initially characterize the extent of chronic, autoimmune-mediated pulmonary 
inflammation histopathological as well as functional examinations of lungs from healthy SPC-
HA control mice and pre-diseased SPC-HAxTCR-HA mice were conducted. In line with 
previous observations (Bruder, Westendorf et al. 2004) lung histology of the SPC-HAxTCR-
HA mice showed peribronchiolar and perivascular lymphocytic cuffings, hemosiderosis and 
alveolar emphysema (Figure 12a). These histopathological findings mirror the lymphocyte-
driven disease etiology in SPC-HAxTCR-HA mice, suggesting lymphocyte recruitment and/or 
local proliferation within the lung parenchyma. The presence of hemosiderosis furthermore 
indicates pulmonary hemorrhage, i.e. the leak of blood components into the airspaces, finally 
leading to hemosiderin-laden airway macrophages in SPC-HAxTCR-HA mice. Moreover, the 
finding of emphysema demonstrates airway remodeling, possibly impairing effective 
ventilation in SPC-HAxTCR-HA mice. In order, to test whether the observed structural 
alterations in SPC-HAxTCR-HA mice would manifest in reduced physiological organ function 
and thus insufficient oxygen supply in this group, pulse oximetry analyses were performed. 
These however revealed similar arterial blood oxygen saturation levels in SPC-HA and SPC-
HAxTCR-HA mice (Figure 12b), indicating an unaffected respiratory capacity and thus 
excluding severe injury of the respiratory epithelium in this group.  
As the presence of hemosiderosis suggested a decreased mucosal barrier function in SPC-
HAxTCR-HA lungs, the extent of pulmonary leakage was tested. To this end, serum albumin 
levels in bronchoalveolar lavage fluid (BALF) were determined by ELISA. Albumin usually is 
a serum component, which upon injury and/or activation of pulmonary capillaries and 
epithelial cells can passively diffuse into the airspaces, and BALF albumin levels are typically 
used as readout for pulmonary injury. Indeed, BALF from SPC-HAxTCR-HA mice contained 
about 35.6% more serum albumin compared to SPC-HA control samples (Figure 12c), 
indicating an increased pulmonary leak in SPC-HAxTCR-HA mice while at the same time 
linking chronic lung inflammation to impaired epithelial and/or endothelial barrier function. 
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Figure 12: Lung pathology in a model of chronic autoimmune-mediated lung inflammation. 
(a) Hematoxylin and eosin stained lung tissue sections of SPC-HA and SPC-HAxTCR-HA mice (representative of 
n=3/group; scale bar =100µm) (b) Blood oxygen saturation (SpO2) (c) Albumin concentration in bronchoalveolar 
lavage fluid (BALF) ***p<0.001 Black scale bars: 100µm, magnification: 10x 
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 SPC-HAxTCR-HA mice display enhanced immunity to respiratory 5.1.2
infection with Streptococcus pneumoniae 
In numerous infectious (Habibzay et al. 2013) and non-infectious (Sethi, Wrona et al. 2008, 
Talbot et al. 2005) etiologies, lung inflammation correlates with an increased susceptibility to 
infections and lung permeability enhances bacterial tissue penetration (LeMessurier et al. 
2013). In order to determine how the above described chronic airway inflammation would 
affect the efficacy of local antibacterial mechanisms an encapsulated serotype 4 strain 
(TIGR4) of Streptococcus pneumoniae was chosen for infection experiments in healthy SPC-
HA control mice and pre-diseased SPC-HAxTCR-HA mice. In this model, death from 
infection is typically preceded by pneumococcal invasion into pulmonary tissue and the 
subsequent development of bacteremia. As lungs of SPC-HAxTCR-HA mice displayed 
increased permeability, it seemed likely to detect enhanced pneumococcal invasion in these 
mice. To test this, SPC-HA and SPC-HAxTCR-HA mice were oropharyngeally inoculated 
with S.pneumoniae and the number of pneumococci residing in the airways (BALF) and the 
lung tissue at 4h and 24h following infection was determined. To exclude contaminations with 
bloodstream-derived pneumococci a sub-lethal infection dose (1.5x104 CFU), which typically 
does not cause bacteremia within 24h, was chosen. 
Already at 4h post infection BALF of SPC-HAxTCR-HA mice contained significantly 
decreased bacterial numbers compared to SPC-HA control mice. At 24h no pneumococci 
were detectable in nearly 50% of the SPC-HAxTCR-HA BALF samples (compared to only 
25% of SPC-HA samples). Furthermore, the median bacterial burden in the BALF did not 
increase over the first 24h following infection in SPC-HAxTCR-HA mice whereas there was 
an almost 9-fold increase in SPC-HA mice at this time point (Figure 13a). Consistent with 
reduced CFU in BALF, reduced proportions of lungs were invaded by S.pneumoniae in SPC-
HAxTCR-HA mice at 4h (25% vs. 87.5%) and 24h after pneumococcal infection (22.2 % vs. 
62.5%; Figure 13b). 
In order to assess whether the observed reduction in the early bacterial burden would affect 
the ultimate outcome of infection, survival following inoculation with a lethal pneumococcal 
dose (1.5x106 CFU) was monitored. Here 60% mortality within 3 days in SPC-HA mice was 
observed compared to only 27% mortality in SPC-HAxTCR-HA mice. Seven days post 
infection, all infected SPC-HA mice had succumbed whereas 20% of the SPC-HAxTCR-HA 
mice survived (Figure 13b). These data indicate that endogenous pulmonary inflammation as 
displayed by SPC-HAxTCR-HA mice gives rise to a milieu that improves early innate 
resistance mechanisms towards respiratory S. pneumoniae infection leading to a significant 
advantage in pathogen clearance and survival and thus surprisingly contradicts the initial 
expectation of enhanced bacteremia as a consequence of the increased pulmonary leak as 
observed in Figure 12c. 
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Figure 13: Improved antipneumococcal resistance of SPC-HAxTCR-HA mice. 
Mice were oropharyngeally inoculated with ~1.5x10
4
 CFU S.pneumoniae TIGR4 and were sacrificed at the 
indicated time points. The bacterial burden in (a) bronchoalveolar lavage fluid (BALF) and (b) lung tissue 
homogenates was determined. Data are shown for individual animals pooled from 2 independent experiments. 
Dashed lines indicate the detection limit. *p<0.05. (c) Mice were oropharyngeally inoculated with ~1.5x10
6
 CFU 
S.pneumoniae TIGR4 and survival was followed over a period of 14 days. Statistical significance was determined 
using the Log-rank test, *p<0.05 (n=15/group, 2 independent experiments) 
 
 Similar phagocytic capacity of SPC-HA vs. SPC-HAxTCR-HA-derived 5.1.3
alveolar macrophages 
Alveolar macrophages (AMs) have pleiotropic protective functions during pulmonary infection 
including early phagocytic uptake and killing of airborne pathogens. Given the finding of 
significantly decreased airway CFU counts already 4h after pneumococcal infection it 
seemed likely that enhanced macrophage phagocytosis could be a mechanism involved in 
the improved disease outcome in SPC-HAxTCR-HA mice. To test this hypothesis, mice were 
oropharyngeally inoculated with fluorescently labelled pneumococci and bacterial uptake by 
AMs was quantified at 90min post infection by flow cytometric analyses. Macrophages were 
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identified as F4-80+SSChighautofluorescencehigh cells. However, no significant differences 
became apparent between SPC-HA and SPC-HAxTCR-HA mice regarding the proportions of 
AMs that had taken up pneumococci as well as the individual phagocytic capacity (Figure 
14a,b). To rule out the possibility that different AM numbers and hence an altered a priori 
pathogen/phagocyte ratio would mask potential differences in phagocytosis, absolute 
macrophage numbers in BALF of in SPC-HA and SPC-HAxTCR-HA mice were determined. 
Again, no significant differences between both mouse groups were observed (Figure 14c). 
Likewise, BALF neutrophil numbers were similar between non-infected SPC-HA and SPC-
HAxTCR-HA mice and these phagocytes were virtually absent in both groups (data not 
shown). Therefore the amended disease outcome in SPC-HAxTCR-HA mice was probably 
not a consequence of enhanced early phagocytic bacterial uptake. 
 
Figure 14: Similar phagocytic activity of SPC-HA and SPC-HAxTCR-HA alveolar macrophages.  
Mice were oropharyngeally inoculated with ~5x10
6
 CFU eFluor®670-stained S.pneumoniae TIGR4. 
Bronchoalveolar lavage cells were isolated 90min post infection and analyzed by flow cytometry to (a) quantify the 
portion of eFluor®670
+
 alveolar macrophages out of all recovered alveolar macrophages. (b) The relative 
fluorescence index of eFluor®670
+
 macrophages of each mouse was determined as the ratio of the median 
fluorescence intensity (MFI) of eFluor®670+ macrophages over the mean MFI of the SPC-HA control group 
samples. (c) Absolute macrophage numbers in BALF were determined by cell counting and flow cytometric 
analyses. Data are pooled from at least 2 independent experiments with similar results. 
 
 Chronic lung inflammation in SPC-HAxTCR-HA mice does not 5.1.4
involve an IL-6 / TNF-α cytokine milieu 
Based on the previous findings of improved antipneumococcal immunity in the SPC-
HAxTCR-HA group it became obvious that inflammatory priming favors the generation of a 
protective environment in these mice. In several studies respiratory priming with PAMP-
receptor agonists was linked to improved immunity to secondary infection with airborne 
pathogens (Errea et al. 2010, Evans et al. 2010, Tritto et al. 2007, Tuvim et al. 2009). In 
these reports protective immune stimulation involved among others the induction of local as 
well as systemic IL-6 and TNF-α cytokine responses. In order to test a possible role of these 
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pro-inflammatory mediators in the SPC-HAxTCR-HA mouse model, BALF and serum 
samples from uninfected SPC-HA and SPC-HAxTCR-HA mice were analyzed by ELISA. 
However, no significant differences in the local (BALF) and systemic (serum) cytokine milieu 
were found - both TNF-α as well as IL-6 were almost not detectable in the two mouse groups 
and compartments (Figure 15). This suggested other immunological mechanisms to be 
involved in the generation of the protective microenvironment of SPC-HAxTCR-HA lungs. 
 
Figure 15: Chronic pulmonary inflammation is not associated with increased local nor systemic IL-6 and 
TNF-α levels.  
Bronchoalveolar lavage fluid (BALF) and serum samples from uninfected SPC-HA and SPC-HAxTCR-HA mice 
(n=5-6/group) were analyzed by ELISA. Dashed line indicates limit of detection. 
 
 Transcriptional signature in SPC-HAxTCR-HA lungs points to an 5.1.5
induction of humoral immunity  
To identify molecular mechanisms possibly contributing to the improved antipneumococcal 
resistance in the inflamed lung genome-wide comparative transcriptome analyses of lung 
tissue from naive SPC-HA and SPC-HAxTCR-HA mice were performed using triplicate 
microarray analysis. Based on the comparison of the mean signal intensities of the 
microarray triplicates from SPC-HAxTCR-HA vs. SPC-HA lung samples and applying a fold 
change threshold of ± 2 a total of 378 transcripts were found to be differentially expressed in 
SPC-HAxTCR-HA lungs, of which 326 were up-regulated and 52 down-regulated (Figure 16). 
For better visualization the individual normalized log2 transformed signal intensities of the 378 
differentially expressed transcripts were z-score transformed and hierarchically clustered 
using a k-means cluster algorithm resulting in 5 different clusters containing 200, 25, 38, 63 
and 52 transcripts, respectively (Figure 16a). Clusters 1, 2, 3 and 4 contain transcripts which 
are up-regulated (fold change ≥ 2) and cluster 5 contains transcripts which are down-
regulated (fold change ≤ -2) in SPC-HAxTCR-HA vs. SPC-HA lungs. Annotated transcripts 
from cluster 1-5 are indicated in Figure 17 and Figure 18a-d, respectively. Table 5 shows the 
top20 up-regulated genes and their respective fold changes.  
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Figure 16: Transcriptional profile of whole lung tissue from SPC-HA vs. SPC-HAxTCR-HA mice.  
RNA from lung tissue of SPC-HA and SPC-HAxTCR-HA mice (n=3/group) was isolated and samples were 
analyzed on whole transcriptome microarrays. (a) Expression data of 378 regulated transcripts in SPC-HA and 
SPC-HAxTCR-mice were clustered according to expression profile similarities (k-means clustering followed by 
hierarchical clustering of transcripts within clusters). Color code represents z-score; red=transcript induction, 
blue=transcript repression. (b) Scatter plot of all normalized log2 transformed signal intensities (SI). Red dots 
represent transcripts with a fold change ≥ 2 (up-regulated); blue dots represent transcripts with a fold change ≤ -2 
(down-regulated). Black dots represent transcripts not considered regulated (fold change between -2 and 2). 
Gene symbols of the top6 up-/down-regulated genes are indicated as well. 
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Figure 17: Expression data of genes in k-means cluster 1 (see Figure 16a). 
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Figure 18: Expression data of genes in k-means cluster 2 (a), 3 (b), 4 (c) and 5(d); (see Figure 16a). 
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The differential expression of chosen candidate transcripts (Clca3, Glycam1, Igj, Cxcl9) was 
confirmed by qRT-PCR (Figure 19). The microarray analyses revealed Clca3 (FC Array 29.4, 
FC qRT-PCR 262.8), encoding for an epithelial chloride channel protein associated with 
mucus production in respiratory epithelial cells to be most up-regulated gene (Figure 19, 
Table 5). In a murine asthma model Clca3 was associated with goblet cell metaplasia and is 
discussed to be a probable target for intervention of hypersecretory lung diseases (Nakanishi 
et al. 2001). Moreover, Glycam1 (FC Array 23.1, FC qRT-PCR 194.8), encoding for an 
addressin found in high endothelial venules, was found to be highly up-regulated in SPC-
HAxTCR-HA lungs (Figure 19, Table 5). The Cxcl9 transcript (FC Array 12, FC qRT-PCR 
69.6, Figure 19, Table 5) encodes for the T cell-attracting chemokine CXCL9. CXCL9, which 
is also known as monokine induced by gamma interferon (MIG), is induced as a response to 
IFN-γ. Increased levels of CXCL9 were found in induced sputum from patients with COPD 
(Costa et al. 2008) and this cytokine is discussed to potentially perpetuate COPD by 
attracting Th1 and Tc1 cells into the lung which in turn are a major source of CXCL9-inducing 
IFN-γ (Barnes 2008). Also the eosinophil-associated RNase (Ear) 11 was found to be 
induced (FC Array 8.6, Table 5). Ear11 is expressed as response to Th2 cytokines, IL-33 
stimulation and after bacterial priming of the respiratory mucosa. This RNase also possesses 
chemotactic activity for tissue macrophages (Yamada et al. 2015).  
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Table 5: List of top20 most up-regulated transcripts in SPC-HAxTCR-HA lungs. 
Data represent mean ± SD of log2 normalized signal intensities (SI) of triplicate microarray analyses. Expressional fold change (FC) in SPC-HAxTCR-HA lung samples was 
calculated in reference to the SPC-HA lung samples. 
Annotation Description 
SPC-HA  
[log2 SI ±SD] 
SPC-HAxTCR-HA 
[log2 SI ±SD] 
FC 
Clca3 calcium-activated chloride channel, expressed in mucus-producing cells 6,8 ± 0,2 11,7 ± 0,2 29,4 
Glycam1 ligand for L-selectin, expressed in high endothelial venules 6,6 ± 0,2 11,1 ± 0,3 23,1 
Gm5571 immunoglobulin kappa chain variable 9-120 7,6 ± 0,5 11,9 ± 0,1 19,3 
Igk-V1 immunoglobulin kappa chain variable 1 6,1 ± 0,6 9,9 ± 0,6 14,2 
LOC672291 similar to Ig kappa chain V-V region MOPC 173 7,3 ± 0,5 11,1 ± 0,5 14,2 
Igj immunoglobulin joining chain 7,5 ± 0,2 11,2 ± 0,2 13,6 
Cxcl9 chemokine, induced by interferon-gamma 7,3 ± 0,1 10,9 ± 0,4 12 
LOC672291|Igk-J1 similar to Ig kappa chain V-V region MOPC 173|immunoglobulin kappa joining 1 7,5 ± 0,5 11,1 ± 0,3 11,8 
Igk-V19-14 immunoglobulin kappa variable 6-14 7,5 ± 0,4 11,1 ± 0,8 11,6 
Gm4964 immunoglobulin kappa variable 1-135 7,3 ± 0,2 10,6 ± 0,1 9,6 
Gm1502|Gm8760|Igkv4-71 immunoglobulin kappa chain variable 4-70| immunoglobulin kappa variable 4-59| 
immunoglobulin kappa chain variable 4-71 
7,4 ± 0,4 10,6 ± 0,3 9,4 
LOC100046496 similar to Ig kappa V-region 24B 7,2 ± 0,2 10,4 ± 0,8 8,8 
Igl-V1|Igl-V2|LOC433053 immunoglobulin lambda chain, variable 1|immunoglobulin lambda chain, variable 2|similar 
to Ig lambda-1 chain C region 
8,5 ± 0,5 11,7 ± 0,3 8,7 
Ear11 eosinophil-associated, ribonuclease A family, member 11 6,0 ± 0,1 9,1 ± 0,8 8,6 
Igkv4-71|Gm8760|Gm1499 immunoglobulin kappa chain variable 4-71|immunoglobulin kappa variable 4-
59|immunoglobulin kappa chain variable 4-72 
8,5 ± 0,2 11,6 ± 0,1 8,6 
Dnase1l3 deoxyribonuclease 1-like 3 7,0 ± 0,2 10,1 ± 0,5 8,5 
Gm16848 immunoglobulin kappa chain variable 12-41 6,7 ± 0,3 9,7 ± 0,8 8,1 
Igl-V2|Igl-C2 immunoglobulin lambda chain variable 2 | immunoglobulin lambda chain constant region 2 7,4 ± 0,1 10,4 ± 0,3 8 
Gm10880 immunoglobulin kappa variable 4-74 8,0 ± 0,3 11,0 ± 0,1 7,8 
Gm16970|Igh-VX24 immunoglobulin heavy variable 2-2| immunoglobulin heavy chain (X24 family) 8,1 ± 0,2 11,1 ± 0,1 7,7 
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Figure 19: Validation of genes found to be up-regulated (FC>2) in SPC-HAxTCR-HA lungs by qRT-PCR. 
Total lung RNA from SPC-HA and SPC-HAxTCR-HA mice (n=3/group) was isolated and reversely transcribed 
into cDNA. Samples were analyzed by SYBR Green-based qRT-PCR analyses using the ∆∆Ct algorithm. Relative 
expression of indicated transcripts was normalized to the expression of rps9 housekeeping gene. Data represent 
mean ± SD. The expressional fold change of SPC-HAxTCR-HA vs. SPC-HA is indicated. 
 
In order to elucidate the functional meaning of the observed differential gene expression in 
SPC-HAxTCR-HA lungs Gene Ontology (GO) enrichment analyses using Kyoto 
Encyclopedia of Genes and Genomes (KEGG) pathway annotation terms was performed. 
GO analyses of the differentially regulated set of genes revealed highly significant over-
representation of genes associated with the KEGG terms B cell receptor signaling pathway 
(19.2% associated genes, Figure 20) and Intestinal immune network for IgA production 
(19.0% associated genes, Figure 20). Moreover, KEGG terms like T cell receptor signaling 
pathway, Chemokine signaling pathway and Cytokine-cytokine receptor interaction were also 
significantly overrepresented (Table 6) suggesting possible involvement of other functional 
gene groups apart from the abovementioned two. 
Remarkably, among the 20 most intensely up-regulated genes 15 (75%) were 
immunoglobulin-specific (Table 5), including Igj (FC Array 13.6, FC qRT-PCR 192.6, Figure 
19, Table 5), which encodes for the J chain. Taken together, the differential gene expression 
observed in the microarray analyses could be confirmed by the results obtained by qRT-
PCR. 
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Table 6: KEGG pathway enrichment analyses of genes found to be up-regulated (fold change≥2) in SPC-
HAxTCR-HA lungs.  
KEGG ID GO term % associated genes Term p-value corrected 
with Bonferroni 
4662 B cell receptor signaling pathway 19,2 1,20E-11 
4672 Intestinal immune network for IgA 
production 
19 1,70E-06 
4640 Hematopoietic cell lineage 14 3,10E-08 
4660 T cell receptor signaling pathway 13,3 2,10E-09 
4062 Chemokine signaling pathway 10,2 2,10E-11 
4664 Fc epsilon RI signaling pathway 10 1,00E-03 
4666 Fc gamma R-mediated phagocytosis 9,1 5,60E-04 
4514 Cell adhesion molecules (CAMs) 8,8 5,90E-07 
4612 Antigen processing and presentation 8,6 2,60E-03 
4060 Cytokine-cytokine receptor 
interaction 
8,3 8,00E-11 
4064 NF-kappa B signaling pathway 7,9 1,50E-03 
4610 Complement and coagulation 
cascades 
7,8 1,50E-02 
4650 Natural killer cell mediated 
cytotoxicity 
6,7 4,90E-03 
4670 Leukocyte transendothelial migration 6,6 5,50E-03 
4145 Phagosome 5,7 2,80E-03 
 
 
 
Figure 20: Expression data of transcripts from indicated GO terms in SPC-HA and SPC-HAxTCR-HA mice.  
Color code represents z-score, red=transcript induction, blue=transcript repression. 
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Altogether, these findings reveal that local chronic inflammatory imprinting encompasses 
substantial alterations in the lung tissue transcriptome. These most likely reflect disease-
driven alterations in cytokine-orchestrated recruitment of leukocytes as well as their 
intercellular communication pathways. This suggests a markedly changed pulmonary cellular 
composition in SPC-HAxTCR-HA mice - which is well in line with e.g. the lymphocytic 
infiltrates previously observed in this group (Bruder, Westendorf et al. 2004, Figure 12a). 
Particularly correlating with this finding is the great dominance of B-lymphocyte specific 
transcripts among the top20 up-regulated transcripts (Table 5). The latter in combination with 
the general enrichment of transcripts with roles in B cell- and IgA-specific immune networks, 
respectively (Figure 20, Table 6); also suggests a possible role for humoral immunity in 
antimicrobial host defense in SPC-HAxTCR-HA lungs. 
 
 Altered BALF proteome composition in SPC-HAxTCR-HA mice 5.1.6
The finding that bacterial transmigration was blunted in SPC-HAxTCR-HA mice despite 
unaltered phagocyte function suggested an altered composition of soluble factors (e.g. 
secreted proteins) lining the airway mucosal surface in these mice. Well in line with this, the 
microarray analyses indicated an induction of several soluble mediators with hypothetical 
contributions to humoral immunity in SPC-HAxTCR-HA lungs. In a next step, it should thus 
be determined whether the proteins present in the airways differ between both mouse 
groups. 
To this end BALF proteome (BALFome) analyses were performed using LC-MS/MS 
technology. BALF represents a highly diluted form of the lung mucosal fluid and besides 
leukocytes contains proteins with broad antimicrobial functions. The analysis of BALF 
samples pooled from 5 mice per group revealed a total of 602 proteins of which 372 (~60%) 
were present in BALF of both groups. 129 proteins were exclusively present in SPC-HA 
BALF whereas 101 proteins were only present in SPC-HAxTCR-HA BALF (Figure 21a). To 
identify the major biological pathways represented by the identified proteins, gene ontology 
(GO) analyses of the complete BALFome of SPC-HA mice (501 proteins) and SPC-HAxTCR-
HA mice (473 proteins) were performed using KEGG pathway annotation terms. This yielded 
similar coverages of associated factors of the top5 terms (Proteasome, Pyruvate metabolism, 
Glutathione metabolism, Pentose phosphate pathway, Glycolysis/Gluconeogenesis) that are 
involved in protein degradation and carbohydrate metabolism in SPC-HA and SPC-HAxTCR-
HA BALF. These analyses also yielded GO terms uniquely detected in BALFomes of SPC-
HA (e.g. valine, leucine and isoleucine degradation) or SPC-HAxTCR-HA mice (regulation of 
actin cytoskeleton, see section 7.1.2, Table 15) indicating that inflammatory priming 
encompasses distinct proteomic adaptions affecting metabolic and cytoskeletal cellular 
activities on the mucosal surface. 
Interestingly, the comparison of all up-regulated and annotated transcripts from SPC-
HAxTCR-HA lungs (251 identified genes) with the proteins (identified by protein accession 
ID) exclusively detected in SPC-HAxTCR-HA BALF yielded an overlap of 10 proteins (Figure 
21b). Among those were macrophage metalloelastase (Mmp12, FC Array 5.2, see section 
7.1.1, Table 10) and cathepsin S (Ctss, FC Array 2.4, see section 7.1.1, Table 10), which has 
been shown to be expressed by AMs and AECs (Shi et al. 1992, Storm van's Gravesande et 
al. 2002). These proteases have elastolytic activity and are associated with the development 
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of alveolar emphysema (Zheng et al. 2000). Moreover, chitinase-like 3 protein (Chil3, FC 
Array 4.0, see section 7.1.1, Table 10) and resistin-like alpha (Retnla, FC Array 6.6, see 
section 7.1.1, Table 10) were also uniquely detected in the SPC-HAxTCR-HA BALFome. 
Both proteins are produced by airway macrophages and AECs and are found in settings of 
sterile pulmonary inflammation (Dasgupta et al. 2011). Interestingly, and in line with the 
transcriptome data, 3 proteins associated with secretory antibody-mediated immunity were 
identified: the immunoglobulin alpha chain C region (Igh-VJ558, FC Array 3.9, see section 
7.1.1, Table 10), the immunoglobulin J chain (Igj, Table 5, Figure 19) and the polymeric 
immunoglobulin receptor (Pigr, FC Array 3.4, see section 7.1.1, Table 10). In summary, 
these proteome analyses complemented the previous transcriptome analyses and 
strengthened the hypothesis of an enhancement of humoral immunity in SPC-HAxTCR-HA 
mice.  
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Figure 21: Comparison of BALF proteome from SPC-HA vs. SPC-HAxTCR-HA mice. 
(a) Venn diagram comparing LC-MS/MS-identified proteins from bronchoalveolar lavage fluid (BALF) of SPC-HA 
and SPC-HAxTCR-HA mice. Samples were pooled from 5 mice/group. (b) Venn diagram comparing the presence 
of transcripts with a fold change (FC) ≥ 2 in lungs of SPC-HAxTCR-HA mice vs. the presence of proteins uniquely 
detected in BALF from SPC-HAxTCR-HA mice. 
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 Elevated secretory antibody levels in the airways of SPC-HAxTCR-5.1.7
HA mice 
Based on the previous findings the absolute levels of BALF immunoglobulins (Igs) in healthy 
and chronically inflamed lungs were compared by ELISA. This revealed an >11-fold increase 
in IgA levels in BALF of SPC-HAxTCR-HA mice compared to SPC-HA mice. Likewise, BALF 
IgM levels were elevated to an equal extent (Figure 22a). Interestingly, serum IgA and IgM 
levels were similar between both groups (Figure 22b), suggesting that elevated BALF IgA 
and IgM levels arise from increased Ig transport from the lung tissue into the lung lumen in 
SPC-HAxTCR-HA mice. However, since SPC-HAxTCR-HA BALF also contained increased 
albumin levels (Figure 12c), it had to be tested whether the increase in airway IgA and IgM is 
due to active pIgR-mediated transcytosis through the epithelial barrier rather than to passive 
diffusion of serum components. To this end, the abundance of secretory IgA (SIgA) in BALF 
was compared by ELISA using an anti-IgA capture antibody and a specific anti-pIgR 
detection antibody. By doing so, the specific abundance of pIgR-associated and thus 
transcytosed SIgA – but no monomeric or conventional dimeric IgA molecules - was 
quantified. Indeed, significantly higher mean ODs (>6-fold at 1:10 BALF dilution) were 
detected in BALF samples from SPC-HAxTCR-HA mice (Figure 22c), confirming that the 
increase in airway IgA levels arose from amplified mucosal transport rather than passive 
transepithelial diffusion. This is likely to hold true also for SIgM since both molecules share 
the same transport mechanism (Strugnell and Wijburg 2010). 
  
Results 
59 
 
 
Figure 22: Secretory antibody levels in SPC-HA vs. SPC-HAxTCR-HA mice. 
Absolute IgA and IgM levels in (a) bronchoalveolar lavage fluid and (b) serum of SPC-HA and SPC-HAxTCR-HA 
mice were determined by ELISA. (c) Relative secretory IgA concentrations in serial dilutions of BALF samples 
were determined by ELISA. Results are expressed as the mean optical density (OD) at 450nm ± SEM, *p< 0.05, 
** p<0.01 (n=6-7 mice/group). 
Previous studies reported inflammatory stimuli to lead to increased pIgR levels and an up-
regulation of SIg transport by mucosal epithelial cells (Cao et al. 2012, Jaffar, Ferrini et al. 
2009). Taking the elevated BALF SIgA protein levels in the SPC-HAxTCR-HA group into 
account (Figure 22c), elevated pulmonary Pigr gene expression was expected, as the 
pIgR/SIgA binding & transport mechanism involves a 1:1 stoichiometry (Kaetzel et al. 1991). 
In line with this, the microarray analyses already revealed Pigr up-regulation in SPC-
HAxTCR-HA lungs (see section 7.1.1, Table 10). For this reason pIgR abundance in the 
respiratory tract of SPC-HAxTCR-HA and SPC-HA mice was probed in more detail. Initially, 
Pigr gene expression was probed by qRT-PCR using total RNA from whole lung 
homogenates of SPC-HA and SPC-HAxTCR-HA mice (n=3/group). Pigr gene expression 
was confirmed to be up-regulated 3.3-fold in SPC-HAxTCR-HA vs. SPC-HA lungs (Figure 
23a). Next, using whole lung homogenates from both mouse groups (n=4/group) pIgR 
protein abundance was analyzed by Western Blot. High pIgR levels were found in the SPC-
HAxTCR-HA group whereas this protein was almost not detectable in the SPC-HA group 
(Figure 23b). Given the rather modest increase in transcript levels this suggests pIgR protein 
levels to be regulated at a translational (or post-translational) rather than at the 
transcriptional level. In order to examine the spatial distribution of pIgR expression in more 
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detail immunofluorescence analyses of lung tissue sections from SPC-HA and SPC-
HAxTCR-HA mice were conducted. Briefly, 6µm acetone-fixed lung cryosections were 
blocked and incubated with an anti-pIgR primary antibody as well as FITC-labelled 
secondary antibody. Additionally, in order to better identify the respective pulmonary 
microstructures, DAPI nuclear counterstain was performed. Interestingly, localization 
analyses revealed increased pIgR protein expression in the alveoli of SPC-HAxTCR-HA 
mice, where it was restricted to single, cuboidal epithelial cells; likely to be ATII (Figure 23c). 
Taken together, these data closely link chronic endogenous airway inflammation to the boost 
of epithelial-governed pIgR-dependent transport of mucosal antibodies which may improve 
immunity to Streptococcus pneumoniae. 
 
Figure 23: Increased pIgR-expression in SPC-HAxTCR-HA lungs. 
(a) Pigr gene expression was quantified by qRT-PCR. Results are depicted as relative expression values 
normalized to Actb housekeeping gene expression. (b) anti-pIgR immunoblot of whole lung homogenates of SPC-
HA and SPC-HAxTCR-HA mice. (c) Lung tissue sections were stained with goat anti-pIgR and detected by 
secondary anti-goat FITC-labeled antibody (green), depicted are representative alveolar structures from 
n=3/group from one of two independent experiments with similar outcome. Magnification: 20x 
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 BALF from SPC-HAxTCR-HA mice has an increased pneumococcal 5.1.8
binding capacity 
SIgA and SIgM are key components of the mucosal barrier towards viral and bacterial 
pathogens and SIg deficiency is associated with increased susceptibility to respiratory 
infections in mice (Brown, Hussell et al. 2002, Sun, Johansen et al. 2004) and humans (Latiff 
et al. 2007, Louis et al. 2014). To test a possible link between elevated SIg levels in the 
BALF (Figure 22c) and enhanced antipneumococcal resistance (Figure 13) in SPC-HAxTCR-
HA mice flow cytometry-based bacterial binding assays were performed (see section 4.2.12 
for further details). Briefly, pneumococci were incubated with BALF supernatants from SPC-
HA and SPC-HAxTCR-HA mice and opsonized bacteria were identified by surface staining 
against IgA or IgM, respectively. Pneumococci were subsequently analyzed by FACS for the 
percentage of positively stained bacterial cells and their respective fluorescence intensities. 
As controls unopsonized pneumococci were incubated with the respective anti-IgA or anti-
IgM antibodies (see Figure 24a and d). Despite increased SIgA concentrations in SPC-
HAxTCR-HA BALF (Figure 22c), similar fractions of IgA-positive pneumococci following 
incubation with both SPC-HAxTCR-HA as well as SPC-HA BALF (5.7% vs. 6.6%) were 
detected (Figure 24b). Quantification of relative fluorescence however indicated a 
significantly higher IgA deposition on pneumococci that were incubated with BALF from SPC-
HAxTCR-HA mice (median index 1.16 vs. 1.01, Figure 24c). Moreover, incubation with BALF 
from SPC-HAxTCR-HA mice yielded increased portions of IgM-positive pneumococci (Figure 
24e) as well as enhanced IgM deposition when compared to incubation with BALF from 
SPC-HA mice (Figure 24f).  
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Figure 24: Increased pneumococcal binding capacities by lung mucosal fluid of SPC-HAxTCR-HA mice. 
S.pneumoniae TIGR4 were inoculated with bronchoalveolar lavage fluid (BALF) supernatants from SPC-HA and 
SPC-HAxTCR-HA mice. Bacteria were stained with anti-mouse IgA or anti-mouse IgM antibodies and analyzed 
by flow cytometry. (a) Representative FACS plots of IgA
+
 pneumococci incubated with BALF from SPC-HA or 
SPC-HAxTCR-mice; control samples (CTRL) were stained with anti-IgA without prior incubation with BALF (b) 
Percentages of IgA
+
 pneumococci and (c) relative fluorescence intensities of IgA
+
 pneumococci. (d) 
Representative FACS plots of IgM
+
 pneumococci incubated with BALF from SPC-HA or SPC-HAxTCR-mice; 
control samples (CTRL) were stained with anti-IgM without prior incubation with BALF. (e) Percentages of IgM
+
 
pneumococci and (f) relative fluorescence intensities of IgM
+
 pneumococci. Relative fluorescence intensities are 
calculated by the ratio of the MFI of each individual sample over the mean MFI of the SPC-HA control group. Data 
are pooled from 2 independent experiments with similar results. *p<0.05 **p<0.01, ***p<0.001 
 
In conclusion, by using the SPC-HAxTCR-HA transgenic model for CRD it was demonstrated 
in the first part of this thesis that chronic inflammatory imprinting in the lung is associated 
with marked changes in the transcriptomic and proteomic pulmonary profile indicating 
inflammation-induced milieu adaptations. Microarray and mass spectrometric analyses 
pointed towards a beneficial enhancement of the SIg axis in inflamed lungs and suggested a 
possible involvement of the pulmonary epithelium therein. Finally, increased pIgR-mediated 
SIg transepithelial transport led to augmented pneumococcal binding by IgA and IgM. These 
findings point towards a fundamental role of inflammation-primed airway epithelial cells in 
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humoral antimicrobial immunity by reinforcing the mucosal barrier and thereby counteracting 
pneumococcal adhesion and tissue penetration.  
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5.2 Phenotype and function of alveolar macrophages (AMs) in 
chronic endogenous lung inflammation 
 AMs from SPC-HAxTCR-HA mice show an altered phenotype 5.2.1
While the first part of this work focussed on the immunological implications of CRD on 
pulmonary antibacterial defense, the second part specifically addressed the contributions of 
AMs to immune regulation and inflammation within the chronically diseased lung.  
Endogenous lung inflammation as displayed by SPC-HAxTCR-HA mice has previously been 
shown to involve a complex network of autoreactive and immunoregulatory mechanisms that 
are associated with substantial molecular and phenotypic alterations in the self-reactive T 
cell pool as well as in alveolar epithelial type II cells (Bruder, Westendorf et al. 2004, Gereke 
et al. 2007). Of note, it was previously demonstrated by others that alveolar macrophages 
are able to communicate with both ATII and effector T cells (Bingisser, Tilbrook et al. 1998, 
Blumenthal, Campbell et al. 2001, Bourdonnay, Zaslona et al. 2015, Westphalen, Gusarova 
et al. 2014). Yet, the role of AMs in chronic, pulmonary inflammation is not completely 
understood. Despite the unaltered numbers and phagocytosis rates of AMs in SPC-HAxTCR-
HA mice it is conceivable that the inflammatory milieu and/or immunoregulatory mechanisms 
might affect the phenotype and immunologic functions of these cells. Therefore, the second 
part of this work aimed to examine the AM phenotype in the SPC-HAxTCR-HA model. 
For a primary characterization of the AM phenotype in chronic lung inflammation, these cells 
were recovered from SPC-HA and SPC-HAxTCR-HA mice by BAL and were subjected to 
morphologic analyses by conventional flow cytometry (FACS) as well as imaging flow 
cytometry. In FACS analyses AMs were identified as FSChighSSChighF4-
80+autofluorescencehigh cells. FACS analyses revealed AMs from diseased SPC-HAxTCR-
HA mice to have significantly smaller size compared to AMs from healthy SPC-HA control 
mice - indicated by reduced forward scatter (FSC) properties. Moreover, quantification of 
autofluorescence – an intrinsic AM-characteristic generally caused by electron-dense 
molecules – resulted in significantly reduced indices for AMs from SPC-HAxTCR-HA mice 
(Figure 25a). 
In imaging flow cytometry, AMs were identified as F4-80+CD11c+CD3- cells. These analyses 
yielded altered cytoplasmic signals in AMs from SPC-HAxTCR-HA mice reflected by 
alterations of side scatter (SSC) characteristics (area, general intensity and bright detail 
intensity, Figure 25b), indicating a markedly changed cellular texture of alveolar 
macrophages in a persistent inflammatory pulmonary environment. In summary these results 
evidence chronic lung disease as displayed by SPC-HAxTCR-HA mice to manifest in distinct 
modifications affecting natural cellular fluorescence as well as refractive properties of AMs, 
thereby suggesting substantial qualitative and/or quantitative alterations in the intracellular 
molecular composition. 
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Figure 25: Flow cytometric analyses of AM morphology in SPC-HA vs. SPC-HAxTCR-HA lungs. 
(a) BAL cells from SPC-HA (n=6) and SPC-HAxTCR-HA (n=6) mice were analyzed by FACS; AMs were identified 
as FSC
high
SSC
high
F4-80
+
autofluorescence
high
 cells. Relative FSC and autofluorescence was calculated by: median 
fluorescence intensity (MFI) of individual sample over the mean MFI of the SPC-HA (healthy) control group. 
Representative histogram depicts autofluorescent signal intensities of AMs from SPC-HA (grey shaded) vs. SPC-
HAxTCR-HA (dashed line) mice and their respective MFI (see numbers). (b) BAL cells from SPC-HA (n=5) and 
SPC-HAxTCR-HA (n=6) mice were analyzed by imaging flow cytometry (analyzed SSC-parameters: intensity, 
area, bright detail intensity); AMs were identified as F4-80
+
CD11c
+
CD3
- 
cells. Statistical analyses were performed 
by using unpaired, two-tailed Mann-Whitney-test. * p<0.05, ** p<0.01 (c) Representative images from imaging 
flow cytometer FlowSight® of alveolar macrophages from SPC-HA and SPC-HAxTCR-HA mice, PB: pacific blue 
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 AMs from SPC-HAxTCR-HA mice display an activated phenotype 5.2.2
Further comparative morphologic analyses of alveolar macrophages were conducted using 
Pappenheim-stained cytospin samples of bronchoalveolar lavage fluid cells from SPC-HA 
and SPC-HAxTCR-HA mice. Microscopic evaluation demonstrated AMs from diseased SPC-
HAxTCR-HA mice to display an activated phenotype, specified by increased formations of 
membrane protrusions (see black arrows in Figure 26).  
Together, the observed morphologic alterations provide further evidence for an impact of 
chronic pulmonary inflammation on cellular properties of alveolar macrophages and establish 
a basis for extended investigations regarding functional alterations of AMs in murine lung 
disease. 
 
Figure 26: Analyses of AM morphology by light microscopy. 
Cytospins from BAL samples from SPC-HA and SPC-HAxTCR-HA were stained with May-Grünwald and Giemsa 
reagent (Pappenheim method) and cell morphology was analyzed by light microscopy. Depicted are 
representative images of alveolar macrophages from n=4 mice/group at 63x magnification. Scale bar: 10µm. 
Black arrows indicate membrane protrusions. 
 M2 signature of AMs from SPC-HAxTCR-HA mice 5.2.3
Inflammatory conditions in multiple infectious as well as non-infectious disease settings are 
intimately linked to macrophage polarization into classically activated M1 or alternatively 
activated M2 phenotypes (see sections 2.5 and 2.7). Briefly, M1 macrophages are 
considered to play roles in the initiation and maintenance of inflammation (e.g. acute 
infection, immunologic inflammatory disorders) whereas M2 phenotypes are implicated in 
resolution of inflammation and wound healing but also in several settings of chronic 
inflammation and infection (Sica and Mantovani 2012). Previous results from whole lung 
microarray and BALFome analyses yielded the following proteins to be specifically induced 
and overrepresented in SPC-HAxTCR-HA lungs: Chitinase-like 3 protein (also known as 
Ym1) and resistin-like alpha as well as macrophage metalloelastase 12 (Figure 21b). 
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Noteworthy, these 3 factors are typical M2-markers (Kahnert, Seiler et al. 2006, Raes et al. 
2002) which are associated with the breakdown and reorganization of extracellular matrix 
(Mosser and Edwards 2008) and the development of pulmonary emphysema in COPD 
patients (Molet et al. 2005), respectively. Based on these observations it seemed likely to 
discover M2-polarized AMs in SPC-HAxTCR-HA mice. In order to test this hypothesis, BALF 
cells from SPC-HA and SPC-HAxTCR-HA mice were isolated and AMs were purified by 
adhesion (see section 4.2.8). This method allowed for the fast and efficient isolation of highly 
pure (~95%) alveolar macrophages as illustrated in Figure 27.  
 
Figure 27: Purification of AMs by adhesion. 
Alveolar macrophages (AMs) from erythrocyte-depleted BALF cell suspensions were purified by adhesion (90min, 
37°C) on bacteriological plastic, detached by trypsin-EDTA treatment and purity was verified by FACS analysis. 
Left square depicts percentages of AMs (CD11c
high
, F4-80
+
) of analyzed singlets in non-purified BALF samples 
from SPC-HAxTCR-HA mice. Right square depicts AM percentages of BALF cells from SPC-HAxTCR-HA mice 
after purification. Note the decreased abundance of the surface molecule CD11c on AMs after trypsin-EDTA 
detachment. 
 
Next, comparative gene expression analyses of total RNA isolated from purified, pooled AM 
samples (n=3-5 mice/group) from SPC-HA vs. SPC-HAxTCR-HA mice were conducted by 
quantitative real-time RT-PCR. Here, up-regulation of the genes encoding for the secreted 
protein resistin-like alpha (Retlna, fold change 16.1) and also the extracellular receptor 
macrophage scavenger receptor 1 (Msr1, fold change 5.5, Figure 28). Expression of 
macrophage scavenger receptor 1, also known as scavenger receptor A1 or CD204, is 
increased in M2 macrophages and contributes to increased uptake of low-densitity 
lipoprotein, but also of apoptotic cell material by these cells (Canton et al. 2013).  
Collectively, these results support the hypothesis of an M2 AM-phenotype – associated with 
increased expression of specific surface molecules and secreted products - in SPC-
HAxTCR-HA lungs and moreover suggest these cells likely to be the cellular source of the 
M2-proteins found in the BALF from this group. 
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Figure 28: AMs from SPC-HAxTCR-HA mice display an M2-signature. 
Purified alveolar macrophages from SPC-HA and SPC-HAxTCR-HA mice were pooled (n=3-5 mice/group), RNA 
was extracted and relative expression of indicated transcripts (normalized to Actb housekeeping gene) was 
determined by one-step qRT-PCR. Relative gene expression was normalized to the SPC-HA control group.  
 
 AMs from SPC-HAxTCR-HA mice are hyporesponsive to stimulation 5.2.4
with pneumococcal ligands 
Following recognition of respiratory pathogens alveolar macrophages mount a pro-
inflammatory immune response by secreting (among other mediators) TNF-α (Schabbauer et 
al. 2010). This step is critical for the rapid elimination of microbial threats but on the other 
hand involves the risk to develop immune pathology at the expense of lung tissue integrity. In 
order to test the influence of chronic lung inflammation on the AM-mediated pro-inflammatory 
response following pathogen recognition, SPC-HAxTCR-HA mice and SPC-HA control mice 
were oropharyngeally inoculated with ethanol-killed Streptococcus pneumoniae TIGR4. 
Here, application of inactivated pneumococci allowed to study the very early innate 
recognition-triggered cytokine response while at the same time excluding confounding effects 
(e.g. from differential bacterial replication and invasion rates) to be detected. The early 
airway inflammatory response was quantified by assessing TNF-α levels in BALF at 4h 
following inoculation by ELISA. As expected, bacterial recognition led to an early and robust 
cytokine response in the airways of healthy SPC-HA mice. Strikingly, TNF-α levels were 
~60% decreased in the pre-diseased SPC-HAxTCR-HA group (Figure 29, left panel). 
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Figure 29: Blunted inflammatory response towards bacterial ligands in SPC-HAxTCR-HA mice is AM-
dependent. 
Mice were oropharyngeallly inoculated with 50µL clodronate liposomes on d0, control mice received PBS. At d3 
mice were administered 10
6
 CFU ethanol-killed S. pneumoniae TIGR4 (ek S.pn.) or PBS, respectively. 4h after 
bacterial inoculation, mice were sacrificed and TNF-α levels in bronchoalveolar lavage fluid was determined by 
ELISA. Depicted are mean results ± SEM of pooled samples from 2 independent experiments. (n=6-10/group). 
Statistical significance was calculated using two-way ANOVA followed by Bonferroni post-test. *** p<0.001. 
 
In order to verify that this blunted inflammatory response was mediated by alveolar 
macrophages, these cells were depleted by oropharyngeal administration of clodronate 
liposomes (Clod) 3 days prior bacterial stimulation. Clodronate treatment lead to a 75% 
reduction of viable AM numbers in the BALF (Mean ± SEM AM counts of PBS-group vs. Clod 
group: 25383±6040 vs. 6330±1536) within 3 days, whereas the single administration of 
control liposomes (PBS-Lip) or carrier solution (PBS) had no effect on alveolar macrophage 
numbers (Figure 30, upper panel). Moreover, quantitative analyses of macrophage subsets 
in the lung tissue 3 days post treatment revealed that the reduction of alveolar macrophages 
was restricted to bronchoalveolar spaces whereas the percentages of lung-tissue resident 
alveolar macrophages (AMs) and interstitial macrophages (IMs) remained unaffected (Figure 
30, lower panel). These findings confirmed that the chosen clodronate-depletion strategy is 
an adequate tool to specifically study the function of alveolar macrophages within the airways 
in vivo. Notably, TNF-α levels following bacterial stimulation in AM-depleted mice were 
substantially reduced and close to detection limit in both mouse groups (Figure 29, right 
panel). Taken together, this validates AMs to be the main early airway TNF-α source 
following pneumococcal stimulation and, more importantly, suggests a functional adaptation 
of these cells in chronic lung disease. 
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Figure 30: Oropharyngeal clodronate treatment selectively depletes macrophages in bronchoalveolar 
spaces. 
SPC-HA mice were oropharyngeally inoculated with 50µL Clodronate-Liposomes (Clod), PBS-Liposomes (PBS-
Lip) or PBS only. At d3 post administration mice were sacrificed, alveolar macrophages (CD11c
high
F4-
80
+
autofluorescence
high
) in BALF and lung tissue (CD11c
high
 CD11b
dim
 F4-80
+
) and interstitial macrophages (IMs, 
CD11c
high
 CD11b
high
 F4-80
+
) in lung tissue were quantified by flow cytometry. Data from BALF analyses were 
pooled from two independent experiments with similar outcomes. Statistical significance was calculated using 
one-way ANOVA followed by Bonferroni post-test. * p<0.05; **p<0.01. 
 
 Absence of AMs aggravates disease pathology and establishes 5.2.5
bronchopneumonia in SPC-HAxTCR-HA mice 
So far, the obtained data have revealed a substantially different alveolar macrophage 
phenotype and function in SPC-HAxTCR-HA mice. In a next step, the immunological role of 
these cells in the context of chronic lung inflammation was to be further explored by in vivo 
clodronate-depletion experiments. In order to consider possible effects of short-term as well 
as medium-term macrophage depletion, analyses were performed either at d3 or at d10 (the 
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latter included two additional successive clodronate administrations at d5 and d8) post 
primary clodronate treatment, respectively (n=6-8/group, see Figure 31). Lungs from 
clodronate-treated as well as PBS–treated control mice were removed either on d3 or d10 
post treatment and histopathological evaluation of lung tissue sections were performed; the 
latter especially under the aspect of lung infiltrating lymphocytes. Here, a scoring ranging 
from 1 to 4 was applied in which 1 means minimal, 2 means moderate, 3 is profound and 4 
indicates severe lymphocytic infiltrations. 
 
Figure 31: Experimental strategy of clodronate-mediated alveolar macrophage-depletion. 
 
As described in section 5.1.1 lung pathology in SPC-HAxTCR-HA mice is generally 
characterized by mild to moderate multifocal, peribronchiolar and perivascular lymphocytic 
infiltrations. Interestingly, already at d3 after macrophage depletion one third of SPC-
HAxTCR-HA mice displayed severe lymphocytic infiltrations and at d10 post primary 
depletion even 50% of SPC-HAxTCR-HA lungs are affected by severe lymphocytic 
infiltrations. In large contrast, alveolar macrophage depletion in SPC-HA mice is neither 
associated with lymphocytic infiltrations nor other histopathological manifestations (Figure 
32). 
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Figure 32: Absence of AMs increases lung pathology in SPC-HAxTCR-HA mice. 
SPC-HA and SPC-HAxTCR-HA mice were inoculated with clodronate liposomes according to the scheme in 
Figure 31. Control mice were inoculated with PBS. At indicated time points post primary clodronate treatment, 
mice were sacrificed and lung pathology was evaluated by hematoxylin and eosin (H&E) staining. Depicted are 
representative microscopy images and histological scores indicating the degree of lymphocytic infiltration 
(1=minimal, 2=moderate, 3=profound, 4=severe) from two independent experiments with similar results. 
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(n=6-8/group) Black scale bar: 100µm, magnification: 10x 
Of note, histopathological analyses also revealed the development of mild to severe 
multifocal, catarrhal-ulcerous and necrotizing bronchopneumonia at d10 post depletion in 
SPC-HAxTCR-HA mice, i.e. the presence of mucous and leukocyte - especially neutrophilic 
granulocytes - exudates as well as tissue necrosis (Figure 33). 
 
Figure 33: Absence of AMs provokes bronchopneumonia in SPC-HAxTCR-HA mice. 
SPC-HA and SPC-HAxTCR-HA mice were inoculated with clodronate liposomes according to the scheme in 
Figure 31. At d10 post primary clodronate treatment, mice were sacrificed and lung pathology was evaluated by 
hematoxylin and eosin (H&E) staining. Depicted are representative images and histological scores from SPC-
HAxTCR-HA lungs from two independent experiments with similar results.(n=6-8/group). Black scale bar: 50µm, 
magnification: 20x 
 
Well in line with this finding, flow cytometric analyses of BALF cells from SPC-HA and SPC-
HAxTCR-HA mice at d10 post primary depletion revealed a pronounced infiltration of viable 
neutrophilic granulocytes into the airways of SPC-HAxTCR-HA mice, indicative of florid lung 
inflammation (Figure 34). 
Results 
 
 
74 
 
 
Figure 34: Pronounced neutrophilic airway infiltration in AM-depleted SPC-HAxTCR-HA mice. 
SPC-HA and SPC-HAxTCR-HA mice were inoculated with clodronate liposomes according to the scheme in 
Figure 31. At d10 post primary clodronate treatment, mice were sacrificed and bronchoalveolar lavage cells were 
analyzed by FACS. Neutrophils were identified as CD11b
high
 and Ly6G
high
 cells (red oval). Alveolar macrophage 
populations (autofluorescence
high
) are indicated by red arrows. (b) Total neutrophil counts in bronchoalveolar 
lavage fluid. Data are pooled from two independent experiments with similar outcomes. Statistical significance 
was calculated using two-way ANOVA followed by Bonferroni post-test. *** p<0.001. 
 
In summary, these data suggest that alveolar macrophages are involved in the maintenance 
of disease regulation in SPC-HAxTCR-HA lungs. Consequently their absence amplifies the 
typical disease pattern of chronic, autoimmune-mediated lung inflammation. More 
importantly, the AM–dependent appearance of non-typical disease pathology (neutrophilic 
bronchopneumonia) in SPC-HAxTCR-HA mice clearly indicated a unique, previously 
unknown, regulatory role of these cells within the inflammatory framework of SPC-HAxTCR-
HA lungs which needed to be further investigated. 
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 No impact of AM-depletion on CD43 expression on autoreactive T 5.2.6
cells  
SPC-HAxTCR-HA mice develop severe acute lung inflammation shortly after birth which is 
associated with strong T cell activation and the resulting pathologic immune responses 
orchestrated by these cells. Yet, during adolescence immunological tolerance mechanisms 
are established in SPC-HAxTCR-HA mice. These include reduced proliferative capacity of 
auto-reactive T cells as well as their conversion into Foxp3+ regulatory T cells (Tregs) and 
are associated with a state of chronic - but controlled - inflammation in adult SPC-HAxTCR-
HA mice (Bruder, Westendorf et al. 2004, Gereke, Jung et al. 2009). Of note, macrophages 
are able to interfere with T cell activation as well as participate in Treg induction (see section 
2.6.1)  
Pulmonary macrophages can potently suppress T cell activation by TGFβ and prostaglandins 
(Roth and Golub 1993). Moreover, AM-derived TGFβ and retinoic acid has been associated 
with the induction of Tregs (Soroosh, Doherty et al. 2013). Given these macrophage-inherent 
mechanisms of controlling T lymphocyte immunity and the observation that AM-abolishment 
coincided with lymphocyte influx in SPC-HAxTCR-HA lungs it seemed conceivable to expect 
increased activity of the autoreactive T cell pool as a result of the loss of direct or indirect 
immunoregulatory mechanisms. Accordingly, the observed pathologic neutrophil infiltrations 
in this group would be a side effect mediated by over-exuberant T cell immune responses 
and the resulting tissue injury. 
In order to test this hypothesis, the role of AMs in immune regulation of HA-specific T cell 
activation in SPC-HAxTCR-HA lungs was assessed. The number of HA-specific (CD3+6.5+) T 
cells in bronchoalveolar spaces (BALF) as well as the lung tissue was determined in PBS-
treated and clodronate-treated (d10) SPC-HAxTCR-HA mice. Significantly increased 
numbers of HA-specific CD3+ T cells were found in BALF from AM-depleted compared to 
PBS-treated SPC-HAxTCR-HA mice (Figure 35, upper left panel). This was however not 
accompanied with significantly increased numbers of HA-specific CD3+ T cells in lung tissue 
from AM-depleted SPC-HAxTCR-HA mice (Figure 35, lower left panel) Moreover, the 
activation status of HA-specific CD3+ T cells was determined by quantification of the surface 
marker CD43 (leukosialin). In a model of respiratory virus infection CD43 was shown to be 
highly expressed on activated memory CD4+ T cells in the BAL fluid as well in the lung tissue 
(Hogan et al. 2001). Furthermore antigen-specific CD8+ effector T cells have been shown to 
up-regulate CD43 (Harrington et al. 2000). Using CD43-expression as a readout for cellular 
activation of HA-specific T cells, no significant differences between T cells isolated from 
either AM-sufficient and AM-deficient SPC-HAxTCR-HA lungs became apparent (Figure 35, 
upper and lower right panel).  
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Figure 35: Bronchopneumonia induced by AM-depletion in SPC-HAxTCR-HA mice is not associated with 
autoreactive T cell activation. 
SPC-HAxTCR-HA mice were inoculated with clodronate liposomes (Clod-group) according to the scheme in 
Figure 31. Control mice were inoculated with PBS (CTRL-group). At d10 post primary clodronate treatment, mice 
were sacrificed and the number of autoreactive T cells (CD3
+
6.5
+
) in the airways (BALF) and the lung tissue was 
determined by cell counting and FACS analyses. CD43 expression on CD3
+
6.5
+
 T cells was quantified by 
assessing CD43 median fluorescence intensity (MFI) and results are expressed as relative fluorescence indices. 
Depicted are pooled results from two independent experiments with similar results (n=6-7/group). Statistical 
analyses were performed by using unpaired, two-tailed Mann-Whitney-test. ** p≤0.01 
 
In order to further examine the possible role of AM/T cell interaction (for details see above) in 
SPC-HAxTCR-HA mice, gene expression of TGFβ (Tgfβ), prostaglandin-endoperoxide 
synthase 2 (Ptgs2, catalyzes first conversion step from arachidonic acid to prostaglandins) 
and retinaldehyde dehydrogenase 2 (Raldh2, catalyzes synthesis of retinoid acid from 
retinaldehyde) in alveolar macrophages from SPC-HA control and SPC-HAxTCR-HA mice 
was compared. This revealed only a slight (FC<2) up-regulation of all three transcripts in 
AMs from SPC-HAxTCR-HA mice.  
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Figure 36: AMs from SPC-HAxTCR-HA mice have slightly elevated expression of genes involved in AM/T 
cell interaction. 
Purified alveolar macrophages from naive SPC-HA and SPC-HAxTCR-HA mice were pooled (n=3-5 mice/group), 
RNA was extracted and relative expression of indicated transcripts was determined. Gene expression was 
normalized to the SPC-HA control group. 
 
In summary, these data could not support the hypothesis of a contribution of the AM/T cell 
axis to immunoregulatory mechanisms in SPC-HAxTCR-HA lungs. Accordingly, pathologic 
immune responses of re-activated self-antigen specific T cells do not – or only partly - 
contribute to the histopathological findings in AM-depleted SPC-HAxTCR-HA lungs. It is 
however possible that AM-depletion (albeit not linked to amplified T cell activation, as shown 
by unchanged expression of CD43) could indirectly affect T cell mechanisms by e.g. 
changing the effector T cell/Treg ratio. Yet, it appears also greatly conceivable that the 
increased numbers of intra-alveolar HA-specific T cells could be indicative of a passive influx 
of lymphocytes, most likely as a result of the neutrophilic inflammation coinciding with 
increased epithelial and/or endothelial permeability. 
 ATII cells from SPC-HAxTCR-HA mice express increased levels of 5.2.7
neutrophil-attractants in steady state steady state and pathological 
conditions 
In mice the human IL-8 analogues CXCL1, CXCL2 and CXCL5 - all signal via CXCR2 on the 
neutrophil surface - were shown to be involved in neutrophil mobilization into the inflamed 
airways. This recruitment is usually a result of concerted chemokine production by myeloid 
and airway epithelial cells (Pittet, Quinton et al. 2011, Yamamoto, Ahyi et al. 2014). However, 
by the effective depletion of alveolar macrophages (Figure 30, upper panel) these cells were 
withdrawn from being the cellular source of these chemokines in SPC-HAxTCR-HA lungs - 
and consequently from actively orchestrating the development of neutrophilic 
bronchopneumonia. As ATII cells have previously been shown to be important producers of 
these molecules (Farnand et al. 2011, Bello-Irizarry et al. 2012, Gibbs, Ince et al. 2014) 
these cells were subjected for further investigation. To this end, SPC-HA and SPC-HAxTCR-
HA mice were treated as described in Figure 31 with either PBS or clodronate liposomes and 
at d10 post primary treatment ATII cells were isolated by FACS using a previously described 
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sorting method (Gereke, Autengruber et al. 2012). Briefly, whole lung tissue homogenates 
were enzymatically digested and pooled samples of lung cell suspensions were fluorescently 
labelled with antibodies against the lineage markers CD45, CD11c, F4-80, CD11b, CD16/32 
and CD19. In flow cytometric sorting ATII cells were identified by their SSChigh and lineage-
negative profile (Figure 11). This sorting strategy yielded ATII cells with a purity between 83 
and 88% (data not shown). RNA from sorted ATII samples was extracted and relative 
expression of the genes Cxcl1, Cxcl2 and Cxcl5 was analyzed by qRT-PCR. In Figure 37 
RNA transcript levels (expressed as relative levels compared to housekeeping gene Actb) in 
ATII cells from PBS-treated and clodronate treated SPC-HA and SPC-HAxTCR-HA mice are 
depicted. 
 
Figure 37: Increased RNA-levels of neutrophil-attracting chemokines in ATII from SPC-HA-HAxTCR-HA 
mice in steady state (AM-sufficient) and pathological (AM-deficient) conditions. 
SPC-HA and SPC-HAxTCR-HA mice were treated according to Figure 31 with either PBS (CTRL-group) or 
clodronate liposomes (Clod-group). At d10 post primary clodronate treatment  ATII cells were isolated by FACS, 
RNA of pooled samples (n= 5-6 mice/group) was extracted and transcript levels of indicated genes were 
quantified by qRT-PCR. Results are expressed as the ratio: gene of interest vs. the housekeeping gene beta-actin 
(Actb).  
 
Additionally, individual fold changes between groups were calculated and are presented in 
Table 7, Table 8 and Table 9, respectively. Comparison of gene expression in steady state 
conditions (PBS-treated control groups) generally revealed increased expression of all three 
chemokines in ATII cells from SPC-HAxTCR-HA mice (FC Cxcl1 4.3; Cxcl2 2.5; Cxcl5 2.7). 
Interestingly, clodronate-induced AM-abolishment was intimately linked to the induction of 
Cxcl1, Cxcl2 and Cxcl5 in ATII cells from SPC-HA as well as SPC-HAxTCR-HA mice. 
Notably, especially the induction of Cxcl5 transcripts was greatly enhanced in SPC-HA (FC 
over PBS-group 34.4) as well as SPC-HAxTCR-HA mice (FC over PBS-group 28.5). By 
comparing ATII transcript levels between AM-depleted SPC-HA and AM-depleted SPC-
HAxTCR-HA groups it was found that all three chemokine transcripts were up-regulated in 
ATII from the SPC-HAxTCR-HA group ( FC Cxcl1 2.2; Cxcl2 2.6; Cxcl5: 2.2, see Table 7, 
Table 8 and Table 9). 
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Table 7: List of calculated fold changes (FCs) of Cxcl1 gene expression in ATII cells. 
Individual FCs are read as the ratio: group of interest (column) vs. group of reference (row). 
Cxcl1 
SPC-HA 
CTRL 
SPC-HAxTCR-HA 
CTRL 
SPC-HA 
Clod 
SPC-HAxTCR-HA 
Clod 
SPC-HA CTRL 1.0 4.3 5.3 11.8 
SPC-HAxTCR-HA CTRL  1.0 1.3 2.8 
SPC-HA Clod   1.0 2.2 
SPC-HAxTCR-HA Clod    1.0 
 
Table 8: List of calculated fold changes (FCs) of Cxcl2 gene expression in ATII cells. 
Individual FCs are read as the ratio: group of interest (column) vs. group of reference (row). 
Cxcl2 
SPC-HA 
CTRL 
SPC-HAxTCR-HA 
CTRL 
SPC-HA 
Clod 
SPC-HAxTCR-HA 
Clod 
SPC-HA CTRL 1.0 2.5 4.4 11.2 
SPC-HAxTCR-HA CTRL  1.0 1.7 4.5 
SPC-HA Clod   1.0 2.6 
SPC-HAxTCR-HA Clod    1.0 
 
Table 9: List of calculated fold changes (FCs) of Cxcl5 gene expression in ATII cells. 
Individual FCs are read as the ratio: group of interest (column) vs. group of reference (row). 
Cxcl5 
SPC-HA 
CTRL 
SPC-HAxTCR-HA 
CTRL 
SPC-HA 
Clod 
SPC-HAxTCR-HA 
Clod 
SPC-HA CTRL 1.0 2.7 34.4 75.6 
SPC-HAxTCR-HA CTRL  1.0 13.0 28.5 
SPC-HA Clod   1.0 2.2 
SPC-HAxTCR-HA Clod    1.0 
 
In summary, these data generally imply an altered chemokine regulation of ATII cells in the 
chronically inflamed lung which is well in line with previously published data (Gereke, Grobe 
et al. 2007). Moreover, it became apparent that alveolar macrophages regulate the 
expression of ATII-derived neutrophil-chemoattractants – especially CXCL5 - in healthy as 
well as pre-diseased lungs by means of so far unclear mechanisms. Given however this 
universal AM-inherent immunomodulatory function, it remains elusive whether the observed 
differences in ATII-derived CXC-chemokine levels between AM-depleted SPC-HA and SPC-
HAxTCR-HA mice are sufficient and causative for the pathologic, neutrophil airway 
infiltrations that are exclusively detected in SPC-HAxTCR-HA lungs. 
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 Bronchopneumonia in AM-depleted SPC-HAxTCR-HA mice is not 5.2.8
mediated by MAMP-dependent pulmonary immune responses  
By the intrinsic development of a pulmonary leak in SPC-HAxTCR-HA mice (Figure 12c), 
increased amounts of blood components diffuse into the airways thereby inevitably providing 
this compartment with serum-derived nutrients and consequently potential benefits for 
microbial growth. Alveolar macrophages critically contribute to airway homeostasis by their 
function as pulmonary scavengers, i.e. they clear microbes from the lower respiratory tract 
and thereby antagonize microbial outgrowth in the lung. As the depletion of AMs coincided 
with neutrophil-dominated bronchopneumonia (Figure 33, Figure 34) - which is a typical 
hallmark of respiratory bacterial infection - it seemed likely that immune responses towards 
the increase of microbial associated molecular patterns (MAMPs) are involved in the 
observed histopathological manifestations. These are likely driven by airway epithelial cells, 
as they possess a wide array of pathogen-recognition receptors (PRRs) and were shown to 
produce neutrophil-attractant chemokines following PRR stimulation (Cai et al. 2010, Gibbs, 
Ince et al. 2014, Jeyaseelan et al. 2005). Importantly the finding of increased IL-8 analogues 
in ATII following clodronate treatment (Figure 37) corroborated the idea of MAMP-dependent 
neutrophil recruitment in SPC-HAxTCR-HA lungs. Accordingly, reducing the lower airway 
microbial burden would ultimately prevent or decrease neutrophil infiltrations in the lungs of 
AM-depleted mice. To test this hypothesis, mice were treated with broad-spectrum antibiotics 
(ABX) for 20 days prior to clodronate treatment and during the following 10 days post primary 
clodronate administration (Figure 38). As readout for antibiotic efficacy bacterial loads in the 
trachea and lung were determined by cultivation of tissue homogenates on Columbia Agar, 
incubation for 1 day (37°C, 5% CO2) and subsequent CFU counting. 
 
Figure 38: Experimental strategy for antibiotics-mediated airway microbiota reduction. 
For oral antibiotics (ABX) treatment ampicillin and chloramphenicol and sucrose were added to the drinking water. 
Control (CTRL) mice received sucrose water only. 
 
ABX-treatment clearly led to a reduction of the trachea bacterial flora (Figure 39a). In lung 
tissue no CFU were detectable at all times independent of ABX treatment (data not shown). 
Despite the clear CFU reduction, continuous ABX treatment did not reduce pronounced 
neutrophil airway infiltration in clodronate-treated SPC-HAxTCR-HA mice (Figure 39b) 
indicating neutrophil influx to be MAMP-independent. 
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Figure 39: MAMP-driven immune responses do not contribute to bronchopneumonia in AM-depleted SPC-
HAxTCR-HA lungs. 
(a) SPC-HA and SPC-HAxTCR-HA mice were treated with antibiotics (ABX), control animals received sucrose 
water. After 10d mice were sacrificed and bacterial burden in tracheal tissue was determined by plating tissue 
homogenates on Columbia blood agar plates. Dashed line indicates limit of detection. (b) SPC-HA and SPC-
HAxTCR-HA mice were treated with antibiotics (ABX) or sucrose water (CTRL) and alveolar macrophages were 
depleted according to scheme in Figure 38. At 10d post depletion neutrophils in the BALF were quantified by 
FACS and cell counting.  
 
Collectively, these results suggest that the neutrophil-dominated disease phenotype in AM-
depleted lungs of SPC-HAxTCR-HA mice is a consequence of the established T cell-induced 
chronic inflammatory microenvironment and more specifically the accompanied 
reprogramming of the lung epithelium itself which in steady state conditions may be counter-
regulated by direct or indirect interactions with appropriately programmed AMs adapted to 
the same milieu. 
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6  Discussion 
6.1 Chronic lung inflammation and pneumococcal infection 
While it has been extensively studied and is widely accepted that viral priming of the 
respiratory tract manifests in a poor outcome of secondary bacterial infection (Habibzay, 
Weiss et al. 2013), analogous research focusing on non-viral and non-infectious settings is 
yielding controversial results, thus demanding a more complex view on pulmonary 
inflammatory networks. Airway epithelial cells (AECs) and alveolar macrophages (AMs) are 
key cellular components of the pulmonary network. Given their large array of receptors and 
effector molecules and their multifaceted roles for protective immunity during pulmonary 
infection (see section 2), the specific contributions of particular cell functions of AECs and 
AMs to antibacterial defense in hosts with chronic respiratory disease (CRD) were of special 
interest for this study. 
In this work the SPC-HAxTCR-HA transgenic mouse model for T cell-mediated lung 
inflammation was utilized. In these mice the concomitant expression of a neo-self-antigen 
(HA) by alveolar type II epithelial cells (ATII) and the generation of self-antigen specific (HA-
specific) CD4+ T lymphocytes evokes the development of autoimmune pulmonary 
inflammation in newborn mice as well as the rapid induction of a complex set of 
immunoregulatory mechanisms (e.g. conversion of HA-specific CD4+ T cells into Foxp3+ 
regulatory T cells), finally leading to chronic, yet controlled, lung inflammation in adult SPC-
HAxTCR-HA mice (Bruder, Westendorf et al. 2004, Gereke, Grobe et al. 2007, Gereke, Jung 
et al. 2009). Despite different etiologies, a participation of lymphocyte immune responses has 
been suggested for the pathogenesis of several chronic respiratory disorders such as COPD 
(Cosio et al. 2009), sarcoidosis (ATS&ERS,1999) and allergic lung inflammation (ALI; 
Schaller et al. 2005) and SPC-HAxTCR-HA lungs phenocopy histopathological 
manifestations of human CRD e.g. airway remodeling and lymphocytic infiltrations (Bruder, 
Westendorf et al. 2004). The well-established SPC-HAxTCR-HA model therefore represents 
an appropriate and valuable tool to study the impact of CRD on respiratory pneumococcal 
infection in vivo. In murine infection models the human pneumococcal isolate TIGR4 was 
previously shown to cause pneumonia as well as invasive pneumococcal disease (IPD; 
Sandgren, Albiger et al. 2005), therefore this serotype 4 strain was chosen for all 
experiments in this study aiming to elucidate the impact of CRD on local antibacterial 
defense as well as on the development of IPD. 
The present study revealed sterile lung inflammation to involve marked immune pathology 
(Figure 12a) and a compromised pulmonary barrier, leading to increased diffusion of serum 
components, like albumin (Figure 12c), into the airways of SPC-HAxTCR-HA mice. Besides 
ubiquitous antibodies and complement proteins serum also contains a plethora of factors 
essential for pneumococcal survival and virulence such as glucose, amino acids and trace 
elements. Accordingly the “serum-enriched” airspaces of SPC-HAxTCR-HA mice can be 
assumed to provide a potential benefit for bacterial outgrowth. In addition, reduced barrier 
integrity as a consequence of low tight junction protein expression has been described to 
correlate with enhanced pneumococcal transmigration and invasion of lung epithelial and 
endothelial cells (LeMessurier, Hacker et al. 2013). Unexpectedly, infection experiments with 
S. pneumoniae TIGR4 revealed increased resistance of SPC-HAxTCR-HA mice to 
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pneumococcal growth and pulmonary invasion as well as to the subsequent development of 
IPD (Figure 13), thereby linking chronic lung inflammation to a protective microenvironment 
in SPC-HAxTCR-HA mice. In accordance with this finding, it was recently shown that mice 
with allergic lung inflammation (ALI) displayed increased protection to respiratory infection 
with an invasive pneumococcal serotype 3 strain which was associated with enhanced 
phagocytic capacity of a newly recruited population of AMs in ALI-mice (Sanfilippo et al. 
2015). 
Phagocytic AMs are among the first cells to encounter pathogens immediately after 
pulmonary infection. Of note, by using mice deficient for the phagocytic receptors MARCO 
(macrophage receptor with collagenous structure) or CD36 it has been shown that AM 
phagocytosis is a process that critically contributes to pulmonary defense following infection 
with S. pneumoniae (Arredouani, Yang et al. 2004, Sharif, Matt et al. 2013). Given the pivotal 
role of AM phagocytosis and the rapid decline in pulmonary bacterial burden observed in 
SPC-HAxTCR-HA mice, it seemed conceivable that enhanced macrophage bacterial uptake 
might contribute to improved antipneumococcal immunity in SPC-HAxTCR-HA mice. Probing 
this hypothesis with in vivo phagocytosis assays however revealed similar phagocytic 
capacities between AMs from SPC-HA and SPC-HAxTCR-HA mice. Also by quantitative 
analyses of AM numbers no significant differences between healthy SPC-HA and pre-
diseased SPC-HAxTCR-HA mice became apparent (Figure 14), thereby ruling out numerical 
AM overrepresentation as a cause for enhanced early bacterial clearance in SPC-HAxTCR-
HA lungs. In contrast, several human and mouse studies demonstrated however elevated 
macrophage numbers in the airspaces of individuals with COPD (Barnes 2004), emphysema 
(Finkelstein, Fraser et al. 1995) and ALI (Draijer et al. 2013, Lee et al. 2015), which is 
believed to be a consequence of the constant inflammatory recruitment of these cells. These 
opposing facts may in turn imply a lack of inflammatory intra-alveolar macrophage 
recruitment in SPC-HAxTCR-HA mice. Yet the fact that the aforementioned diseases 
underlie different etiologies and appear with varying severity, involving heterogeneous 
environmental factors which all shape the inflammatory milieu, makes direct comparisons of 
inflammatory conditions in different CRDs difficult. Moreover, this strongly emphasizes the 
need for better understanding and defining the inflammatory milieus in CRDs in order to 
appropriately interpret phenotypic or functional observations made on the cellular level. 
Interestingly, the inflammatory milieu in SPC-HAxTCR-HA mice cannot be defined by typical 
indicators of acute inflammatory responses like IL-6 and TNF-α (Figure 15). Being innate 
cytokines, TNF-α and IL-6 control a series of immunological reactions during early infection 
e.g. acute-phase protein responses (IL-6; Kopf et al. 1994), regulation of other pro-
inflammatory cytokines and control of pulmonary bacterial growth (IL-6; van der Poll, Keogh, 
Guirao et al. 1997) as well as control of macrophage-dependent cytotoxity (TNF-α; Fan, Fehr 
et al. 1991). Both molecules were shown to be required for host defense during pulmonary 
pneumococcal infection (van der Poll, Keogh, Buurman et al. 1997, van der Poll, Keogh, 
Guirao et al. 1997). As neither of these two cytokines was detectable in SPC-HA and SPC-
HAxTCR-HA mice, it is likely that IL-6/TNF-α triggered mechanisms most likely are not 
involved in the generation of improved immunity towards S. pneumoniae. Still, several 
groups described beneficial effects of inflammatory imprinting in the lung on antimicrobial 
defense. Inflammatory imprinting induced by mucosal administration of LPS (Errea, Moreno 
et al. 2010), mutant E.coli enterotoxin (Tritto, Muzzi et al. 2007) or nontypeable Haemophilus 
influenzae lysate (Clement et al. 2008, Evans, Scott et al. 2010, Tuvim, Evans et al. 2009) 
involved among others both local (airways) and systemic (serum) increases in IL-6 and TNF-
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α. A conceivable explanation for these differing findings is the type of immunologic trigger in 
SPC-HAxTCR-HA mice. In large contrast to the aforementioned studies inflammatory 
imprinting in SPC-HAxTCR-HA lungs is not generated by a singular PAMP receptor 
stimulation (and the resulting early immune response within several hours) but rather 
includes a complex network of auto-reactive and tolerogenic mechanisms and cell subsets, 
respectively (Bruder, Westendorf et al. 2004, Gereke, Grobe et al. 2007, Gereke, Jung et al. 
2009). In summary, the absence of IL-6 and TNF-α in SPC-HAxTCR-HA mice is indicative of 
the non-acute quality of lung inflammation in these animals.  
In order to precisely define the inflammatory milieu in SPC-HAxTCR-HA lungs and to identify 
molecular pathways or single molecules, respectively, that account for the protective 
microenvironment in SPC-HAxTCR-HA lungs comparative transcriptomic and proteomic 
analyses were performed. To this end gene expression in whole lung tissue from uninfected 
SPC-HA vs. SPC-HAxTCR-HA mice was analyzed by whole-genome microarray analyses. In 
addition, the protein composition of the lung mucosal fluid (BALFome) of both mouse groups 
was compared by using LC-MS/MS technology. These experiments generally revealed a 
multitude of genes (378) and proteins (473) likely to participate in the chronic inflammatory 
environment of SPC-HAxTCR-HA lungs (see sections 5.1.5, 5.1.6 and 7). 
Remarkably, a fairly large number of proteins (129) were uniquely found in healthy SPC-HA 
airways (Table 13). This could be indicative of specific post-transcriptional mechanisms that 
control airway protein expression and/or stability in SPC-HAxTCR-HA airways. This is 
supported by the finding that only 52 transcripts were found by whole-lung microarray 
analyses to be over-represented in SPC-HA lungs as compared to SPC-HAxTCR-HA lungs 
(Table 11). One example of such a regulatory mechanism accounting for the divergence 
between gene expression and protein levels might apply to the polymeric Ig receptor (pIgR) 
whose modest increase in transcript numbers found by microarray analyses and qRT-PCR 
(Table 10, Figure 23a) was surprisingly associated with high pulmonary protein levels in the 
SPC-HAxTCR-HA group while being scarcely detectable in SPC-HA lungs (Figure 23b,c). 
Due to the nature of the biological samples (whole lung tissue) analyzed in this study, the net 
differences in relative transcripts levels are influenced by numerical differences in cell types 
expressing a particular transcript as well as quantitative transcript differences on the single 
cellular level. With reference to the KEGG pathway enrichment analyses the GO terms found 
to be over-represented in SPC-HAxTCR-HA lungs (e.g. T cell receptor signaling pathway, 
Chemokine signaling pathway and Cytokine-cytokine receptor interaction, Table 6) can 
therefore be derived from an altered regulation of particular leukocyte signaling pathways but 
as well from the different pulmonary cellular composition found in this group (Bruder, 
Westendorf et al. 2004). 
The antimicrobial peptides (APs) “cathelin-related antimicrobial peptide” and lactotransferrin 
were uniquely detected in airway mucosal lining fluid of SPC-HAxTCR-HA mice (Table 14). 
Lactotransferrin binds to S. pneumoniae (Hammerschmidt et al. 1999), however its 
antipneumococcal activity has been questioned and binding to lactotransferrin has been 
suggested as a pneumococcal iron-supply mechanism (Lee et al. 2004). Interestingly, AECs 
are potent producers of APs (Bals 2000) and other groups have previously shown that AECs 
have a key role in AP-mediated inducible host defense against pathogens (Cleaver, You et 
al. 2014, Evans, Scott et al. 2010). Altogether, the present study could not exclude a 
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potential connection between mucosal AEC-derived APs and the enhanced innate resistance 
towards S. pneumoniae. Moreover, the proteome analyses give no information on the cellular 
source of these molecules. It is however reasonable to assume that the substantial 
differences in protein composition between airway mucosal lining fluid from SPC-HA vs. 
SPC-HAxTCR-HA mice most likely reflect a combination of altered production rates by lung-
resident cells, altered active transepithelial transport and passive transepithelial diffusion of 
serum or interstitial components (Figure 12c). In view of this assumption the minimal overlap 
of only 10 proteins between induced genes and BALF proteins uniquely identified in SPC-
HAxTCR-HA mice becomes more significant (Figure 21b). These overlapping proteins found 
in the BALF of SPC-HAxTCR-HA mice are to be derived either from increased local 
production by bronchoalveolar cells (AECs or AMs) or from increased production and 
transport from cells from adjacent interstitial compartments.  
Importantly, the extensive description of the inflammatory milieu by means of microarray and 
proteomics approaches allows concluding one major effect of chronic inflammatory 
imprinting: the development of secretory immunoglobulin-specific patterns in SPC-HAxTCR-
HA lung tissue as well as in the airway mucosal lining fluid. This finding was of particular 
interest as secretory immunoglobulins (SIgs) as well as their exclusive transepithelial 
transporter, the polymeric immunoglobulin receptor (pIgR) have previously been shown to be 
critically involved in mucosal antibacterial defense (Blutt, Miller et al. 2012, Brown, Hussell et 
al. 2002, Sun, Johansen et al. 2004, Tjarnlund, Rodriguez et al. 2006). Thus, in order to 
estimate a possible role of pIgR and SIgs in enhanced immunity to pneumococci in SPC-
HAxTCR-HA lungs, pIgR-expression in lung tissue as well as SIg levels in the airway 
mucosal fluid (BALF) were compared in uninfected SPC-HA and SPC-HAxTCR-HA mice.  
In accordance with previous studies (Jaffar, Ferrini et al. 2009, Ohlmeier et al. 2012) lung 
inflammation was associated with elevated epithelial expression of pIgR in SPC-HAxTCR-HA 
mice (Figure 23c). Mechanistically, in SPC-HAxTCR-HA mice self-antigen recognition after 
birth is associated with a transient activation of autoreactive CD4+ T cells leading to acute, 
severe pneumonitis in young mice (Bruder, Westendorf et al. 2004). Upon activation self-
specific CD4+ T cells secrete IFN-γ (Bruder, Westendorf et al. 2004, Huang et al. 2003), a 
potent inducer of pIgR-expression in vitro (Sollid, Kvale et al. 1987). Furthermore, 
transcriptomic analyses of auto-reactive CD4+ T cells from SPC-HAxTCR-HA mice revealed 
IL-17 gene induction in these cells (Bruder, Westendorf et al. 2004). In consideration of the 
fact that IL-17 signaling has formerly been shown to substantially enhance pIgR-expression 
(and consequently SIg transcytosis through the epithelium) in airway (Jaffar, Ferrini et al. 
2009) and intestinal mucosal inflammation (Cao, Yao et al. 2012), it becomes likely that IL-17 
secretion by self-specific CD4+ T cells might effect pIgR-mediated SIg transport onto the 
mucosal surface in SPC-HAxTCR-HA mice. However, given the known pleiotropic factors 
(cytokines, hormones, dietary factors) identified as regulators of pIgR-expression (Table 1), it 
remains unclear whether pIgR-induction is a consequence of the effector T cell phase in 
newborn SPC-HAxTCR-HA mice or rather a hallmark of immunoregulatory mechanisms that 
are established during their adolescence. 
A correlation between inflammation and pIgR-expression was also demonstrated for human 
CRD by Ohlmeier and colleagues who found in a proteomics approach elevated pIgR levels 
in sputum, alveolar and bronchial epithelium of smokers and individuals with mild-to-
moderate COPD (Ohlmeier, Mazur et al. 2012). These findings were further extended by 
Gohy et al. who described bronchial epithelial pIgR-downregulation to correlate with disease 
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severity in COPD patients and showed that TGFβ1 and possibly the epithelial reprogramming 
pathways orchestrated by this protein inhibit pIgR-expression in advanced COPD (Gohy, 
Detry et al. 2014). In this regard, it would be interesting to clarify whether a direct correlation 
between the levels of pulmonary pIgR-expression and the incidence of bacterial infections in 
the respective COPD patient cohorts exists.  
Several studies addressed also a direct role of pIgR in the pathogenesis of bacterial disease 
in potentially promoting bacterial invasion. It was shown in vitro that the pneumococcal 
surface protein CbpA interacts with human pIgR (Zhang et al. 2000). Furthermore, CbpA 
protein revealed to be involved in pneumococcal transmigration of the murine blood-brain 
barrier (Orihuela et al. 2004) and pneumococci even co-localize with murine pIgR expressed 
on endothelial cells (Iovino et al. 2014). In contrast, Sun et al. described in vivo that 
abrogated mucosal SIgA transport in vaccinated pIgR knockout mice caused a loss of 
protection against nasopharyngeal pneumococcal colonization despite the presence of an 
otherwise proper vaccine-induced humoral immunity. This emphasizes the necessity of pIgR 
and SIgs in airway antipneumococcal immunity in vivo (Sun, Johansen et al. 2004). 
One key reason for the abovementioned conflicting in vitro vs. in vivo findings with regard to 
pIgR function might be the restricted complexity of in vitro conditions. These poorly mimic the 
in vivo situation where increased pIgR-expression inevitably leads to a reinforcement of 
mucosal surfaces by SIgs (Cao, Yao et al. 2012, Jaffar, Ferrini et al. 2009) thereby 
compensating the fact that pIgR can in principle adhere to epithelial cells. Accordingly, by 
quantifying the levels of airway immunoglobulins this study confirmed that pIgR up-regulation 
ultimately provokes increased airway sIgA and IgM contents in SPC-HAxTCR-HA mice as 
compared to SPC-HA mice (Figure 22).  
By using mice deficient for pIgR or its cargo molecules IgA and IgM, several groups have 
demonstrated a central role of the SIg axis in controlling airway pneumococcal burden and 
tissue invasion (Brown, Hussell et al. 2002, Sun, Johansen et al. 2004). Importantly, 
recurrent respiratory infections are comorbidities associated with selective IgM or IgA 
deficiencies in humans (Latiff and Kerr 2007, Louis and Gupta 2014). Following the 
hypothesis that enhanced antipneumococcal resistance in SPC-HAxTCR-HA mice directly 
originated from increased airway mucosal SIgA or SIgM concentrations, pneumococcal 
binding assays were performed. Indeed, significantly increased IgA and IgM coverage of 
pneumococcal surfaces as well as increased portions of IgM+ pneumococci using SPC-
HAxTCR-HA BALF could be detected. Comparison of the fractions of IgA+ vs. IgM+ 
pneumococci generally revealed that larger fractions of bacteria were IgA+ (~4-17%) whereas 
IgM+ fractions ranged only between ~0.2-1.5% (Figure 24). This finding likely resembles 
individual abundances of IgA and IgM in BALF (Figure 22), different binding affinities or -
kinetics of IgA and IgM.  
In conclusion, based on the data obtained in this part of the thesis, the following mechanism 
(summarized in Figure 40) is proposed: Alveolar self-antigen (HA) recognition by self-antigen 
specific CD4+ T cells effects autoimmune-mediated lung inflammation. As a result of 
inflammatory pathways during acute inflammatory phase and/or immunoregulatory 
mechanisms established during adolescence, ATII cells up-regulate pIgR-expression. 
Increased pIgR-expression effects increased transcytosis of natural IgA & IgM (produced 
locally and/or transported into the lung via the blood stream) into the alveoli, SIgA and SIgM 
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bind to S. pneumoniae and antagonize pneumococcal outgrowth and invasion by immune 
exclusion and complement-dependent pathways. 
While lower airway colonization with bacterial pathogens such as Streptococcus pneumoniae 
has been identified to be present in 25-50% of COPD patients (Wedzicha et al. 2003), details 
of the causal relationship between colonization and infection, respectively, and disease 
exacerbations are under debate. In stable disease the airway CFU burden was found to 
correlate with airway inflammatory markers, and thus infection is intimately linked to 
inflammation (Hill et al. 2000). Also, it was demonstrated that colonization is associated with 
increased exacerbation frequency (Patel et al. 2002). In principle two conceivable 
mechanisms might underlie these observations, either as single or as concurring causes. 
Firstly, it is possible that bacterial infections in those patients occur as results of insufficient 
host defense (e.g. decreased mucociliary clearance, dysfunctional alveolar macrophages) 
and thus increased bacterial growth and the associated increase in PAMPs as well as 
bacterial cytotoxic products cause (immune) pathology. Secondly, as a consequence of a 
chronic inflammatory microenvironment (associated with a wide range of constant 
immunologic triggers) an inflammation-induced reprogramming of innate immune cells (e.g. 
AEC) manifests in a dysregulation of PAMP-receptor pathways (e.g. TLR expression and 
downstream signaling cascades) resulting in inappropriate, exuberant immune responses to 
microbial ligands and thus the development of an exacerbation. In this regard, by using the 
SPC-HAxTCR-HA model two basic cellular adaptations that in principle could promote the 
development of an infection-induced exacerbation were identified: the blunted AM-dependent 
pro-inflammatory immune response towards pneumococcal ligands as well as the 
inflammation-primed ATII cells, which upon loss of AMs drive the development of neutrophilic 
bronchopneumonia even in an environment with low or no MAMPs (see section 5.2.8, Figure 
39). Despite the unexpected finding of a beneficial role of inflammation-induced 
microenvironmental changes (i.e. pIgR-mediated SIg transport) in the pre-diseased lung, the 
fashion and magnitude of an AM- and AEC-dependent pro-inflammatory immune response 
during the course of an actual pneumococcal infection has so far not been addressed and 
thus remains subject for future investigation.  
The evidence of pIgR/SIg mechanisms as effectors of improved respiratory immunity is of 
fundamental interest for future investigations. Despite the findings of unaltered phagocytosis 
in the SPC-HAxTCR-HA model, patients with severe asthma and COPD are frequently 
diagnosed with impaired AM capacity (Berenson, Garlipp, et al. 2006, Liang et al. 2014), thus 
revealing insufficient myeloid-dependent host defense while at the same time underlining the 
important role of humoral immunity and the airway epithelium in ensuring broad protection 
against airborne pathogens. 
Further studies are needed to explore whether prophylactic pIgR-enhancement serves as a 
therapeutic strategy for CRD patients with recurrent pneumococcal infections. Here, the 
mode of pIgR-induction would be of utmost importance as several immunologic stimuli that 
have been shown to enhance pIgR-expression also are considered to be key components 
involved in the pathogenesis of CRD. For example, the pIgR-inducing cytokine IL-17 also 
effects the production of neutrophil-attracting chemokines in AECs (Liu et al. 2011) and 
airway smooth muscle cells (Dragon et al. 2007) and is thus discussed to participate in 
neutrophilic lung inflammation in asthma and COPD (Barnes 2008). Moreover, pIgR-inducing 
IFN-γ is believed to play an important role in COPD pathogenesis, as it orchestrates the 
infiltrations of Th1 and Tc1 cells into the lung by upregulating chemokines as well as 
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chemokine receptors on these cells (Barnes 2008). Given the aforementioned two examples 
of pIgR-inducers, it becomes evident that therapeutic manipulation in CRD-patients with a 
diagnosed or suspected inflammatory disease etiology by triggers with known pro-
inflammatory function would probably include severe adverse effects that might further 
compromise tissue integrity. 
On the molecular level, within the human PIGR gene promoter region several regulatory 
motifs, which can serve as binding sites for transcription factors (TFs) e.g. USF1&2 and 
C/EBP, have been identified (Martin et al. 1998, Verrijdt et al. 1997). These TFs participate in 
various physiologic reactions, such as cellular glucose- and iron metabolism (Nicolas et al. 
2001, Wang et al. 1995) and ATII-proliferation (Sugahara et al. 2001). This suggests the 
existence of multiple – yet unknown- molecular pathways which are possibly involved in 
epithelial pIgR-expression and, consequently, may be target for therapeutic manipulation of 
this mucosal defense mechanism. Therefore, further screenings for pathways and molecular 
targets involved in regulation of pIgR-expression would be of particular interest for 
prospective studies. 
Figure 40: Proposed mechanism for enhanced pIgR-mediated antipneumocoocal defense in SPC-
HAxTCR-HA lungs. 
See text for details. 
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6.2 Phenotype and role of alveolar macrophages in chronic lung 
inflammation 
The aim of the second part of this thesis was the elucidation of the phenotype of alveolar 
macrophages (AMs) as well as their contributions to immuneregulation and inflammation in 
CRD. 
By using fluorescence-based cytometric assays several important morphological changes of 
AMs were detected in the SPC-HAxTCR-HA in vivo model. In detail, it was shown that their 
size, structural and intrinsic fluorescence properties are significantly affected within an 
inflammatory environment (Figure 25). Here, the reduced autofluorescence in the SPC-
HAxTCR-HA group was of exceptional interest. Natural cellular autofluorescence is 
considered to be caused by electron-dense molecules such as nicotinamide adenine 
dinucleotide (NAD+), riboflavins or flavin coenzymes (Aubin 1979, Benson et al. 1979). 
Moreover, hemosiderin, an iron-storage complex associated with the breakdown of 
erythrocytes, is another autofluorescent secondary metabolite present in AMs from 
individuals with immune alveolar hemorrhage, a feature of several chronic immunological 
disorders (Leatherman 1987). As pulmonary hemosiderosis (the presence of hemosiderin-
laden macrophages) is a pathologic hallmark associated with lung disease in SPC-HAxTCR-
HA mice (see section 5.1.1 and Bruder, Westendorf et al. 2004) it seemed conceivable to 
expect increased autofluorescence of AMs in this group. Given the reverse finding, which is 
further accompanied by their decreased size (FSC) and an altered intensity and distribution 
of cytoplasmic structures (SSC), it seems likely that CRD also manifests in distinct 
adaptations within intracellular AM-compartments probably covering various aspects of 
metabolic activities and products apart from hemosiderin. Here, comparative in-depth 
analyses of the AM-metabolome would allow expanding knowledge on molecular pathways 
possibly involved in the development and maintenance of an altered AM-phenotype in CRD. 
Interestingly, alterations in airway macrophage side scatter and autofluorescence properties 
have also been reported in another study in SHIP1 (an inositol polyphosphate-5-
phosphatase)-deficient mice, that spontaneously develop severe lung inflammation 
associated with a pathologic M2-macrophage phenotype (Duan et al. 2012). 
The altered intensity and distribution of fluorescent and refractive structures might be of 
general interest for two reasons. First, FACS technology provides a valuable and commonly 
utilized tool to characterize inflammatory processes on airway mucosal surfaces. Yet the 
massive autofluorescence signals of airway macrophages within the FITC, PE and PerCp 
detectors require well-considered panel design and the utilization of additional control 
stainings to correctly separate large intrinsic (false) from antibody-derived (true) fluorescence 
signals. Since this and other studies have revealed fundamental differences of AM 
fluorescence properties in healthy vs. pathologic conditions, it is likely to observe similar 
effects in other non-infectious and infectious respiratory disease settings in which AMs are in 
the focus of interest. In practice, this would adversely affect accuracy of e.g. cell surface 
molecule quantitation on AMs. Thus, for further investigations using comparative flow 
cytometric analyses of airway macrophages, the aforementioned effects should definitely be 
considered. Second, information on parameters describing the intracellular fluorescence 
distribution, as derived from microscopy-based techniques - offer a simple additive tool to 
characterize the AM phenotype in more detail and to detect morphologic alterations that 
possibly hint to molecular and functional cellular adaptations. Accordingly, this study 
Discussion 
 
 
90 
 
describes a link between affected fluorescent properties and activation, polarization and 
functional alterations of AMs in CRD. 
In this regard, the blunted AM-dependent TNF-α response towards Gram-positive bacterial 
ligands in SPC-HAxTCR-HA airways (Figure 29) suggests a functional impairment of these 
cells during infection with airborne pathogens. Functionally, TNF-α was shown to exert 
protective efficacy in several models of acute respiratory bacterial and fungal infection by 
promoting pathogen clearance (Blanchard et al. 1988, Buret et al. 1994, Chen et al. 1992, 
Gosselin et al. 1995). In detail, TNF-α in infection not only acts on one of its producers, the 
macrophages themselves, but also on neutrophils by enhancing phagocytosis of opsonized 
bacteria and antibody-dependent cytotoxicity (Fan, Fehr et al. 1991, Pierangeli et al. 1993). 
Irrespective of the influence of TNF-α on AMs, it was previously demonstrated that lung-
specific overexpression of TNF-α in mice was linked to a disease phenotype mirroring 
hallmark features of emphysema and pulmonary fibrosis (Lundblad et al. 2005). In this 
context, it seems plausible that silencing of a microbial-induced TNF-α AM response has 
evolved as a mechanism that prevents TNF-α-driven immunopathology which might further 
compromise tissue integrity in the pre-diseased lung as shown by SPC-HAxTCR-HA mice. In 
line with this interpretation, macrophages from pre-diseased human and murine lungs were 
found to mount blunted cytokine responses (e.g. TNF-α, KC, IL-1β) upon stimulation with 
bacterial ligands like Haemophilus outer membrane protein or flagellin (Berenson, Wrona, et 
al. 2006, Didierlaurent et al. 2008). However, given the two faces of TNF-α (and other pro-
inflammatory molecules) in alveolar macrophage-mediated immune responses, further 
studies will be needed to specifically explore their role on the shape of antibacterial host 
defense in the pre-diseased lung. 
This however raises the question for conceivable cellular mechanisms preventing pro-
inflammatory cytokine responses from AMs. Under this aspect it is noteworthy that down-
regulation of TLR2 - a PRR involved in recognizing among others S. pneumoniae and 
subsequently orchestrating TNF-α immune responses - was reported for AMs from COPD 
patients (Droemann et al. 2005). Didierlaurent and colleagues furthermore reported that an 
antecedent influenza infection manifests in an inhibition of TLR-induced NF-ĸB signaling in 
AMs correlating with desensitization towards bacterial ligands (Didierlaurent, Goulding et al. 
2008). Interestingly, SOCS1 which is highly up-regulated in M2 macrophages (Whyte et al. 
2011) interferes with TLR4-related downstream NF-ĸB signaling cascades (Yoshimura et al. 
2007) and SOCS1-deficient mice are hypersensitive to endotoxin challenge, i.e. they 
overproduce TNF-α upon LPS administration (Nakagawa et al. 2002). In summary, an 
altered regulation of TLR expression or altered downstream TLR signaling cascades in SPC-
HAxTCR-HA AMs are probable mechanisms underlying the blunted TNF-α response 
following bacterial challenge. 
Further molecular indications for an altered AM phenotype in SPC-HAxTCR-HA mice could 
be demonstrated in the present work by measuring increased M2-marker gene expression 
(Msr1 and Retlna) in AMs from these mice (Figure 28). Furthermore, BALFome analyses 
revealed several proteins (MMP-12, chitinase-like protein 3 and resistin-like alpha; Figure 
21b) typically produced by M2 macrophages to be exclusively present in SPC-HAxTCR-HA 
airways. Taken together these findings support the hypothesis of an M2-dominated milieu in 
the present CRD model. In line with this, M2 polarization of AMs is a known feature of other 
CRD-related mouse models. For instance, in a mouse parainfluenza virus (also known as 
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Sendai virus) infection model the special dominance of M2 pulmonary macrophages was 
associated with the development of postviral CRD (Wu et al. 2015). Moreover, in murine 
models for allergic lung inflammation the typical M2 markers resistin-like alpha (Retlna) and 
Ym-1 (chitinase-like protein 3) were overexpressed by lung macrophages in asthmatic mice 
(Draijer, Robbe et al. 2013, Moreira et al. 2010). The latter M2 markers were also found to be 
associated with CRD in the SPC-HAxTCR-HA model (Figure 21, Figure 28). Notably, 
excessive production of Retlna and Ym-1 is thought to contribute to inflammation and airway 
remodeling in the allergic lung (Cai et al. 2009, Dong et al. 2008). Thus, it becomes apparent 
that M2-polarization of AMs as found in SPC-HAxTCR-HA lungs is not a unique trait of the 
utilized mouse model, but rather appears to have general biological relevance in chronic 
inflammatory lung conditions. 
Based upon the previous findings two questions arise: Firstly, which cell type constitutes the 
cytokine source skewing AMs into an M2 phenotype in SPC-HAxTCR-HA lungs? As stated in 
the introduction, the Th2 cytokines IL-4 and IL-13 typically orchestrate the induction of M2 
phenotypes. Upon stimulation with self-antigen lymphocytes from SPC-HAxTCR-HA lungs 
were previously shown to secrete among others IL-5, another hallmark cytokine of the Th2 
lineage, however no IL-4 production was found (Bruder, Westendorf et al. 2004). With regard 
to IL-13, it is known that apart from Th2 cells, pulmonary type 2 innate lymphoid cells (ILC2) 
are potent producers of this cytokine. Interestingly, an accumulation of pulmonary ILC2 is 
reported for murine models of allergic asthma and respiratory viral infection (Klein Wolterink 
et al. 2012, Monticelli et al. 2011) and increased numbers of these cells could as well be 
detected in SPC-HAxTCR-HA lungs (own unpublished observations). In this context, further 
studies dissecting lung leukocyte composition and cytokine milieu during the course of 
disease establishment and its regulation in SPC-HAxTCR-HA mice would be necessary in 
order to prove a potential role for ILC2 (and possibly IL-13)-orchestrated generation of M2 
macrophages in SPC-HAxTCR-HA mice. 
The second question: Is there a pathologic or beneficial role of M2-polarized alveolar 
macrophages in SPC-HAxTCR-HA lungs in steady state conditions? This issue was 
addressed in this work in several in vivo depletion experiments (see sections 5.2.5 - 5.2.8). 
By using the AM-depletion strategy it became apparent that AMs are critical cellular players 
that help to preserve pulmonary architecture in SPC-HAxTCR-HA lungs. Consequently, their 
short-term (3d) and mid-term (10d) absence was associated with an amplification of the 
typical disease pattern of SPC-HAxTCR-HA lungs, i.e. lymphocytic infiltrations (Figure 32). 
Moreover, viable polymorphonuclear neutrophils (PMNs) were found to be a major infiltrating 
leukocyte population in AM-depleted SPC-HAxTCR-HA lungs (Figure 34). This was of 
exceptional interest as this AM-dependent effect was specific for pre-diseased mice and has 
so far not been described in the present CRD model. It is worth mentioning that PMNs 
secrete a series of molecules involved in tissue destruction, such as neutrophil elastase (NE) 
or myeloperoxidase (MPO), whose direct or indirect actions trigger emphysema formation 
(Shapiro et al. 2003) and the generation of reactive oxygen species in AECs (Yang et al. 
2001), respectively. Importantly, NE levels in COPD sputum samples were shown to 
correlate with disease severity (Paone et al. 2011) and NE concentration increased during 
COPD-exacerbations compared to stable disease phases (Ilumets et al. 2008). Similarly, 
increased sputum MPO levels are found in COPD patients as compared to healthy 
individuals and levels of this enzyme increase as well during exacerbations (Zhu et al. 2014). 
Given these examples, it becomes evident that the increased presence and activity of 
neutrophils is an element contributing to pathologic physiological reactions in the pre-
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diseased lung. In this context, the infiltrating neutrophils observed in AM-depleted SPC-
HAxTCR-HA lungs presumably are major cellular orchestrators of the necrotizing 
bronchopneumonia in this group. At the same time this highlights the essential 
immunological contribution of AMs to the prevention of neutrophil-driven pathology in the 
inflammatory framework of SPC-HAxTCR-HA lungs.  
Thus in summary, the findings presented in this work revealed a beneficial function of AMs in 
the SPC-HAxTCR-HA model which opposes a number of other studies describing disease-
perpetuating activities of lung macrophages. For example, in a murine emphysema model 
inhalation of alendronate, a nitrogen-containing bisphosphonate, evoked AM-apoptosis which 
correlated with disease amelioration (Ueno, Maeno et al. 2015). Moreover, Th2 and Th17 
allergic lung inflammation and airway remodeling could be attenuated upon AM-depletion in 
mice (Lee, Jeong et al. 2015, Song et al. 2008). There are however also reports 
demonstrating beneficial roles for AMs in the context of sterile lung inflammation. For 
instance Careau and colleagues demonstrated that adoptive transfer of AMs from allergy-
resistant rats into AM-depleted sensitized rats suppressed airway hyperresponsiveness 
following antigen challenge in the recipient group (Careau et al. 2006).  
As a matter of principle, one important factor that must be taken into account when 
evaluating roles of pulmonary macrophages and their known subsets is the clear 
discrimination between resident alveolar vs. recruited macrophages. As inhaled or 
intratracheally administered clodronate (and other bisphosphonates) liposomes non-
specifically target all airway macrophages, a clear-cut determination of the immunologic role 
of a particular subset is not feasible by using this strategy. Using local vs. systemic depletion 
strategies ZasƗona and colleagues (at least partly) addressed this issue and demonstrated 
opposing functions of resident alveolar macrophages (suppressive) and recruited monocytes 
(inflammatory) in murine models of asthma (Zaslona et al. 2014). All in all, the controversial 
results on the immunologic roles of airway macrophage subsets in different CRDs most likely 
result from the different etiopathologies and thus, a more accurate discrimination between 
acute vs. chronic phase and resident vs. recruited macrophages would be necessary to 
clearly define the immunologic potential of airway macrophage populations in the pre-
diseased individual. However, in the present SPC-HAxTCR-HA model it was observed that 
the alveolar macrophage population uniformly had a CD11chigh F4-80+ autofluorescencehigh 
profile, a hallmark of resident alveolar macrophages (Duan, Li et al. 2012, Guth et al. 2009, 
Hussell and Bell 2014). These were specifically depleted by the administration of clodronate 
without affecting the pulmonary interstitial macrophage pool (Figure 30). Also, the unaltered 
numbers of AMs retrieved from untreated SPC-HA vs. SPC-HAxTCR-HA mice (Figure 14) 
further supported a negligible role for intra-alveolar recruitment of the macrophage/monocyte 
lineage in chronic lung inflammation as displayed by SPC-HAxTCR-HA mice. Moreover, as 
the neutrophil-dominated bronchopneumonia in AM-depleted SPC-HAxTCR-HA mice was 
likely not a secondary effect of AM-dependent reactivation of auto-reactive T cells (Figure 35, 
Figure 36) the observed immunologic effects following clodronate administration could be 
specifically attributed to the abolition of resident AM-inherent functions in PMN containment. 
In order to interpret a functional link between AM-depletion and neutrophil influx in the lungs 
of SPC-HAxTCR-HA mice the biology of neutrophils must be taken into account. Neutrophils 
are short–lived effector cells; a majority of studies using ex vivo labelling approaches to 
determine the life span of these cells under homeostatic and non-homeostatic conditions 
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reported half-lives of several hours up to approximately 1 day (Tak et al. 2013). The 
presence of viable neutrophils in the airspaces of AM-depleted SPC-HAxTCR-HA mice thus 
suggests a continuous recruitment of this short-lived cell population rather than a response to 
a singular preceding stimulus. CXCL1 (KC), CXCL2 (MIP-2α) and CXCL5 (LIX) are major 
factors involved in neutrophil chemoattraction to sites of inflammation (Cai, Batra et al. 2010, 
Driscoll et al. 1995, Mei et al. 2010). In this context, pulmonary epithelial cells were 
previously shown to direct pulmonary neutrophil immigration in response to infectious stimuli 
such as respiratory bacteria or TLR ligands (Gibbs, Ince et al. 2014, Jeyaseelan, Manzer et 
al. 2005, Yamamoto, Ahyi et al. 2014). In the present work increased transcription of all three 
chemokines in ATII isolated from AM-depleted SPC-HAxTCR-HA lungs (Figure 37,Table 7-
Table 9) corroborated the hypothesis of epithelial-driven neutrophilic bronchopneumonia in 
this group. Moreover, this further confirms CXCL5 as a predominant neutrophil-attractant 
produced by alveolar epithelial cells (Jeyaseelan, Manzer et al. 2005, Nouailles et al. 2014). 
Importantly, the present study indicates microbiota-independent neutrophil recruitment 
(Figure 39) thereby describing a non-significant role of AMs as microbial scavengers and 
rejecting the assumption of MAMP-dependent epithelial PMN recruitment in SPC-HAxTCR-
HA lungs. 
Again referring to the above described effect of AM-abolishment on lung pathology in the 
SPC-HAxTCR-HA group, the chemokine expression results obtained by qRT-PCR analyses 
of ATII cells disclose two important phenomena. Firstly, an increase of chemokine transcripts 
as a general response of ATII cells to the loss of AMs and secondly an excess of this effect 
in ATII from mice with a pre-existing respiratory disorder (Figure 37,Table 7-Table 9). Here, 
in order to determine the functional magnitude of chemokine expression following AM-
depletion in the airways, it would be of utmost importance to verify the obtained qRT-PCR 
results on a protein level e.g. by BALF-ELISA. Moreover, in order to estimate the specific 
contribution of the AM/ATII axis in pulmonary homeostasis, chemokine expression in other 
lung epithelial cell types (e.g. bronchial epithelial cells, Clara cells, and ATI cells) should be 
examined in more detail. 
In this context, MMP-12, a protease secreted by M2-macrophages and found to be induced 
in SPC-HAxTCR-HA airways (Figure 21), might partially explain the observed effects in SPC-
HAxTCR-HA lungs. Via cleavage of CXCL1, CXCL2 and CXCL5 this molecule is known to 
interfere with the establishment of a functional chemokine-gradient (Dean, Cox et al. 2008) 
and thus could antagonize neutrophil-mobilization into SPC-HAxTCR-HA airways in steady 
state conditions. However, upon clodronate-induced macrophage abolishment and the 
resulting absence of MMP-12 protease activity in SPC-HAxTCR-HA airways functional 
CXCL1, CXCL2 and CXCL5 can mediate chemoattraction of neutrophils from blood stream 
and lung tissue into the airways of SPC-HAxTCR-HA lungs and thus the development of 
bronchopneumonia in this group. M2 macrophage-derived MMP-12 activity might therefore 
provide one explanatory mechanism for the contradictory findings of neutrophil absence 
despite increased epithelial chemokine expression in AM-sufficient SPC-HAxTCR-HA mice. 
According to this hypothesis, administration of murine MMP-12 into AM-depleted SPC-
HAxTCR-HA airways would ultimately prevent or decrease pathologic neutrophil influx in this 
group. However given the opposing roles of this enzyme in blocking neutrophil recruitment 
(Dean, Cox et al. 2008) and on the other hand promoting emphysema formation (Trojanek et 
al. 2014) it is likely that therapeutic administration could inadvertently result in tissue 
damage, remodeling and finally a loss in organ functionality in pre-diseased SPC-HAxTCR-
HA lungs.  
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With regard to chemokine gene induction in ATII cells as a general response to the loss of 
AMs it became evident that AM/AEC crosstalk is a constitutive element in healthy as well as 
pre-diseased lungs (Figure 37,Table 7-Table 9). This raises the question for relevant cellular 
interaction interfaces between AMs and ATII cells. A possible answer to this question may be 
the gap junction protein Cx43 (expressed by AMs and AECs), which was recently described 
to be involved in a cell-cell contact dependent mechanism by which AMs communicate 
immunosuppressive signals to AECs (and vice versa) during LPS induced lung inflammation 
(Westphalen, Gusarova et al. 2014). However, that study also described that no AM/AEC 
signaling could be detected under non-inflammatory conditions thereby making Cx43-
dependent mechanisms unlikely to be involved in AM-dependent chemokine transcript 
induction in the healthy SPC-HA control group. 
Another AM/ATII interaction interface by which epithelial cytokine signaling pathways can be 
downmodulated may be the constitutive secretion of AM-derived SOCS-protein containing 
exosomes and microparticles which are subsequently taken up by AECs (Bourdonnay, 
Zaslona et al. 2015). SOCS1, which is up-regulated in M2 macrophages (Whyte, Bishop et 
al. 2011), can interfere with NF-ĸB signaling pathways by decreasing the stability of the NF-
ĸB-subunit p65 in the nucleus (Strebovsky et al. 2011). In this context, it was demonstrated 
that he transcription of IL-8 and IL-8-related chemokines essentially requires NF-ĸB signaling 
(Kim et al. 2006). Albeit primarily proposed as a constitutive AM-to-AEC immunoregulatory 
signaling strategy (Bourdonnay, Zaslona et al. 2015), transcellular delivery of SOCS1 
containing particles possibly is a mechanism that is up-regulated in an M2-polarized 
microenvironment as displayed in SPC-HAxTCR-HA lungs and thus can decrease 
chemokine transcripts levels in healthy as well as pre-conditioned lung epithelial cells in a 
varying degree. With reference to the ATII cells analyzed in this work it was found that these 
however produce higher levels of IL-8 analogues in steady state conditions (Figure 37,Table 
7-Table 9) indicative of either irreversible inflammatory imprinting during the phase of acute 
lung inflammation or continuous immunologic triggers which are present in the phase of 
controlled, chronic lung disease. 
In addition to the possible implications of soluble and membrane-bound proteins in AM/ATII 
immunomodulatory interactions, lipid mediators represent another group of interesting 
candidate components possibly involved in this regulatory axis. Lipid mediators (lipoxins, 
resolvins, protectins, maresins) fulfill pleiotropic anti-inflammatory and pro-resolving functions 
by acting on macrophages themselves as well as on other leukocytes and non-hematopoetic 
cells (see section 2.6.3). Lipoxins are derivates of arachidonic acid, whose release is a result 
of enzymatic cleavage of membrane phospholipids catalyzed by phospholipase A2 (Pla2). Of 
note, alveolar macrophages are able to produce several isoforms of secretory Pla2 (Kitsiouli 
et al. 2009) and gene expression of the Pla2-IID isoform, is indeed found to be up-regulated 
in SPC-HAxTCR-HA lung tissue (FC: 4.8; see section 7.1.1, Table 10). This suggests that 
production of arachidonate-derived anti-inflammatory lipid mediators could as well be 
increased in SPC-HAxTCR-HA lungs. Due to the experimental protocol applied for the LC-
MS/MS BALFome analyses in this work it was not possible to detect bronchoalveolar lipid 
components by using this method. Yet, in order to more precisely define the pulmonary 
inflammatory milieu and to corroborate a role for lipid mediators in SPC-HAxTCR-HA mice, 
supplementary mass spectrometry analyses of the BALF lipidome would be an interesting 
approach.  
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In this regard, LipoxinA4 is a promising candidate mediator, as this molecule was shown to 
reduce IL-8 production by epithelial cells (Gewirtz et al. 2002) but also to inhibit interaction of 
neutrophils with endothelial and epithelial cells (Fierro et al. 2003). Given the example of 
LipoxinA4 it becomes evident that pathologic neutrophil infiltrations in clodronate-treated 
SPC-HAxTCR-HA mice might indeed be the net result from AM-dependent reactivation 
events in the adjacent epithelial but also parenchymal (endothelium, neutrophils) and 
systemic (neutrophils) compartments. As a secondary effect of increased endothelial and 
epithelial permeability the influx of other leukocytes would be a likely consequence following 
AM-depletion in the pre-diseased lung which would somewhat explain the parenchymal and 
intra-alveolar lymphocytic infiltrations in SPC-HAxTCR-HA mice (Figure 32, Figure 35).  
In conclusion, based on the data obtained in this part of the thesis, the following mechanism 
(summarized in Figure 41) is proposed: Chronic autoimmune-mediated lung inflammation is 
associated with polarization of alveolar macrophages into an M2 phenotype as well as an 
induction of CXCL1, 2, 5 gene expression in ATII cells. AMs antagonize ATII-chemokine 
production by cell-cell-contact dependent pathways and/or by secreted factors (e.g. lipid 
mediators, microparticles). M2-macrophage-derived MMP-12 can proteolytically inactivate 
alveolar CXCL1, 2, 5 and thus prevent establishment of a functional chemokine gradient in 
steady state conditions. Moreover, AM-derived products may also act on adjacent epithelial 
(e.g. ATI) or distal (e.g. endothelial) cell types. Upon loss of AMs ATII cells produce 
increased amounts of CXCL1, 2, 5. Functional CXCL1, 2, 5 gradients mediate attraction and 
transmigration of neutrophils from local (interstitium) and/or systemic (blood stream) 
compartments into the alveoli. 
In summary, the results obtained in this part of the thesis extend our knowledge about the 
cellular players orchestrating immuneregulation in the SPC-HAxTCR-HA mouse model for 
CRD. While ATII and HA-specific CD4+Foxp3+ T cells have been demonstrated to be critical 
participants during acute inflammation and subsequent tolerance induction in autoimmune-
mediated lung disease (Gereke, Grobe et al. 2007, Gereke, Jung et al. 2009), respectively, 
the roles of AMs were so far unresolved. Based on the fact that AMs were found to acquire 
fundamentally changed characteristics in chronic lung disease, further elucidating the 
functional implications of these alterations for the pre-diseased host is of highest interest for 
future investigations. Here, comparative analyses of the AM transcriptome, metabolome and 
also secretome would help to identify elements (secreted lipids/proteins vs. cell-cell contact-
dependent mechanisms) involved in immunoregulatory networks in SPC-HAxTCR-HA lungs. 
Given the observed prominent roles of AMs in suppressing potentially harmful pulmonary 
epithelial immune responses comprehensive investigation of the ATII-phenotype following 
macrophage depletion would probably shed light on pathways involved in AM/epithelial 
communication. In the future, these findings could be particularly promising for those CRD 
cohorts in which this communication axis is interrupted or dysfunctional due to the loss of 
AMs (e.g. as a consequence of myeloablative therapy, hematologic malignancies or smoke 
exposure) and reactivation of the inflammation-imprinted pulmonary epithelium would further 
compromise tissue integrity and physiological function in the pre-diseased lung. 
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Figure 41: Proposed mechanism for AM-dependent immunoregulatory circuits in SPC-HAxTCR-HA lungs. 
See text for details. 
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7  Appendix 
7.1 Supplemental tables 
 Microarray 7.1.1
Table 10: Genes found to be up-regulated (=fold change [FC] ≥ 2) in lungs of SPC-HAxTCR-HA mice when 
compared to lung tissue from SPC-HA control mice (Ʃ 326).  
Transcript 
cluster ID 
Gene symbol FC 
10502622 Clca3 29,4 
10433172 Glycam1 23,1 
10538882 Gm5571 19,3 
10545231  18,9 
10538880 Igk-V1 14,2 
10545173 LOC672291 14,2 
10531126 Igj 13,6 
10545249  13,4 
10531407 Cxcl9 12,0 
10545175 LOC672291|Igk-J1 11,8 
10545247 Igk-V19-14 11,6 
10538921  10,3 
10538868  10,1 
10538871 Gm4964 9,6 
10545187 Gm1502|Gm8760|Igkv4-71 9,4 
10545237  9,1 
10538924 LOC100046496 8,8 
10438405 Igl-V1|Igl-V2|LOC433053 8,7 
10419568 Ear11 8,6 
10545198 Igkv4-71|Gm8760|Gm1499 8,6 
10417526 Dnase1l3 8,5 
10545190  8,5 
10545220 Gm16848 8,1 
10438415 Igl-V2|Igl-C2 8,0 
10545177  7,9 
10545184 Gm10880 7,8 
10402991 Gm16970|Igh-VX24 7,7 
10466172 Ms4a1 7,7 
10545205 Gm1418 7,1 
10403034 LOC100046275 6,8 
10545239  6,7 
10562812 Spib 6,7 
10545202 Gm1077 6,7 
10436095 Retnla 6,6 
10545196 Gm1419|Igkv4-71|Gm1524|Igk-C|Gm10880 6,3 
10379535 Ccl8 6,1 
10545233 Gm10883 6,1 
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10403018 IghmAC38.205.12|AI324046 6,0 
10403015 AI324046|IghmAC38.205.12|LOC634541|LOC634206 6,0 
10545212 Gm5574 6,0 
10403063 LOC100046275 5,9 
10545194 Rprl1|Gm8760|Igkv4-71 5,8 
10551025 Cd79a 5,7 
10403021  5,6 
10545180 Gm10879 5,6 
10361292 Cr2 5,6 
10402981 Gm900 5,5 
10545208 Gm189 5,5 
10545215 Igk-V28|Igkv12-46 5,4 
10403006 Gm7112 5,4 
10582882  5,3 
10403054 LOC435333 5,3 
10545569 Reg3g 5,3 
10583056 Mmp12 5,2 
10403048 Ighv1-72|LOC631518 5,2 
10582888  5,1 
10576757 Fcer2a 5,0 
10538903 Igk-V28|Gm7202|Igk-V21-4|Igkv6-25|Gm16939 5,0 
10512470 Cd72 4,9 
10403060 Ighv1-72|LOC382693|Gm16710 4,9 
10509577 Pla2g2d 4,8 
10349593 Faim3 4,8 
10603228  4,7 
10582890  4,7 
10485357  4,6 
10403079 LOC435333 4,6 
10523359 Cxcl13 4,5 
10599092  4,5 
10545235  4,4 
10450880 H2-M2 4,4 
10502335 Bank1 4,4 
10550509 Pglyrp1 4,4 
10545242 Igk-V19-20|Igk-V28 4,3 
10392142 Cd79b 4,3 
10403046 AI324046 4,3 
10403028 LOC382693|Gm16710 4,2 
10403009 Ighg|LOC100045391 4,2 
10517165 Cd52 4,2 
10582899  4,2 
10593015 Cd3g 4,1 
10563597 Saa3 4,1 
10522788 Stap1 4,1 
10567863 Cd19 4,0 
10598225 Gm2799|Gm2825|Gm2863|Gmcl1l|Gm14346 4,0 
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10501020 Chi3l3 4,0 
10538885  3,9 
10379727 Gm11428 3,9 
10402864 Ighg|Igh-VJ558|AI324046|LOC544903|Igh-6|Igh-5|Ighg1|Igh-
3|Igh-VS107|LOC380804|LOC630565|Igh-VX24|Ighv14-2|Igh-2 
3,9 
10367532 5830405N20Rik 3,8 
10547894 Cd4 3,8 
10545200  3,8 
10403057  3,7 
10406928 Cd180 3,6 
10512372 Ccl19|LOC100043921|Gm13309|Gm2442 3,6 
10466200 Ms4a7 3,5 
10512322 Ccl19|LOC100043921|Gm13309|Gm2442 3,5 
10504159 Ccl19|LOC100043921|Gm13309|Gm2442 3,5 
10585276 Pou2af1 3,5 
10349580 Pigr 3,4 
10347915 Gm7609|Csprs|Gm7592 3,4 
10606178 Xist 3,4 
10504188 Ccl19|LOC100043921|Gm13309|Gm2442 3,4 
10545217  3,4 
10598077  3,3 
10598229  3,3 
10598062  3,3 
10403821 Tcrg-V3|Tcrg-V2 3,3 
10486061 Rasgrp1 3,3 
10404606 Ly86 3,3 
10598187  3,2 
10601416 P2ry10 3,2 
10597996 Xcr1 3,2 
10351691 Slamf6 3,1 
10598064  3,1 
10347925 Gm7609|Csprs|Gm7592 3,1 
10545245  3,1 
10403023 Gm7016 3,1 
10504132 Ccl19|LOC100043921|Gm13309|Gm2442 3,1 
10517513 C1qc 3,1 
10574213 Ccl22 3,0 
10563178 Cd37 3,0 
10598075  3,0 
10574226 Ccl17 3,0 
10429560 Ly6i 3,0 
10346799 Icos 3,0 
10590623 Cxcr6 3,0 
10582879 Csprs|Gm7609|Gm7592 2,9 
10582916  2,9 
10492971 Fcrl1 2,9 
10461594 Ms4a4c 2,9 
10390640 Ikzf3 2,9 
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10545210 Gm1524 2,9 
10403825 Tcrg-C 2,9 
10582896  2,8 
10557177 Prkcb 2,8 
10351873 Pyhin1 2,8 
10469278 Il2ra 2,8 
10430818 Tnfrsf13c 2,8 
10466210 Ms4a6d 2,8 
10356274 Csprs|Gm7609|Gm7592 2,8 
10444236 H2-DMb2|H2-DMb1 2,8 
10395365 Agr2 2,8 
10347888 Ccl20 2,8 
10467508 Blnk 2,8 
10444284 H2-Ob 2,8 
10517508 C1qb 2,8 
10450325 Cfb 2,7 
10403038 LOC382693|Gm16710 2,7 
10547657 C3ar1 2,7 
10530145 Tlr1 2,7 
10349648 Ctse 2,7 
10601424 Gpr174 2,7 
10517517 C1qa 2,7 
10389214 Ccl9 2,7 
10544588 Gimap3 2,7 
10360406 Ifi205 2,7 
10591739 Acp5 2,7 
10525365 Hvcn1|Tctn1 2,7 
10460146  2,6 
10455970 BC023105 2,6 
10471912 Kynu 2,6 
10408557 Serpinb1a 2,6 
10531737 Hpse 2,6 
10432675 I730030J21Rik 2,6 
10407940 Tcrg-V2|Tcrg-V1 2,6 
10592888 Cxcr5 2,6 
10576034 Irf8 2,6 
10590631 Ccr2 2,6 
10403043 Ighv1-72 2,5 
10564163 Snord116|Snord116l1|Snord116l2 2,5 
10564179 Snord116|Snord116l1|Snord116l2 2,5 
10548892 Arhgdib 2,5 
10564181 Snord116|Snord116l1|Snord116l2 2,5 
10564165  2,5 
10407982 A530099J19Rik 2,5 
10564205 Snord116 2,5 
10564175 Snord116|Snord116l1|Snord116l2 2,5 
10564207 Snord116 2,5 
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10564187 Snord116|Snord116l1|Snord116l2 2,5 
10564167 Snord116|Snord116l1|Snord116l2 2,5 
10564185 Snord116|Snord116l1|Snord116l2 2,5 
10564171 Snord116|Snord116l1|Snord116l2 2,5 
10564193 Snord116|Snord116l1|Snord116l2 2,5 
10564201 Snord116 2,5 
10564173 Snord116|Snord116l1|Snord116l2 2,5 
10564197 Snord116|Snord116l1|Snord116l2 2,5 
10564195 Snord116|Snord116l1|Snord116l2 2,5 
10564199 Snord116|Snord116l1|Snord116l2 2,5 
10564189 Snord116|Snord116l1|Snord116l2 2,5 
10564191 Snord116|Snord116l1|Snord116l2 2,5 
10414811 Gm13969 2,5 
10564161 Snord116|Snord116l1|Snord116l2 2,5 
10455961 Iigp1 2,5 
10414937 Gm13969 2,5 
10593024 Cd3e 2,5 
10347218  2,5 
10399854 Slc26a4 2,5 
10430372 Rac2 2,5 
10603860 Cfp 2,5 
10385533 Tgtp1|Tgtp2|Gm12185 2,5 
10567825 Lat 2,5 
10444752 Ltb 2,5 
10439312 Cd86 2,4 
10455954 Gm4951 2,4 
10516620 Lck 2,4 
10519497 Steap4 2,4 
10351658 Cd48 2,4 
10444306 H2-Eb2 2,4 
10461614 Ms4a6c 2,4 
10564159  2,4 
10385518 Tgtp1|Tgtp2|Gm12185 2,4 
10360028 Fcgr2b 2,4 
10547621 Apobec1 2,4 
10494271 Ctss 2,4 
10531415 Cxcl10 2,4 
10404389 Irf4 2,4 
10590635 Ccr5|Ccr2 2,4 
10404840 Cd83 2,4 
10597960 Slc6a20a 2,4 
10598013 Ccr5|Ccr2 2,3 
10564183 Snord116 2,3 
10461622 Ms4a6b 2,3 
10564169  2,3 
10480238 St8sia6 2,3 
10516906 Snora73b 2,3 
10439744 Cd96 2,3 
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10387699 Acap1 2,3 
10557342 Il21r 2,3 
10599487 Sash3 2,3 
10562132 Cd22 2,3 
10501063 Cd53 2,3 
10570634 4930467E23Rik|Gm15319|Trim44|Gm7827 2,3 
10430344 Il2rb 2,3 
10548817 Plbd1 2,3 
10568024 Coro1a 2,3 
10477495 U46068 2,3 
10438769 Cldn1 2,3 
10435982 Btla 2,3 
10418848 Wdfy4 2,3 
10360158 Ly9 2,3 
10548375 Clec7a 2,3 
10385118 Dock2 2,3 
10516908 Snora73a 2,3 
10389143 Slfn8 2,3 
10444298 H2-Eb1 2,3 
10548333 Cd69 2,3 
10433507 Ciita 2,3 
10398907 Pld4 2,2 
10450374 D17H6S56E-5 2,2 
10572527 4930467E23Rik|Gm15319|Gm7827|Trim44 2,2 
10378286 Itgae 2,2 
10379524 Ccl11 2,2 
10496539 Gbp5 2,2 
10385428 Itk 2,2 
10567366 Gp2 2,2 
10360018 Fcrla 2,2 
10374333 Ikzf1 2,2 
10439527 Tigit 2,2 
10542164 Clec12a 2,2 
10360173 Slamf7 2,2 
10605034 Xlr4c|Xlr4b|Xlr4a 2,2 
10422760 Fyb 2,2 
10597420 Ccr4 2,2 
10445412 Nfkbie 2,2 
10446253 Vav1 2,2 
10409240 Sema4d 2,2 
10519811 Speer8-ps1|Speer7-ps1 2,2 
10351197 Sell 2,2 
10552743 Il4i1|Nup62-il4i1 2,2 
10551666 Map4k1 2,2 
10358224 Ptprc 2,2 
10360382 Ifi204|Mnda 2,2 
10597074  2,1 
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10494978 Ptpn22 2,1 
10358408 Rgs1 2,1 
10606694 Btk 2,1 
10564177 Snord116 2,1 
10512669 Pax5 2,1 
10582884  2,1 
10579054 4930467E23Rik|Gm15319|Trim44 2,1 
10582985 Casp1 2,1 
10502801 H28 2,1 
10579060 4930467E23Rik|Gm15319|Trim44 2,1 
10349571 Fcamr 2,1 
10360370 BC094916 2,1 
10461765 Lpxn 2,1 
10598041  2,1 
10593050 Il10ra 2,1 
10427628 Il7r 2,1 
10508719 Snora16a 2,1 
10354374 Slc40a1 2,1 
10375145 Lcp2 2,1 
10444291 H2-Ab1 2,1 
10427336 Nckap1l 2,1 
10381708 Fmnl1 2,1 
10577361 4930467E23Rik|Gm15319|Trim44|Gm7827 2,1 
10468898 Lax1 2,1 
10449893 Rasal3|A530088E08Rik 2,1 
10538936  2,1 
10390763 Ccr7 2,0 
10402512 Scarna13 2,0 
10346783 Cd28 2,0 
10347222  2,0 
10425053 Ncf4 2,0 
10413615 Itih4 2,0 
10397645 Gpr65 2,0 
10574098 Nlrc5 2,0 
10575799 Plcg2 2,0 
10425726 Sep 03 2,0 
10605143 Arhgap4 2,0 
10598073  2,0 
10522182 Rhoh 2,0 
10425410 Grap2 2,0 
10577388 4930467E23Rik|Gm15319|Trim44|Gm7827 2,0 
10376324 Gm12250 2,0 
10557895 Itgax 2,0 
10471929 Arhgap15 2,0 
10487011 Gatm 2,0 
10481627 Lcn2 2,0 
10435565 Hcls1 2,0 
10438098 Sdf2l1 2,0 
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10361215 Traf3ip3 2,0 
10460371 Ptprcap|Rps6kb2 2,0 
10578264 Msr1 2,0 
10550193 Gm3994|Gm10679 2,0 
10566583 Gm8995 2,0 
 
Table 11: Genes found to be down-regulated (=fold change [FC] ≤-2) in lungs of SPC-HAxTCR-HA mice 
when compared to lung tissue from SPC-HA control mice (Ʃ 52). 
Transcript 
Cluster ID 
Gene symbol  FC 
10399360 Rhob -2,0 
10443690 Glp1r -2,0 
10353450 Gm4956 -2,0 
10425283 Maff -2,0 
10450038 Angptl4 -2,0 
10352918 Mir29c|A330023F24Rik -2,1 
10358515 Hmcn1 -2,1 
10407122  -2,1 
10510574 Errfi1 -2,1 
10426110 Pim3 -2,1 
10462132 E030010A14Rik|Pgm5 -2,2 
10479975  -2,2 
10396419  -2,2 
10526410 Hspb1|Gm9817 -2,2 
10408928 Hspb1|Gm9817 -2,2 
10449741 Sik1 -2,2 
10578950  -2,2 
10412699 Gm10404 -2,3 
10369290 Ddit4 -2,3 
10400095 Ifrd1|Gm7008 -2,3 
10578136  -2,4 
10482772 Nr4a2 -2,4 
10459288 Adrb2 -2,4 
10377439 Per1 -2,4 
10531610 Rasgef1b -2,4 
10575873 Osgin1 -2,5 
10357875 Btg2 -2,5 
10449284 Dusp1 -2,5 
10509965 Epha2 -2,5 
10580183 Ier2 -2,6 
10495675 F3 -2,6 
10514466 Jun -2,6 
10474972 Chac1 -2,6 
10504838 Nr4a3 -2,7 
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10597758 Csrnp1 -2,7 
10543017 Pdk4 -2,7 
10561453 Zfp36 -2,7 
10433885 Cebpd -2,8 
10541071 8430408G22Rik -2,9 
10363735 Egr2 -2,9 
10434925 Hes1 -3,2 
10366346 Phlda1 -3,3 
10450367 Hspa1a|Hspa1b -3,8 
10444589 Hspa1a|Hspa1b -3,8 
10560481 Fosb -3,8 
10573198 Dnajb1 -4,3 
10450369 Hspa1a -4,5 
10350516 Ptgs2 -5,8 
10427035 Nr4a1 -7,5 
10397346 Fos -7,5 
10454782 Egr1 -7,8 
10361091 Atf3 -10,4 
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 BALFome analyses 7.1.2
Table 12: List of proteins identified in BALF from SPC-HA and SPC-HAxTCR-HA mice (Ʃ372). 
Accession 
ID 
Protein Gene 
symbol 
Entrez 
Gene ID 
Q64433 10 kDa heat shock protein, mitochondrial Hspe1 15528 
Q9CQV8 14-3-3 protein beta/alpha Ywhab 54401 
P62259 14-3-3 protein epsilon Ywhae 22627 
P68510 14-3-3 protein eta Ywhah 22629 
P61982 14-3-3 protein gamma Ywhag 22628 
O70456 14-3-3 protein sigma Sfn 55948 
P68254 14-3-3 protein theta Ywhaq 22630 
P63101 14-3-3 protein zeta/delta Ywhaz 22631 
Q99L13 3-hydroxyisobutyrate dehydrogenase, 
mitochondrial 
Hibadh 58875 
Q8BWT1 3-ketoacyl-CoA thiolase, mitochondrial Acaa2 52538 
P62858 40S ribosomal protein S28 Rps28 54127 
P63038 60 kDa heat shock protein, mitochondrial Hspd1 15510 
P14869 60S acidic ribosomal protein P0 Rplp0 11837 
P99027 60S acidic ribosomal protein P2 Rplp2 67186 
P53026 60S ribosomal protein L10a Rpl10a 19896 
P35979 60S ribosomal protein L12 Rpl12 269261 
Q9DCD0 6-phosphogluconate dehydrogenase, 
decarboxylating 
Pgd 110208 
Q9R1Z7 6-pyruvoyl tetrahydrobiopterin synthase Pts 19286 
P20029 78 kDa glucose-regulated protein Hspa5 14828 
Q8QZT1 Acetyl-CoA acetyltransferase, mitochondrial Acat1 110446 
Q99KI0 Aconitate hydratase, mitochondrial Aco2 11429 
P60710 Actin, cytoplasmic 1 Actb 11461 
Q9JM76 Actin-related protein 2/3 complex subunit 3 Arpc3 56378 
P59999 Actin-related protein 2/3 complex subunit 4 Arpc4 68089 
Q9CPW4 Actin-related protein 2/3 complex subunit 5 Arpc5 67771 
P11031 Activated RNA polymerase II transcriptional 
coactivator p15 
Sub1 20024 
O55137 Acyl-coenzyme A thioesterase 1 Acot1 26897 
Q9QYR9 Acyl-coenzyme A thioesterase 2, 
mitochondrial 
Acot2 171210 
P50247 Adenosylhomocysteinase Ahcy 269378 
Q9WTP6 Adenylate kinase 2, mitochondrial Ak2 11637 
P40124 Adenylyl cyclase-associated protein 1 Cap1 12331 
P61205 ADP-ribosylation factor 3 Arf3 11842 
Q8QZR5 Alanine aminotransferase 1 Gpt 76282 
Q9JII6 Alcohol dehydrogenase [NADP(+)] Akr1a1 58810 
O35945 Aldehyde dehydrogenase, cytosolic 1 Aldh1a7 26358 
P47738 Aldehyde dehydrogenase, mitochondrial Aldh2 11669 
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G3X982 Aldehyde oxidase 3 Aox3 71724 
Q8K157 Aldose 1-epimerase Galm 319625 
P45376 Aldose reductase Akr1b1 11677 
Q8VCR7 Alpha/beta hydrolase domain-containing 
protein 14B 
Abhd14b 76491 
Q7TPR4 Alpha-actinin-1 Actn1 109711 
P57780 Alpha-actinin-4 Actn4 60595 
P17182 Alpha-enolase Eno1 13806 
P12023 Amyloid beta A4 protein App 11820 
P07356 Annexin A2 Anxa2 12306 
Q9Z0X1 Apoptosis-inducing factor 1, mitochondrial Aifm1 26926 
P05201 Aspartate aminotransferase, cytoplasmic Got1 14718 
P05202 Aspartate aminotransferase, mitochondrial Got2 14719 
Q9Z2W0 Aspartyl aminopeptidase Dnpep 13437 
Q03265 ATP synthase subunit alpha, mitochondrial Atp5a1 11946 
P56480 ATP synthase subunit beta, mitochondrial Atp5b 11947 
Q9D3D9 ATP synthase subunit delta, mitochondrial Atp5d 66043 
Q91V92 ATP-citrate synthase Acly 104112 
Q9R069 Basal cell adhesion molecule Bcam 57278 
P09803 Cadherin-1 Cdh1 12550 
P62204 Calmodulin Calm1 12315 
O35887 Calumenin Calu 12321 
P28651 Carbonic anhydrase-related protein Ca8 12319 
P08074 Carbonyl reductase [NADPH] 2 Cbr2 12409 
Q8VCT4 Carboxylesterase 1D Ces1d 104158 
P24270 Catalase Cat 12359 
P26231 Catenin alpha-1 Ctnna1 12385 
P10605 Cathepsin B Ctsb 13030 
P18242 Cathepsin D Ctsd 13033 
Q61490 CD166 antigen Alcam 11658 
Q61362 Chitinase-3-like protein 1 Chi3l1 12654 
Q9Z1Q5 Chloride intracellular channel protein 1 Clic1 114584 
Q9QYB1 Chloride intracellular channel protein 4 Clic4 29876 
P23198 Chromobox protein homolog 3 Cbx3 12417 
Q06890 Clusterin Clu 12759 
Q5XJY5 Coatomer subunit delta Arcn1 213827 
Q9QZE5 Coatomer subunit gamma-1 Copg1 54161 
P18760 Cofilin-1 Cfl1 12631 
P45591 Cofilin-2 Cfl2 12632 
P01027 Complement C3 C3 12266 
O35658 Complement component 1 Q 
subcomponent-binding protein, 
mitochondrial 
C1qbp 12261 
O08997 Copper transport protein ATOX1 Atox1 11927 
Q8CCK0 Core histone macro-H2A.2 H2afy2 404634 
P30275 Creatine kinase U-type, mitochondrial Ckmt1 12716 
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Q6ZQ38 Cullin-associated NEDD8-dissociated 
protein 1 
Cand1 71902 
P21460 Cystatin-C Cst3 13010 
P97315 Cysteine and glycine-rich protein 1 Csrp1 13007 
Q9DCT8 Cysteine-rich protein 2 Crip2 68337 
P62897 Cytochrome c, somatic Cycs 13063 
O88487 Cytoplasmic dynein 1 intermediate chain 2 Dync1i2 13427 
Q9CPY7 Cytosol aminopeptidase Lap3 66988 
Q91V12 Cytosolic acyl coenzyme A thioester 
hydrolase 
Acot7 70025 
Q9D1A2 Cytosolic non-specific dipeptidase Cndp2 66054 
O35215 D-dopachrome decarboxylase Ddt 13202 
P10518 Delta-aminolevulinic acid dehydratase Alad 17025 
Q9R0P5 Destrin Dstn 56431 
O08749 Dihydrolipoyl dehydrogenase, mitochondrial Dld 13382 
O08553 Dihydropyrimidinase-related protein 2 Dpysl2 12934 
P97821 Dipeptidyl peptidase 1 Ctsc 13032 
Q99KK7 Dipeptidyl peptidase 3 Dpp3 75221 
P28843 Dipeptidyl peptidase 4 Dpp4 13482 
Q99KJ8 Dynactin subunit 2 Dctn2 69654 
Q9D8Y0 EF-hand domain-containing protein D2 Efhd2 27984 
P70372 ELAV-like protein 1 Elavl1 15568 
P10126 Elongation factor 1-alpha 1 Eef1a1 13627 
O70251 Elongation factor 1-beta Eef1b 55949 
P57776 Elongation factor 1-delta Eef1d 66656 
Q9D8N0 Elongation factor 1-gamma Eef1g 67160 
P58252 Elongation factor 2 Eef2 13629 
P57759 Endoplasmic reticulum resident protein 29 Erp29 67397 
P08113 Endoplasmin Hsp90b1 22027 
P42125 Enoyl-CoA delta isomerase 1, mitochondrial Eci1 13177 
Q6ZWX6 Eukaryotic translation initiation factor 2 
subunit 1 
Eif2s1 13665 
Q99L45 Eukaryotic translation initiation factor 2 
subunit 2 
Eif2s2 67204 
Q9ERK4 Exportin-2 Cse1l 110750 
P26040 Ezrin Ezr 22350 
P47754 F-actin-capping protein subunit alpha-2 Capza2 12343 
P47757 F-actin-capping protein subunit beta Capzb 12345 
Q3U0V1 Far upstream element-binding protein 2 Khsrp 16549 
Q920E5 Farnesyl pyrophosphate synthase Fdps 110196 
P19096 Fatty acid synthase Fasn 14104 
Q05816 Fatty acid-binding protein, epidermal Fabp5 16592 
P09528 Ferritin heavy chain Fth1 14319 
P29391 Ferritin light chain 1 Ftl1 14325 
Q8BTM8 Filamin-A Flna 192176 
Q80X90 Filamin-B Flnb 286940 
Appendix 
109 
 
P70695 Fructose-1,6-bisphosphatase isozyme 2 Fbp2 14120 
P05064 Fructose-bisphosphate aldolase A Aldoa 11674 
P97807 Fumarate hydratase, mitochondrial Fh 14194 
P35505 Fumarylacetoacetase Fah 14085 
P23591 GDP-L-fucose synthase Tsta3 22122 
P13020 Gelsolin Gsn 227753 
P06745 Glucose-6-phosphate isomerase Gpi 14751 
O08795 Glucosidase 2 subunit beta Prkcsh 19089 
P26443 Glutamate dehydrogenase 1, mitochondrial Glud1 14661 
P97494 Glutamate--cysteine ligase catalytic subunit Gclc 14629 
Q9QUH0 Glutaredoxin-1 Glrx 93692 
P11352 Glutathione peroxidase 1 Gpx1 14775 
P47791 Glutathione reductase, mitochondrial Gsr 14782 
P24472 Glutathione S-transferase A4 Gsta4 14860 
P10649 Glutathione S-transferase Mu 1 Gstm1 14862 
P15626 Glutathione S-transferase Mu 2 Gstm2 14863 
P19157 Glutathione S-transferase P 1 Gstp1 14870 
P51855 Glutathione synthetase Gss 14854 
Q8CI94 Glycogen phosphorylase, brain form Pygb 110078 
Q9ET01 Glycogen phosphorylase, liver form Pygl 110095 
Q9CPV4 Glyoxalase domain-containing protein 4 Glod4 67201 
Q99JX3 Golgi reassembly-stacking protein 2 Gorasp2 70231 
Q99LP6 GrpE protein homolog 1, mitochondrial Grpel1 17713 
Q9WTP7 GTP:AMP phosphotransferase AK3, 
mitochondrial 
Ak3 56248 
P01921 H-2 class II histocompatibility antigen, A-D 
beta chain 
H2-Ab1 14961 
P04227 H-2 class II histocompatibility antigen, A-Q 
alpha chain (Fragment) 
H2-Aa 14960 
Q9CYW4 Haloacid dehalogenase-like hydrolase 
domain-containing protein 3 
Hdhd3 72748 
Q61696 Heat shock 70 kDa protein 1A Hspa1a 193740 
Q61316 Heat shock 70 kDa protein 4 Hspa4 15525 
P63017 Heat shock cognate 71 kDa protein Hspa8 15481 
Q9CQN1 Heat shock protein 75 kDa, mitochondrial Trap1 68015 
P07901 Heat shock protein HSP 90-alpha Hsp90aa1 15519 
P11499 Heat shock protein HSP 90-beta Hsp90ab1 15516 
P17156 Heat shock-related 70 kDa protein 2 Hspa2 15512 
P51859 Hepatoma-derived growth factor Hdgf 15191 
Q99020 Heterogeneous nuclear ribonucleoprotein 
A/B 
Hnrnpab 15384 
P49312 Heterogeneous nuclear ribonucleoprotein 
A1 
Hnrnpa1 15382 
Q8BG05 Heterogeneous nuclear ribonucleoprotein 
A3 
Hnrnpa3 229279 
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Q60668 Heterogeneous nuclear ribonucleoprotein 
D0 
Hnrnpd 11991 
O35737 Heterogeneous nuclear ribonucleoprotein H Hnrnph1 59013 
P61979 Heterogeneous nuclear ribonucleoprotein K Hnrnpk 15387 
Q7TMK9 Heterogeneous nuclear ribonucleoprotein Q Syncrip 56403 
P17710 Hexokinase-1 Hk1 15275 
O54879 High mobility group protein B3 Hmgb3 15354 
P70349 Histidine triad nucleotide-binding protein 1 Hint1 15254 
P15864 Histone H1.2 Hist1h1c 50708 
P43274 Histone H1.4 Hist1h1e 50709 
Q8CGP6 Histone H2A type 1-H Hist1h2ah 319168 
P0C0S6 Histone H2A.Z H2afz 51788 
P10853 Histone H2B type 1-F/J/L Hist1h2bf 665622 
P02301 Histone H3.3C H3f3c 625328 
P62806 Histone H4 Hist1h4a 320332 
Q99L47 Hsc70-interacting protein St13 70356 
P00493 Hypoxanthine-guanine 
phosphoribosyltransferase 
Hprt1 15452 
Q91VM9 Inorganic pyrophosphatase 2, mitochondrial Ppa2 74776 
O55023 Inositol monophosphatase 1 Impa1 55980 
O88844 Isocitrate dehydrogenase [NADP] 
cytoplasmic 
Idh1 15926 
P58044 Isopentenyl-diphosphate Delta-isomerase 1 Idi1 319554 
P02535 Keratin, type I cytoskeletal 10 Krt10 16661 
Q9Z2K1 Keratin, type I cytoskeletal 16 Krt16 16666 
Q9QWL7 Keratin, type I cytoskeletal 17 Krt17 16667 
P05784 Keratin, type I cytoskeletal 18 Krt18 16668 
P19001 Keratin, type I cytoskeletal 19 Krt19 16669 
Q6IFX2 Keratin, type I cytoskeletal 42 Krt42 68239 
P04104 Keratin, type II cytoskeletal 1 Krt1 16678 
Q3UV17 Keratin, type II cytoskeletal 2 oral Krt76 77055 
P50446 Keratin, type II cytoskeletal 6A Krt6a 16687 
Q9DCV7 Keratin, type II cytoskeletal 7 Krt7 110310 
Q8VED5 Keratin, type II cytoskeletal 79 Krt79 223917 
P11679 Keratin, type II cytoskeletal 8 Krt8 16691 
Q9CPU0 Lactoylglutathione lyase Glo1 109801 
Q61029 Lamina-associated polypeptide 2, isoforms 
beta/delta/epsilon/gamma 
Tmpo 21917 
P14733 Lamin-B1 Lmnb1 16906 
P21619 Lamin-B2 Lmnb2 16907 
Q61792 LIM and SH3 domain protein 1 Lasp1 16796 
P06151 L-lactate dehydrogenase A chain Ldha 16828 
P16125 L-lactate dehydrogenase B chain Ldhb 16832 
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P51174 Long-chain specific acyl-CoA 
dehydrogenase, mitochondrial 
Acadl 11363 
Q91X52 L-xylulose reductase Dcxr 67880 
Q99MN1 Lysine--tRNA ligase Kars 85305 
P11438 Lysosome-associated membrane 
glycoprotein 1 
Lamp1 16783 
P08905 Lysozyme C-2 Lyz2 17105 
Q9DAR7 m7GpppX diphosphatase Dcps 69305 
P24452 Macrophage-capping protein Capg 12332 
P14152 Malate dehydrogenase, cytoplasmic Mdh1 17449 
P08249 Malate dehydrogenase, mitochondrial Mdh2 17448 
Q9CXI5 Mesencephalic astrocyte-derived 
neurotrophic factor 
Manf 74840 
P12032 Metalloproteinase inhibitor 1 Timp1 21857 
P26041 Moesin Msn 17698 
Q02496 Mucin-1 Muc1 17829 
Q60605 Myosin light polypeptide 6 Myl6 17904 
Q3THE2 Myosin regulatory light chain 12B Myl12b 67938 
Q6URW6 Myosin-14 Myh14 71960 
Q8VDD5 Myosin-9 Myh9 17886 
P62774 Myotrophin Mtpn 14489 
P70441 Na(+)/H(+) exchange regulatory cofactor 
NHE-RF1 
Slc9a3r1 26941 
Q8K4Z3 NAD(P)H-hydrate epimerase Apoa1bp 246703 
Q9D6J6 NADH dehydrogenase [ubiquinone] 
flavoprotein 2, mitochondrial 
Ndufv2 72900 
Q9DCN2 NADH-cytochrome b5 reductase 3 Cyb5r3 109754 
P06801 NADP-dependent malic enzyme Me1 17436 
Q60817 Nascent polypeptide-associated complex 
subunit alpha 
Naca 17938 
Q99KQ4 Nicotinamide phosphoribosyltransferase Nampt 59027 
Q9CZ44 NSFL1 cofactor p47 Nsfl1c 386649 
O35685 Nuclear migration protein nudC Nudc 18221 
P62960 Nuclease-sensitive element-binding protein 
1 
Ybx1 22608 
P81117 Nucleobindin-2 Nucb2 53322 
P09405 Nucleolin Ncl 17975 
P15532 Nucleoside diphosphate kinase A Nme1 18102 
P29758 Ornithine aminotransferase, mitochondrial Oat 18242 
Q9D0J8 Parathymosin Ptms 69202 
O70400 PDZ and LIM domain protein 1 Pdlim1 54132 
P17742 Peptidyl-prolyl cis-trans isomerase A Ppia 268373 
P24369 Peptidyl-prolyl cis-trans isomerase B Ppib 19035 
P30412 Peptidyl-prolyl cis-trans isomerase C Ppic 19038 
P26883 Peptidyl-prolyl cis-trans isomerase FKBP1A Fkbp1a 14225 
P45878 Peptidyl-prolyl cis-trans isomerase FKBP2 Fkbp2 14227 
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P30416 Peptidyl-prolyl cis-trans isomerase FKBP4 Fkbp4 14228 
P35700 Peroxiredoxin-1 Prdx1 18477 
Q61171 Peroxiredoxin-2 Prdx2 21672 
P99029 Peroxiredoxin-5, mitochondrial Prdx5 54683 
O08709 Peroxiredoxin-6 Prdx6 11758 
P70296 Phosphatidylethanolamine-binding protein 1 Pebp1 23980 
Q9CYR6 Phosphoacetylglucosamine mutase Pgm3 109785 
Q9D0F9 Phosphoglucomutase-1 Pgm1 72157 
P09411 Phosphoglycerate kinase 1 Pgk1 18655 
P22777 Plasminogen activator inhibitor 1 Serpine1 18787 
Q61233 Plastin-2 Lcp1 18826 
Q99K51 Plastin-3 Pls3 102866 
Q08857 Platelet glycoprotein 4 Cd36 12491 
Q9QXS1 Plectin Plec 18810 
Q8CG72 Poly(ADP-ribose) glycohydrolase ARH3 Adprhl2 100206 
P60335 Poly(rC)-binding protein 1 Pcbp1 23983 
Q61990 Poly(rC)-binding protein 2 Pcbp2 18521 
Q3UEB3 Poly(U)-binding-splicing factor PUF60 Puf60 67959 
P29341 Polyadenylate-binding protein 1 Pabpc1 18458 
P0CG49 Polyubiquitin-B Ubb 22187 
Q03958 Prefoldin subunit 6 Pfdn6 14976 
P48678 Prelamin-A/C Lmna 16905 
P62962 Profilin-1 Pfn1 18643 
Q9WU78 Programmed cell death 6-interacting protein Pdcd6ip 18571 
P97371 Proteasome activator complex subunit 1 Psme1 19186 
P97372 Proteasome activator complex subunit 2 Psme2 19188 
Q9R1P4 Proteasome subunit alpha type-1 Psma1 26440 
O70435 Proteasome subunit alpha type-3 Psma3 19167 
Q9R1P0 Proteasome subunit alpha type-4 Psma4 26441 
Q9Z2U1 Proteasome subunit alpha type-5 Psma5 26442 
Q9QUM9 Proteasome subunit alpha type-6 Psma6 26443 
Q9Z2U0 Proteasome subunit alpha type-7 Psma7 26444 
O09061 Proteasome subunit beta type-1 Psmb1 19170 
Q9R1P3 Proteasome subunit beta type-2 Psmb2 26445 
Q9R1P1 Proteasome subunit beta type-3 Psmb3 26446 
P99026 Proteasome subunit beta type-4 Psmb4 19172 
Q60692 Proteasome subunit beta type-6 Psmb6 19175 
P70195 Proteasome subunit beta type-7 Psmb7 19177 
P28063 Proteasome subunit beta type-8 Psmb8 16913 
O35522 Proteasome subunit beta type-9 Psmb9 16912 
P09103 Protein disulfide-isomerase P4hb 18453 
P27773 Protein disulfide-isomerase A3 Pdia3 14827 
P08003 Protein disulfide-isomerase A4 Pdia4 12304 
Q922R8 Protein disulfide-isomerase A6 Pdia6 71853 
Q99LX0 Protein DJ-1 Park7 57320 
Q921M7 Protein FAM49B Fam49b 223601 
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Q9WVE8 Protein kinase C and casein kinase 
substrate in neurons protein 2 
Pacsin2 23970 
P97352 Protein S100-A13 S100a13 20196 
P97816 Protein S100-G S100g 12309 
Q9D1M0 Protein SEC13 homolog Sec13 110379 
Q9EQU5 Protein SET Set 56086 
P26350 Prothymosin alpha Ptma 19231 
P61458 Pterin-4-alpha-carbinolamine dehydratase Pcbd1 13180 
P50405 Pulmonary surfactant-associated protein B Sftpb 20388 
P21841 Pulmonary surfactant-associated protein C Sftpc 20389 
P50404 Pulmonary surfactant-associated protein D Sftpd 20390 
P23492 Purine nucleoside phosphorylase Pnp 18950 
Q11011 Puromycin-sensitive aminopeptidase Npepps 19155 
Q64G17 Putative acidic leucine-rich nuclear 
phosphoprotein 32 family member C 
Anp32c 448829 
P52480 Pyruvate kinase PKM Pkm 18746 
P50396 Rab GDP dissociation inhibitor alpha Gdi1 14567 
Q61598 Rab GDP dissociation inhibitor beta Gdi2 14569 
P26043 Radixin Rdx 19684 
P34022 Ran-specific GTPase-activating protein Ranbp1 19385 
P97855 Ras GTPase-activating protein-binding 
protein 1 
G3bp1 27041 
Q9JKF1 Ras GTPase-activating-like protein IQGAP1 Iqgap1 29875 
Q9DCV4 Regulator of microtubule dynamics protein 
1 
Rmdn1 66302 
P24549 Retinal dehydrogenase 1 Aldh1a1 11668 
Q99PT1 Rho GDP-dissociation inhibitor 1 Arhgdia 192662 
Q91VI7 Ribonuclease inhibitor Rnh1 107702 
Q99PL5 Ribosome-binding protein 1 Rrbp1 81910 
Q9JI75 Ribosyldihydronicotinamide dehydrogenase 
[quinone] 
Nqo2 18105 
Q91VM5 RNA binding motif protein, X-linked-like-1 Rbmxl1 19656 
Q61545 RNA-binding protein EWS Ewsr1 14030 
P56959 RNA-binding protein FUS Fus 233908 
P17563 Selenium-binding protein 1 Selenbp1 20341 
P58389 Serine/threonine-protein phosphatase 2A 
activator 
Ppp2r4 110854 
Q921I1 Serotransferrin Tf 22041 
Q60854 Serpin B6 Serpinb6 20719 
Q9JJU8 SH3 domain-binding glutamic acid-rich-like 
protein 
Sh3bgrl 56726 
Q91VW3 SH3 domain-binding glutamic acid-rich-like 
protein 3 
Sh3bgrl3 73723 
P62320 Small nuclear ribonucleoprotein Sm D3 Snrpd3 67332 
P61957 Small ubiquitin-related modifier 2 Sumo2 170930 
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Q9DBP0 Sodium-dependent phosphate transport 
protein 2B 
Slc34a2 20531 
Q64442 Sorbitol dehydrogenase Sord 20322 
P16546 Spectrin alpha chain, non-erythrocytic 1 Sptan1 20740 
Q62261 Spectrin beta chain, non-erythrocytic 1 Sptbn1 20742 
Q9WTX5 S-phase kinase-associated protein 1 Skp1 21402 
Q9Z1N5 Spliceosome RNA helicase Ddx39b Ddx39b 53817 
Q8VIJ6 Splicing factor, proline- and glutamine-rich Sfpq 71514 
Q60864 Stress-induced-phosphoprotein 1 Stip1 20867 
P28862 Stromelysin-1 Mmp3 17392 
Q9D0K2 Succinyl-CoA:3-ketoacid coenzyme A 
transferase 1, mitochondrial 
Oxct1 67041 
P08228 Superoxide dismutase [Cu-Zn] Sod1 20655 
P09671 Superoxide dismutase [Mn], mitochondrial Sod2 20656 
O35988 Syndecan-4 Sdc4 20971 
P26039 Talin-1 Tln1 21894 
P10639 Thioredoxin Txn 22166 
Q91W90 Thioredoxin domain-containing protein 5 Txndc5 105245 
Q9JMH6 Thioredoxin reductase 1, cytoplasmic Txnrd1 50493 
P20108 Thioredoxin-dependent peroxide reductase, 
mitochondrial 
Prdx3 11757 
P52196 Thiosulfate sulfurtransferase Tst 22117 
P35441 Thrombospondin-1 Thbs1 21825 
Q93092 Transaldolase Taldo1 21351 
Q9WVA4 Transgelin-2 Tagln2 21346 
Q01853 Transitional endoplasmic reticulum ATPase Vcp 269523 
P40142 Transketolase Tkt 21881 
Q62348 Translin Tsn 22099 
Q9JHJ0 Tropomodulin-3 Tmod3 50875 
P58771 Tropomyosin alpha-1 chain Tpm1 22003 
P21107 Tropomyosin alpha-3 chain Tpm3 59069 
Q6IRU2 Tropomyosin alpha-4 chain Tpm4 326618 
P58774 Tropomyosin beta chain Tpm2 22004 
P05213 Tubulin alpha-1B chain Tuba1b 22143 
P68373 Tubulin alpha-1C chain Tuba1c 22146 
P68372 Tubulin beta-4B chain Tubb4b 227613 
Q9CRB6 Tubulin polymerization-promoting protein 
family member 3 
Tppp3 67971 
P48428 Tubulin-specific chaperone A Tbca 21371 
Q62393 Tumor protein D52 Tpd52 21985 
Q9CYZ2 Tumor protein D54 Tpd52l2 66314 
P61087 Ubiquitin-conjugating enzyme E2 K Ube2k 53323 
P68037 Ubiquitin-conjugating enzyme E2 L3 Ube2l3 22195 
P61089 Ubiquitin-conjugating enzyme E2 N Ube2n 93765 
Q9D2M8 Ubiquitin-conjugating enzyme E2 variant 2 Ube2v2 70620 
Q9DBP5 UMP-CMP kinase Cmpk1 66588 
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Q06318 Uteroglobin Scgb1a1 22287 
P54728 UV excision repair protein RAD23 homolog 
B 
Rad23b 19359 
Q9QY76 Vesicle-associated membrane protein-
associated protein B 
Vapb 56491 
P20152 Vimentin Vim 22352 
Q64727 Vinculin Vcl 22330 
P50516 V-type proton ATPase catalytic subunit A Atp6v1a 11964 
P62814 V-type proton ATPase subunit B, brain 
isoform 
Atp6v1b2 11966 
P50518 V-type proton ATPase subunit E 1 Atp6v1e1 11973 
Q9CR51 V-type proton ATPase subunit G 1 Atp6v1g1 66290 
Q00519 Xanthine dehydrogenase/oxidase Xdh 22436 
 
Table 13: List of proteins only identified in BALF from SPC-HA mice (Ʃ129). 
Accession 
ID 
Protein Gene 
symbol 
Entrez 
Gene ID 
Q3UHX2 28 kDa heat- and acid-stable 
phosphoprotein 
Pdap1 231887 
Q9Z0S1 3'(2'),5'-bisphosphate nucleotidase 1 Bpnt1 23827 
Q8QZS1 3-hydroxyisobutyryl-CoA hydrolase, 
mitochondrial 
Hibch 227095 
Q8K010 5-oxoprolinase Oplah 75475 
Q9CQ60 6-phosphogluconolactonase Pgls 66171 
P33434 72 kDa type IV collagenase Mmp2 17390 
Q91XA9 Acidic mammalian chitinase Chia 81600 
Q9Z2N8 Actin-like protein 6A Actl6a 56456 
Q6P5E6 ADP-ribosylation factor-binding protein 
GGA2 
Gga2 74105 
P97449 Aminopeptidase N Anpep 16790 
G5E8K5 Ankyrin-3 Ank3 11735 
O35639 Annexin A3 Anxa3 11745 
O35841 Apoptosis inhibitor 5 Api5 11800 
Q7SIG6 Arf-GAP with SH3 domain, ANK repeat and 
PH domain-containing protein 2 
Asap2 211914 
Q91YI0 Argininosuccinate lyase Asl 109900 
Q9DC29 ATP-binding cassette sub-family B member 
6, mitochondrial 
Abcb6 74104 
Q9JLV1 BAG family molecular chaperone regulator 
3 
Bag3 29810 
Q99NF1 Beta,beta-carotene 9',10'-oxygenase Bco2 170752 
P28653 Biglycan Bgn 12111 
Q8R016 Bleomycin hydrolase Blmh 104184 
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O35855 Branched-chain-amino-acid 
aminotransferase, mitochondrial 
Bcat2 12036 
Q9DB16 Calcium-binding protein 39-like Cab39l 69008 
Q9D7J7 Calpain small subunit 2 Capns2 69543 
Q08093 Calponin-2 Cnn2 12798 
P14211 Calreticulin Calr 12317 
P00920 Carbonic anhydrase 2 Ca2 12349 
Q9D7S9 Charged multivesicular body protein 5 Chmp5 76959 
P83917 Chromobox protein homolog 1 Cbx1 12412 
P59242 Cingulin Cgn 70737 
Q68FD5 Clathrin heavy chain 1 Cltc 67300 
O08585 Clathrin light chain A Clta 12757 
P61924 Coatomer subunit zeta-1 Copz1 56447 
P11087 Collagen alpha-1(I) chain Col1a1 12842 
Q62426 Cystatin-B Cstb 13014 
P99028 Cytochrome b-c1 complex subunit 6, 
mitochondrial 
Uqcrh 66576 
Q8R0Y6 Cytosolic 10-formyltetrahydrofolate 
dehydrogenase 
Aldh1l1 107747 
Q9CQJ6 Density-regulated protein Denr 68184 
P62627 Dynein light chain roadblock-type 1 Dynlrb1 67068 
Q7TNG5 Echinoderm microtubule-associated protein-
like 2 
Eml2 72205 
Q9DCW4 Electron transfer flavoprotein subunit beta Etfb 110826 
Q99K30 Epidermal growth factor receptor kinase 
substrate 8-like protein 2 
Eps8l2 98845 
Q9WUK2 Eukaryotic translation initiation factor 4H Eif4h 22384 
P63242 Eukaryotic translation initiation factor 5A-1 Eif5a 276770 
P97447 Four and a half LIM domains protein 1 Fhl1 14199 
Q921G8 Gamma-tubulin complex component 2 Tubgcp2 74237 
P16406 Glutamyl aminopeptidase Enpep 13809 
P10648 Glutathione S-transferase A2 Gsta2 14858 
P30115 Glutathione S-transferase A3 Gsta3 14859 
P43081 Guanylyl cyclase-activating protein 1 Guca1a 14913 
O88569 Heterogeneous nuclear ribonucleoproteins 
A2/B1 
Hnrnpa2b1 53379 
Q9Z204 Heterogeneous nuclear ribonucleoproteins 
C1/C2 
Hnrnpc 15381 
P63158 High mobility group protein B1 Hmgb1 15289 
P17095 High mobility group protein HMG-I/HMG-Y Hmga1 15361 
Q60972 Histone-binding protein RBBP4 Rbbp4 19646 
Q61425 Hydroxyacyl-coenzyme A dehydrogenase, 
mitochondrial 
Hadh 15107 
P40936 Indolethylamine N-methyltransferase Inmt 21743 
O88792 Junctional adhesion molecule A F11r 16456 
Q3TTY5 Keratin, type II cytoskeletal 2 epidermal Krt2 16681 
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Q99KP3 Lambda-crystallin homolog Cryl1 68631 
P02468 Laminin subunit gamma-1 Lamc1 226519 
P24527 Leukotriene A-4 hydrolase Lta4h 16993 
Q9D358 Low molecular weight phosphotyrosine 
protein phosphatase 
Acp1 11431 
P17047 Lysosome-associated membrane 
glycoprotein 2 
Lamp2 16784 
Q9EQK5 Major vault protein Mvp 78388 
P25785 Metalloproteinase inhibitor 2 Timp2 21858 
Q9Z2D6 Methyl-CpG-binding protein 2 Mecp2 17257 
Q9EQ20 Methylmalonate-semialdehyde 
dehydrogenase [acylating], mitochondrial 
Aldh6a1 104776 
Q9CRB9 MICOS complex subunit Mic19 Chchd3 66075 
Q0P557 Mitochondria-eating protein Spata18 73472 
P62075 Mitochondrial import inner membrane 
translocase subunit Tim13 
Timm13 30055 
Q6PEB6 MOB-like protein phocein Mob4 19070 
Q69ZN7 Myoferlin Myof 226101 
P82343 N-acylglucosamine 2-epimerase Renbp 19703 
Q8BHN3 Neutral alpha-glucosidase AB Ganab 14376 
Q8R1F1 Niban-like protein 1 Fam129b 227737 
P18608 Non-histone chromosomal protein HMG-14 Hmgn1 15312 
P32020 Non-specific lipid-transfer protein Scp2 20280 
Q80XU3 Nuclear ubiquitous casein and cyclin-
dependent kinase substrate 1 
Nucks1 98415 
Q9WV85 Nucleoside diphosphate kinase 3 Nme3 79059 
Q62446 Peptidyl-prolyl cis-trans isomerase FKBP3 Fkbp3 30795 
Q9CWW6 Peptidyl-prolyl cis-trans isomerase NIMA-
interacting 4 
Pin4 69713 
Q9R269 Periplakin Ppl 19041 
Q9DBJ1 Phosphoglycerate mutase 1 Pgam1 18648 
Q9CY58 Plasminogen activator inhibitor 1 RNA-
binding protein 
Serbp1 66870 
O54724 Polymerase I and transcript release factor Ptrf 19285 
P17225 Polypyrimidine tract-binding protein 1 Ptbp1 19205 
Q6NSR8 Probable aminopeptidase NPEPL1 Npepl1 228961 
P50580 Proliferation-associated protein 2G4 Pa2g4 18813 
Q9QUR6 Prolyl endopeptidase Prep 19072 
Q99MN9 Propionyl-CoA carboxylase beta chain, 
mitochondrial 
Pccb 66904 
P49722 Proteasome subunit alpha type-2 Psma2 19166 
O55234 Proteasome subunit beta type-5 Psmb5 19173 
Q9CQ89 Protein CutA Cuta 67675 
Q99LT0 Protein dpy-30 homolog Dpy30 66310 
Q62433 Protein NDRG1 Ndrg1 17988 
Q9CQE1 Protein NipSnap homolog 3B Nipsnap3b 66536 
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P14069 Protein S100-A6 S100a6 20200 
Q91V41 Ras-related protein Rab-14 Rab14 68365 
P62821 Ras-related protein Rab-1A Rab1A 19324 
Q8BHL4 Retinoic acid-induced protein 3 Gprc5a 232431 
Q9CWY8 Ribonuclease H2 subunit A Rnaseh2a 69724 
P52760 Ribonuclease UK114 Hrsp12 15473 
Q9CWZ3 RNA-binding protein 8A Rbm8a 60365 
Q8R4Y8 Rotatin Rttn 246102 
Q99J08 SEC14-like protein 2 Sec14l2 67815 
Q8R0F9 SEC14-like protein 4 Sec14l4 103655 
O55131 Septin-7 Sept7 235072 
Q76MZ3 Serine/threonine-protein phosphatase 2A 65 
kDa regulatory subunit A alpha isoform 
Ppp2r1a 51792 
P07724 Serum albumin Alb 11657 
P55012 Solute carrier family 12 member 2 Slc12a2 20496 
Q9CWK8 Sorting nexin-2 Snx2 67804 
P07214 SPARC Sparc 20692 
Q8K4Z5 Splicing factor 3A subunit 1 Sf3a1 67465 
Q921M3 Splicing factor 3B subunit 3 Sf3b3 101943 
Q9DBG9 Tax1-binding protein 3 Tax1bp3 76281 
P80317 T-complex protein 1 subunit zeta Cct6a 12466 
Q9JLT4 Thioredoxin reductase 2, mitochondrial Txnrd2 26462 
P97493 Thioredoxin, mitochondrial Txn2 56551 
Q8CDN6 Thioredoxin-like protein 1 Txnl1 53382 
P42669 Transcriptional activator protein Pur-alpha Pura 19290 
Q9R1Q8 Transgelin-3 Tagln3 56370 
P17751 Triosephosphate isomerase Tpi1 21991 
O35900 U6 snRNA-associated Sm-like protein 
LSm2 
Lsm2 27756 
Q91ZJ5 UTP--glucose-1-phosphate 
uridylyltransferase 
Ugp2 216558 
P40336 Vacuolar protein sorting-associated protein 
26A 
Vps26a 30930 
Q99KC8 von Willebrand factor A domain-containing 
protein 5A 
Vwa5a 67776 
Q9D1K2 V-type proton ATPase subunit F Atp6v1f 66144 
O88342 WD repeat-containing protein 1 Wdr1 22388 
Q11136 Xaa-Pro dipeptidase Pepd 18624 
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Table 14: List of proteins only identified in BALF from SPC-HAxTCR-HA mice (Ʃ101). 
Accession 
ID 
Protein Gene 
symbol 
Entrez 
Gene ID 
P61161 Actin-related protein 2 Actr2  66713 
P56376 Acylphosphatase-1 Acyp1  66204 
P28474 Alcohol dehydrogenase class-3 Adh5  11532 
P55264 Adenosine kinase Adk  11534 
P47739 Aldehyde dehydrogenase, dimeric NADP-
preferring 
Aldh3a1  11670 
P10107 Annexin A1 Anxa1  16952 
P22892 AP-1 complex subunit gamma-1 Ap1g1  11765 
Q61599 Rho GDP-dissociation inhibitor 2 Arhgdib  11857 
Q9CVB6 Actin-related protein 2/3 complex subunit 
2 
Arpc2  76709 
P01887 Beta-2-microglobulin B2m  12010 
P51437 Cathelin-related antimicrobial peptide Camp  12796 
P35564 Calnexin Canx  12330 
O35350 Calpain-1 catalytic subunit Capn1  12333 
P51125 Calpastatin Cast  12380 
P80314 T-complex protein 1 subunit beta Cct2  12461 
P80318 T-complex protein 1 subunit gamma Cct3  12462 
P80315 T-complex protein 1 subunit delta Cct4  12464 
P42932 T-complex protein 1 subunit theta Cct8  12469 
P10810 Monocyte differentiation antigen CD14 Cd14  12475 
O35744 Chitinase-like protein 3 Chil3  12655 
Q04447 Creatine kinase B-type Ckb  12709 
Q99KN9 Clathrin interactor 1 Clint1  216705 
Q9QXT0 Protein canopy homolog 2 Cnpy2  56530 
O89053 Coronin-1A Coro1a  12721 
Q9CQI6 Coactosin-like protein Cotl1  72042 
Q02248 Catenin beta-1 Ctnnb1  12387 
O70370 Cathepsin S Ctss  13040 
P48024 Eukaryotic translation initiation factor 1 Eif1  20918 
Q60872 Eukaryotic translation initiation factor 1A Eif1a  13664 
Q3UGC7 Eukaryotic translation initiation factor 3 
subunit J-A 
Eif3j1  78655 
P60843 Eukaryotic initiation factor 4A-I Eif4a1  13681 
O55135 Eukaryotic translation initiation factor 6 Eif6  16418 
Q9CQ92 Mitochondrial fission 1 protein Fis1  66437 
P16858 Glyceraldehyde-3-phosphate 
dehydrogenase 
Gapdh  14433 
Q01514 Interferon-induced guanylate-binding 
protein 1 
Gbp1  14468 
Q9Z0E6 Interferon-induced guanylate-binding 
protein 2 
Gbp2  14469 
Q9R111 Guanine deaminase Gda  14544 
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Q9CQM9 Glutaredoxin-3 Glrx3  30926 
Q60631 Growth factor receptor-bound protein 2 Grb2  14784 
P10922 Histone H1.0 H1f0  14958 
P01902 H-2 class I histocompatibility antigen, K-D 
alpha chain 
H2-K1  14972 
P14430 H-2 class I histocompatibility antigen, Q8 
alpha chain 
H2-Q8  15019 
Q61035 Histidine--tRNA ligase, cytoplasmic Hars  15115 
P02088 Hemoglobin subunit beta-1 Hbb-b1  15129 
P43276 Histone H1.5 Hist1h1b  56702 
P13597 Intercellular adhesion molecule 1 Icam1  15894 
P01868 Ig gamma-1 chain C region secreted form Ighg1  16017 
P01872 Ig mu chain C region Ighm  16019 
P01878 Ig alpha chain C region Igh-VJ558 16061 
P01592 Immunoglobulin J chain Igj  16069 
P01837 Ig kappa chain C region Igkc 16071 
Q9QZ85 Interferon-inducible GTPase 1 Iigp1  60440 
Q8CAQ8 Mitochondrial inner membrane protein Immt  76614 
P49442 Inositol polyphosphate 1-phosphatase Inpp1  16329 
O89112 LanC-like protein 1 Lancl1  14768 
Q07797 Galectin-3-binding protein Lgals3bp  19039 
P08071 Lactotransferrin Ltf  17002 
P61327 Protein mago nashi homolog Magoh  17149 
P34960 Macrophage metalloelastase Mmp12  17381 
Q8BPB0 MOB kinase activator 1B Mob1b  68473 
Q922D8 C-1-tetrahydrofolate synthase, 
cytoplasmic 
Mthfd1  108156 
Q9JK81 UPF0160 protein MYG1, mitochondrial Myg1  60315 
Q6PDN3 Myosin light chain kinase, smooth muscle Mylk  107589 
P29595 NEDD8 Nedd8  18002 
Q61937 Nucleophosmin Npm1  18148 
Q02819 Nucleobindin-1 Nucb1  18220 
P56812 Programmed cell death protein 5 Pdcd5  100042424 
Q62048 Astrocytic phosphoprotein PEA-15 Pea15  18611 
O70591 Prefoldin subunit 2 Pfdn2  18637 
Q8CHP8 Phosphoglycolate phosphatase Pgp  67078 
O70570 Polymeric immunoglobulin receptor Pigr  18703 
A3KGF7 1-phosphatidylinositol 4,5-bisphosphate 
phosphodiesterase beta-2 
Plcb2  18796 
Q9Z2M7 Phosphomannomutase 2 Pmm2  54128 
Q9D819 Inorganic pyrophosphatase Ppa1  67895 
Q9CR16 Peptidyl-prolyl cis-trans isomerase D Ppid  67738 
Q61207 Prosaposin Psap  19156 
O35955 Proteasome subunit beta type-10 Psmb10  19171 
Q9EPB4 Apoptosis-associated speck-like protein 
containing a CARD 
Pycard  66824 
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Q8BND5 Sulfhydryl oxidase 1 Qsox1  104009 
P62492 Ras-related protein Rab-11A Rab11a  53869 
Q9EP95 Resistin-like alpha Retnla  57262 
Q9CZX8 40S ribosomal protein S19 Rps19  20085 
P62908 40S ribosomal protein S3 Rps3  27050 
P14206 40S ribosomal protein SA Rpsa  16785 
Q01730 Ras suppressor protein 1 Rsu1  20163 
P56565 Protein S100-A1 S100a1  20193 
Q60710 Deoxynucleoside triphosphate 
triphosphohydrolase SAMHD1 
Samhd1  56045 
P07759 Serine protease inhibitor A3K Serpina3k  20714 
P97290 Plasma protease C1 inhibitor Serping1  12258 
P35242 Pulmonary surfactant-associated protein 
A 
Sftpa1  20387 
Q64105 Sepiapterin reductase Spr  20751 
P13609 Serglycin Srgn  19073 
Q62093 Serine/arginine-rich splicing factor 2 Srsf2  20382 
P37804 Transgelin Tagln  21345 
P10711 Transcription elongation factor A protein 1 Tcea1  21399 
P21981 Protein-glutamine gamma-
glutamyltransferase 2 
Tgm2  21817 
Q9QZE7 Translin-associated protein X Tsnax  53424 
Q9Z0P5 Twinfilin-2 Twf2  23999 
Q02053 Ubiquitin-like modifier-activating enzyme 1 Uba1  22201 
Q9Z1Z0 General vesicular transport factor p115 Uso1  56041 
Q9Z1Q9 Valine--tRNA ligase Vars  22321 
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Table 15: KEGG pathway analyses of SPC-HA and SPC-HAxTCR-HA BALFomes. 
n.e. = no significant enrichment 
  SPC-HA SPC-HAxTCR-HA 
KEGG 
ID 
GOTerm % associated 
genes 
Term p-value 
corrected with 
Bonferroni  
% associated 
genes 
Term p-value 
corrected with 
Bonferroni  
3050 Proteasome 40 3,50E-12 37,8 3,90E-11 
620 Pyruvate 
metabolism 
28,2 2,20E-05 30,8 1,70E-06 
480 Glutathione 
metabolism 
27,3 2,50E-07 20 7,00E-04 
30 Pentose 
phosphate 
pathway 
26,7 1,50E-03 23,3 1,10E-02 
10 Glycolysis / 
Gluconeogenesis 
24,2 4,70E-07 25,8 4,10E-08 
630 Glyoxylate and 
dicarboxylate 
metabolism 
23,1 3,50E-02 23,1 3,30E-02 
280 Valine, leucine 
and isoleucine 
degradation 
22,2 1,00E-04 n.e. n.e. 
640 Propanoate 
metabolism 
22,2 4,20E-02 n.e. n.e. 
4966 Collecting duct 
acid secretion 
22,2 4,20E-02 n.e. n.e. 
20 Citrate cycle 
(TCA cycle) 
21,9 1,80E-02 21,9 1,60E-02 
51 Fructose and 
mannose 
metabolism 
20 3,10E-02 20 2,90E-02 
270 Cysteine and 
methionine 
metabolism 
20 1,30E-02 20 1,20E-02 
40 Pentose and 
glucuronate 
interconversions 
19,4 3,70E-02 n.e. n.e. 
520 Amino sugar and 
nucleotide sugar 
metabolism 
19,1 7,50E-03 n.e. n.e. 
330 Arginine and 
proline 
metabolism 
15,3 4,00E-02 15,3 3,60E-02 
4141 Protein 
processing in 
endoplasmic 
reticulum 
13,6 2,70E-05 13,6 1,90E-05 
3040 Spliceosome 11,9 7,90E-03 n.e. n.e. 
4145 Phagosome 10,9 6,50E-03 13,2 3,10E-05 
4810 Regulation of 
actin 
cytoskeleton 
n.e. n.e. 9,6 1,20E-02 
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7.2 Abbreviations 
α alpha 
A adenosine nucleotide 
AEC  airway epithelial cell 
ALI allergic lung inflammation 
ATI alveolar type I epithelial cell 
ATII  alveolar type II epithelial cell 
AM  alveolar macrophage 
AMDC airway mucosal dendritic cell 
APC allophycocyanin, also: antigen-presenting cell 
ATCC American Type Culture Collection 
  
β beta 
BAL bronchoalveolar lavage  
BALF bronchoalveolar lavage fluid 
BSA bovine serum albumin 
  
°C degree Celsius 
C cytosine nucleotide 
CD cluster of differentiation 
cDNA copy DNA 
CFU colony forming unit 
COPD chronic obstructive pulmonary disease 
CpG cytosine-phosphate-guanine 
CRD chronic respiratory disease 
CTRL control 
CXCL CXC chemokine ligand 
CXCR CXC chemokine receptor 
  
∆ delta 
d day 
Da dalton 
DAMP danger-associated molecular pattern 
DAPI 4',6-diamidino-2-phenylindole 
DNA deoxyribonucleic acid 
ds double-stranded 
  
e.g. exempli gratia 
EDTA ethylenediaminetetraacetic acid 
ELISA enzyme-linked immunosorbent assay 
ELR conserved sequence motif (glutamic acid-leucine-arginine) found in many 
chemokines 
ek ethanol-killed 
et al. et alii 
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FACS fluorescence-activated cell sorting  
FBS fetal bovine serum 
FC fold change 
FITC fluorescein isothiocyanate (fluorophore) 
Foxp3 forkhead box P3 
FSC forward scatter 
  
γ gamma 
g gravitational force, also : gram 
G guanine nucleotide 
GO  gene ontology  
  
h  hour(s) 
H&E hematoxylin and eosin 
HA hemagglutinin 
HRP horseradish peroxidase 
HZI Helmholtz Centre for Infection Research 
  
ICAM intercellular adhesion molecule 
i.e. id est  
IFN interferon 
Ig immunoglobulin 
IL interleukin 
IMDM Iscove’s Modified Dulbecco’s Medium 
IPD invasive pneumococcal disease 
IRF interferon regulatory factor 
  
ĸ kappa 
KC keratinocyte chemoattractant 
kDA kilodalton 
KEGG Kyoto Encyclopedia of Genes and Genomes 
  
L liter 
LC-MS/MS liquid chromatography-tandem mass spectrometry (MS) technique 
log2 binary logarithm 
LPS lipopolysaccharide 
  
µ micro 
m milli 
M molar 
MAMP microbial-associated molecular pattern 
MARCO macrophage receptor with collagenous structure 
MFI median fluorescence intensity 
MHC major histocompatibility complex 
min minute(s) 
MMP matrix metalloproteinase 
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n number; also: nano 
n.e. not significantly enriched 
NO nitric oxide 
n.s. not significant 
  
OD optical density 
  
PAMP pathogen-associated molecular pattern 
PBS phosphate buffered saline 
PCR polymerase chain reaction 
PE phycoerythrin (fluorophore) 
PerCp peridinin chlorophyll (fluorophore) 
PGE2 prostaglandin E2 
pH indicates degree of acidity or basicity 
pIgR polymeric immunoglobulin receptor 
PMN polymorphonuclear neutrophil 
PRR pattern-recognition receptor 
PVDF polyvinylidene fluoride 
  
RNA ribonucleic acid 
RT reverse transcriptase 
  
SC secretory component 
SD standard deviation 
SDS sodium dodecyl sulfate 
sec second(s) 
SEM standard error of the mean 
SIg secretory immunoglobulin 
SOCS suppressor of cytokine signaling 
  
T thymine nucleotide 
TCR T cell receptor 
TF transcription factor 
TGFβ transforming growth factor beta 
Th T helper cell 
TLR Toll-like receptor 
TNF-α tumor necrosis factor alpha 
Treg regulatory T cell 
  
v/v volume per volume 
vs. versus 
  
w/v weight per volume 
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